Selective targeting of MYC by antisense oligonucleotides by Gill, Taylor Elizabeth
Selective Targeting of MYC by Antisense
Oligonucleotides
by
Taylor Elizabeth Gill
B.S., Duke University, 2013
Submitted to the Harvard-MIT Division of Health Sciences and
Technology
in partial fulfillment of the requirements for the degree of
Doctor of Philosophy
at the
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
February 2018
c○ Massachusetts Institute of Technology 2018. All rights reserved.
Author . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Harvard-MIT Division of Health Sciences and Technology
December 6, 2017
Certified by. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Daniel G. Anderson, Ph.D.
Samuel A. Goldblith Professor of Applied Biology and Associate
Professor of Chemical Engineering and Institute for Medical
Engineering and Science, MIT
Thesis Supervisor
Accepted by . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Emery N. Brown, M.D., Ph.D.
Director, Harvard-MIT Program in Health Sciences and Technology and
Professor of Computational Neuroscience and Health Sciences and
Technology
2
Selective Targeting of MYC by Antisense Oligonucleotides
by
Taylor Elizabeth Gill
Submitted to the Harvard-MIT Division of Health Sciences and Technology
on December 6, 2017, in partial fulfillment of the
requirements for the degree of
Doctor of Philosophy
Abstract
MYC is one of the most commonly dysregulated genes across all cancers. As
a master transcription factor with greater than 10,000 binding sites throughout the
genome, the MYC oncoprotein coordinates a transcriptional regulatory network con-
sisting of approximately 15% of all genes, controlling cancer hallmark expression
programs responsible for cellular proliferation, growth, metabolism, and evasion from
apoptosis. MYC dysregulation occurs genetically, epigenetically, and post-transcrip-
tionally through a wide variety of mechanisms. Despite its well-characterized prop-
erties as a proto-oncogene, direct potent and selective inhibition of MYC remains a
significant challenge. Models of systemic MYC inhibition utilizing inducible genetic
constructs in mice have revealed that inhibition of MYC activity leads to potent
tumor regression with an evident therapeutic window, suggesting that pharmaco-
logic MYC inhibition may be a viable cancer therapeutic strategy. Small molecule
inhibitors designed to block MYC protein activity exhibit low potency, display poor
selectivity, and lack antitumor efficacy, which has led MYC to be historically classified
as ‘undruggable.’ Efforts aimed at indirectly targeting MYC transcription often lead
to development of resistance characterized by reinforced expression of MYC. Clearly,
alternate strategies are needed to achieve selective and potent inhibition of MYC.
The goals of this research were to develop antisense oligonucleotides specifically
targeted against the MYC mRNA to achieve potent inhibition of MYC translation,
and to characterize the activity of these molecules as specific modulators of MYC
expression and as prototypical MYC-directed therapeutics.
We designed and synthesized a library of MYC-targeting antisense oligonucleotides
(MYCASOs) containing several chemical synthetic features to increase target affinity
and stability. Treatment of MYC-expressing cancer cells with MYCASOs leads to
RNase H-mediated cleavage of MYC mRNA and a potent decrease in MYC protein
levels. MYC knockdown is accompanied by significant effects on cellular viability
and inhibition of cellular proliferation. Furthermore, MYCASO treatment specif-
ically perturbs MYC-driven gene expression signatures. In a MYC-induced murine
model of hepatocellular carcinoma, MYCASO treatment leads to cleavage of theMYC
transcript, decreased MYC protein levels within tumors, and reduced tumor burden.
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MYCASOs represent a new chemical tool for in vitro and in vivo modulation of
MYC activity, and promising therapeutic agents for MYC-addicted tumors.
Thesis Supervisor: Daniel G. Anderson, Ph.D.
Title: Samuel A. Goldblith Professor of Applied Biology and Associate Professor of
Chemical Engineering and Institute for Medical Engineering and Science, MIT
4
Acknowledgments
The number of people who have helped me along my path towards completing
this dissertation is enormous, and I am immensely thankful to every one of them. I
would like to mention a select few here whose support has been invaluable.
First, to the Bradner laboratory and every member who passed through it. The
Bradner lab was uniquely diverse, incredibly collaborative, remarkably productive,
and filled with some of the smartest and most creative people I have ever met. The
lab held itself to high standards of scientific rigor and teamsmanship that I will always
aspire to emulate and hope to find in future employment. There is not a single person
who passed through the lab that I did not interact with in some fashion, and I am
grateful for all of their scientific and personal contributions to my graduate school
journey.
James Bradner served as my first mentor and advisor, and I am very thankful for
his scientific optimism, creativity, commitment to scientific integrity and academic
rigor, love of smart ideas and quality data, and unwavering support. I am very
grateful to have learned from and worked with him.
Christopher Ott served as a reliable mentor, advisor, teammate, editor, sounding
board, advocate, and motivator for the entirety of my graduate school career, and I
am incredibly grateful for everything he did to aid my research and my development as
a scientist. I feel very lucky to have worked alongside him and can say for certain that
I would not have completed this dissertation were it not for his dedicated mentorship.
I am grateful to my thesis committee members Daniel Anderson, Paula Hammond,
and Angela Koehler for their guidance and advice on tricky scientific and academic
questions.
I am grateful to the Harvard/MIT Division of Health Sciences and Technology,
the Medical Engineering and Medical Physics Program, and all of its staff and admin-
istration. This program offers a truly unique learning and training opportunity, and
I am thankful to have been given the opportunity to be a student in it. I am grateful
for the guidance and support from HST administrators, especially Julie Greenberg
and Laurie Ward.
The support of friends has been a powerful and invaluable force throughout my life,
most of all during my graduate school years. To my Thursday Night Drinking Buddies
Colin Buss and Sam Osseiran, thank you for your steady and reliable friendship. To
Swati Kataria, Giorgia Grisot, and Katelyn Burkhart, thank you for your unending
support, your patience, your laughter, and your beautiful friendship - I could not
have survived these years without you. To my Worst Friends Forever Emily Keller
and Emily Volkmann, thank you for your fierce love and support over all of these
years, I am very lucky to have you by my side. To Rachael Berman, thank you for
your support during the most difficult time of my graduate career, I’m inexpressibly
grateful for all that you’ve done for me.
Finally, my family. To David, Nicholas, and Stephen Gill, thank you for con-
stantly motivating me and pushing me to do the best that I can. Thank you for your
unwavering support throughout my entire life. To my parents David and Toni Gill,
thank you for all of the support you have given me over the last 26 years. Your belief
5
that I could accomplish whatever I set my mind to is what led me to where I am
today, and I know I never would have made it this far without all of your love and
support.
6
Contents
1 Background 27
1.1 The MYC Transcription Factor . . . . . . . . . . . . . . . . . . . . . 27
1.1.1 The Biology of MYC . . . . . . . . . . . . . . . . . . . . . . . 27
1.1.2 MYC Deregulation in Cancer . . . . . . . . . . . . . . . . . . 30
1.1.3 Drugging MYC . . . . . . . . . . . . . . . . . . . . . . . . . . 33
1.2 Antisense Oligonucleotides . . . . . . . . . . . . . . . . . . . . . . . . 36
1.2.1 Introduction to Antisense Oligonucleotides . . . . . . . . . . . 36
1.2.2 Mechanisms of Antisense Oligonucleotide Activity . . . . . . . 37
1.2.3 Chemical Modifications of Antisense Oligonucleotides . . . . . 41
1.2.4 Delivery of Antisense Oligonucleotides . . . . . . . . . . . . . 44
1.2.5 Clinical Status of Antisense Oligonucleotides . . . . . . . . . . 46
1.2.6 Other Nucleic Acid-Based Strategies for Targeting MYC . . . 47
2 MYC-Targeting Antisense Oligonucleotides 49
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
2.2 MYC-Targeting Antisense Oligonucleotide Design . . . . . . . . . . . 52
2.2.1 Experimental Design . . . . . . . . . . . . . . . . . . . . . . . 52
2.2.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
2.2.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
2.3 MYC-Targeting Antisense Oligonucleotide Target Engagement . . . . 57
2.3.1 Experimental Design . . . . . . . . . . . . . . . . . . . . . . . 57
2.3.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
2.3.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
7
2.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
3 MYC-Targeting Antisense Oligonucleotide Activity in Cancer Cell
Lines 63
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
3.2 Screening the MYC-Targeting Antisense Oligonucleotide Library in
MYC-expressing Human Cancer Cell Lines . . . . . . . . . . . . . . . 64
3.2.1 Experimental Design . . . . . . . . . . . . . . . . . . . . . . . 64
3.2.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
3.2.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
3.3 Characterization of Lead MYC-Targeting Antisense Oligonucleotides 69
3.3.1 Experimental Design . . . . . . . . . . . . . . . . . . . . . . . 69
3.3.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
3.3.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
3.4 Mechanism of Action of MYC-Targeting Antisense Oligonucleotides . 76
3.4.1 Experimental Design . . . . . . . . . . . . . . . . . . . . . . . 76
3.4.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
3.4.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
3.5 Phenotypic Consequences of MYC-Targeting Antisense Oligonucleotide
Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
3.5.1 Experimental Design . . . . . . . . . . . . . . . . . . . . . . . 88
3.5.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
3.5.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
3.6 Transcriptional Consequences of MYC-Targeting Antisense
Oligonucleotide Treatment . . . . . . . . . . . . . . . . . . . . . . . . 100
3.6.1 Experimental Design . . . . . . . . . . . . . . . . . . . . . . . 100
3.6.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
3.6.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
3.7 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
8
4 MYC-Targeting Antisense Oligonucleotide Activity in Animal
Models 111
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
4.2 Zebrafish Conditional Transgenic T-Cell Acute Lymphoblastic Leukemia
Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
4.2.1 Experimental Design . . . . . . . . . . . . . . . . . . . . . . . 112
4.2.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
4.2.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
4.3 Tolerability and Toxicity in Mice . . . . . . . . . . . . . . . . . . . . 116
4.3.1 Experimental Design . . . . . . . . . . . . . . . . . . . . . . . 116
4.3.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
4.3.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
4.4 Murine Disseminated Multiple Myeloma Xenograft Model . . . . . . . 119
4.4.1 Experimental Design . . . . . . . . . . . . . . . . . . . . . . . 119
4.4.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
4.4.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
4.5 Murine Orthotopic Hepatocellular Carcinoma Xenograft Model . . . . 123
4.5.1 Experimental Design . . . . . . . . . . . . . . . . . . . . . . . 123
4.5.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
4.5.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
4.6 Murine Conditional Transgenic Renal Cell Carcinoma Model . . . . . 129
4.6.1 Experimental Design . . . . . . . . . . . . . . . . . . . . . . . 129
4.6.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
4.6.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
4.7 Murine MYC Hyperperfusion Hepatocellular Carcinoma Model . . . 131
4.7.1 Experimental Design . . . . . . . . . . . . . . . . . . . . . . . 131
4.7.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
4.7.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
4.8 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
9
5 Off-Target Activity of MYC-Targeting Antisense Oligonucleotides 139
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
5.2 Investigation of Effects of MYCASO Treatment on Potential Off-Target
Binding Partner Transcripts . . . . . . . . . . . . . . . . . . . . . . . 141
5.2.1 Experimental Design . . . . . . . . . . . . . . . . . . . . . . . 141
5.2.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
5.2.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
5.3 Unbiased Transcriptomic Analysis to Evaluate MYCASO Off-Target
Activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
5.3.1 Experimental Design . . . . . . . . . . . . . . . . . . . . . . . 153
5.3.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156
5.3.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
5.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
6 Future Directions 163
6.1 MYCASO In Vivo Studies . . . . . . . . . . . . . . . . . . . . . . . . 164
6.2 Cellular Uptake of Antisense Oligonucleotides . . . . . . . . . . . . . 165
6.3 Antisense Oligonucleotide Delivery . . . . . . . . . . . . . . . . . . . 167
6.4 Analysis of Off-Target Activity of Antisense Oligonucleotides . . . . . 168
A Supplementary Materials and Methods 171
B Supplementary Figures 173
C Supplementary Tables 177
10
List of Figures
1-1 Crystal structure of the basic helix-loop-helix leucine zipper domains of
the MYC/MAX heterodimer bound to a DNA E-box sequence. Protein
Database ID 1NKP.[1] . . . . . . . . . . . . . . . . . . . . . . . . . . 28
1-2 Cellular processes control by MYC during normal conditions and dur-
ing tumorigenesis.[2] . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
1-3 Mechanisms of MYC deregulation in cancer.[3] . . . . . . . . . . . . . 31
1-4 Mechanisms of antisense oligonucleotide activity. In the absence of
ASO, normal gene and protein expression is maintained (1). The
ASO is taken up by cellular endocytosis and can hybridize with target
mRNA in the cytoplasm. Formation of an ASO/mRNA heteroduplex
induces (2) activation of RNase H, leading to selective degradation of
bound mRNA or (3) steric interference of ribosomal assembly. Alterna-
tively, the ASO can enter the nucleus and regulate mRNA maturation
by (4) inhibition of 5’ cap formation, (5) inhibition of mRNA splicing,
or (6) activation of RNase H. All of these activities lead to inhibition
of target protein expression.[4] . . . . . . . . . . . . . . . . . . . . . . 38
1-5 Chemical modifications of antisense oligonucleotides. Structure of first,
second, and third generation antisense oligonucleotides.[5] . . . . . . . 42
2-1 MYCASO target sites are distributed along the MYC mRNA. . . . . 55
11
2-2 MYCASOs have increased binding anity for target mRNA sequences.
MYCASOs or corresponding unmodied DNA oligonucleotides were
incubated with complementary RNA oligonucleotides representative
of the MYCASO MYC mRNA target sites at 2 mM each in SYBR
Select Master Mix. Mixtures were held at 95∘C for 5 min., cooled to
20∘C at 0.1∘C/sec., and then heated to 95∘C at 0.1∘C/sec. with a
fluorescence measurement taken every 5.35 sec. Melting curves were
obtained by plotting the derivative of the fluorescence vs. time plots
vs. time; curves were normalized by fitting a third order polynomial
to the regions of the curves outside of duplex melting (25-40∘C and
85-95∘C) and subtracting the polynomials from the curves. Black data
points represent unmodified DNA/RNA mixtures, and red data points
represent MYCASO/RNA mixtures. All samples were performed in
quadruplicate. The shift in Tm between the DNA/RNA duplex and the
MYCASO/RNA duplex for each molecule is given above the melting
curves, and all Tm’s and DTm’s are presented in the table below. . . 59
2-3 Proposed schematic of MYCASO/RNA duplex melting. We propose
that during melting, the MYCASO/RNA duplex behaves as if it were
three independent duplexes and goes through three distinct stages: (1)
fully bound duplex, (2) an arrangement in which LNA/RNA remains
duplexed and DNA/RNA is melted, (3) fully melted single oligonu-
cleotide strands. This pattern of duplex melting would account for the
bimodal melting curves observed with MYCASO/RNA melting. Black
lines correspond to DNA nucleotides, orange lines to LNA nucleotides,
and grey lines to RNA. . . . . . . . . . . . . . . . . . . . . . . . . . . 61
12
3-1 Screening of MYCASO library in MYC-expressing human cancer cell
lines. Immunoblots for c-MYC andb-tubulin in MYC-expressing can-
cer cell lines after treatment with the full MYCASO library. HeLa
cells (Lipo) were treated with 10 nM MYCASO in Lipofectamine for
24 hours. HeLa cells (gymnotic), CUTLL1 cells, and MM1.S cells were
treated with 10 mM unformulated MYCASO for 72 hours. HLF cells
were treated with 10 mM unformulated MYCASO for 120 hours. The
bar graph shows average percent knockdown of MYC for unformulated
treatment across all four cell lines. Highlighted MYCASOs (3, 9, and
13) were chosen for further study due to their superior knockdown
activity and non-overlapping seed sites along the MYC mRNA. . . . 68
3-2 Knockdown of MYC mRNA and protein expression with MYCASO
treatment. (A) Dose-proportional knockdown of MYC protein expres-
sion with MYCASO treatment. (B) Time-proportional knockdown
of MYC protein expression with MYCASO treatment. (C) Dose-
proportional decrease of MYC mRNA with MYCASO treatment. Val-
ues represent quadruplicate means +/- SD. (D) Time-proportional de-
crease in MYC mRNA with MYCASO treatment. Values represent
quadruplicate means +/- SD. For dose-proportional studies, HeLa cells
were treated with 0, 0.5, 1, 5, 10, and 20 nM MYCASO in Lipofec-
tamine for 24 hours. CUTLL1, MM1.S, and HLF cells were treated
with 0, 0.5, 1, 5, 10, and 20 mM unformulated MYCASO for 72 hours
(CUTLL1 and MM1.S) or 120 hours (HLF). For time-proportional
studies, HeLa cells were treated with 10 nM MYCASO in Lipofec-
tamine for 0, 1, 2, 4, 8, 12, and 24 hours. CUTLL1 and HLF cells were
treated with 10 mM unformulated MYCASO for 24, 48, 72, 96, and 120
hours. MM1.S cells were treated with 10 mM unformulated MYCASO
for 24, 48, and 72 hours. . . . . . . . . . . . . . . . . . . . . . . . . . 74
13
3-3 5’ RACE assay to detectMYC mRNA cleavage with MYCASO treat-
ment. (A) Schematic of 5’ RACE assay. Gene specific primers (GSPs)
are used to capture and amplify MYC mRNA fragments from total
cellular RNA for visualization on an agarose gel and sequencing. Lead
MYCASOs are depicted in red. (B) 5’ RACE PCR products following
MYCASO treatment. MYCASO-treated samples contain fragments
consistent with mRNA cleavage at MYCASO binding sites, whereas
vehicle- and NT-ASO-treated cells produce no fragments. HeLa cells
were treated with 10 nM MYCASO in Lipofectamine for 24 hours.
CUTLL1, MM1.S, and HLF cells were treated with 10 mM unformu-
lated MYCASO for 72 hours (CUTLL1 and MM1.S) or 120 hours
(HLF). (C) MYCASO-mediated cleavage sites of MYC mRNA as de-
termined via sequencing of 5’ RACE PCR products. MYC mRNA is
represented in black, MYCASO binding sites are indicated below the
mRNA in grey or red, with the red representing the indicated MYC-
ASO sequence. Each sequenced 5’ end is indicated with an arrow; the
most abundant cleavage site(s) for each MYCASO treatment is em-
phasized with a tall arrow. PCR products were obtained from MM1.S
and SNU-398 cells treated with 10 mM unformulated MYCASO for 72
hours. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
3-4 Knockdown of RNase H1 rescues MYCASO-mediated downregulation
of MYC mRNA. (A) qRT-PCR for RNASEH1 in HeLa cells follow-
ing treatment with an anti-RNASEH1 ASO (ISIS 194178) in Lipofec-
tamine for 24 hours normalized to vehicle-treated control. (B) qRT-
PCR for MYC in HeLa cells following co-transfection with the indi-
cated doses of anti-RNASEH1 ASO and MYCASO-3 in Lipofectamine
for 24 hours normalized to appropriate controls. With decreased levels
of RNase H1, MYCASO-mediated knockdown of MYC mRNA levels
is rescued. Values represent quadruplicate means +/- SD. . . . . . . . 85
14
3-5 Cell viability eects of MYCASO treatment. (A) Dose-proportional
eect of MYCASO treatment on cellular viability as approximated
by ATP-dependent luminescence normalized to vehicle-treated con-
trol. HeLa cells were treated with the indicated doses of MYCASO
in Lipofectamine for 24 hours. CUTLL1, MM1.S, and HLF cells were
treated with the indicated doses of unformulated MYCASO for 72
hours (CUTLL1 and MM1.S) or 120 hours (HLF). Values represent
quadruplicate means +/- SD. (B) Time-proportional eect of MYC-
ASO treatment on cellular viability as approximated by ATP-dependent
luminescence normalized to vehicle-treated control. HeLa cells were
treated with 10 nM MYCASO in Lipofectamine for the indicated time
periods. CUTLL1, MM1.S, and HLF cells were treated with 10mM un-
formulated MYCASO for the indicated time periods. Values represent
quadruplicate means +/- SD. . . . . . . . . . . . . . . . . . . . . . . 95
3-6 Growth over time with MYCASO treatment. Cell numbers over time
with vehicle, NT-ASO, and MYCASO treatment. Cells were stained
using the Guava ViaCount reagent and counted by a Guava flow cy-
tometer. HeLa cells were treated with 10 nM MYCASO in Lipofec-
tamine. CUTLL1, MM1.S, and HLF cells were treated with 10 mM
unformulated MYCASO. Values represent triplicate means +/- SD. . 96
15
3-7 Rescue of MYCASO-mediated MYC protein knockdown and viability
eects. (A) Rescue of MYCASO-mediated MYC protein knockdown.
Immunoblot for c-MYC and b-tubulin following MYCASO treatment
(10 nM in Lipofectamine for 24 hours) in HeLa cells (pLenti.MYC -
) and in a HeLa-derived cell line stably expressing a MYC construct
containing silent mutations in MYCASO seed sites designed to abro-
gate MYCASO binding (pLenti.MYC +). (B) Rescue of MYCASO-
mediated viability effects. Cellular viability as approximated by ATP-
dependent luminescence following MYCASO treatment (10 nM (left)
or 100 nM (right) in Lipofectamine for 24 hours) in HeLa and mu-
tant MYC over-expressing cells normalized to vehicle-treated control.
Expression of the mutant MYC construct leads to partial rescue of
MYCASO-mediated viability effects. Values represent triplicate means
+/- SD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
16
3-8 Transcriptomic analysis of MYCASO-3 treated cells. (A) RNA-sequencing
was performed on HeLa cells transfected with NT-ASO or MYCASO-3
(10 nM) for either 4 or 18 hours. Lipofectamine 2000 was used as a
delivery vehicle. mRNA reads that were mapped to MYC exons were
plotted for each sample, revealing a slight decrease in MYC -mapped
reads at 4 hours, and a pronounced effect at 18 hours, specifically with
MYCASO-3 treatment. (B) Volcano plots of gene expression differ-
ences comparing NT-ASO and MYCASO-3 treated cells with vehicle
after 4 and 18 hours. (C) Gene set enrichment analysis (GSEA) nor-
malized enrichment scores for MYC-associated gene sets (red and blue)
and the total C2 gene sets as part of MSigDB. Differential expression
analysis was performed with DESeq2 to generate MYCASO-3 specific
expression signatures and total ASO-treated signatures (NT-ASO and
MYCASO-3 samples) as described in Methods. (D) GSEA signatures
for two example gene sets of genes positively regulated by MYC (MYC
‘UP’). (E) GSEA signatures for two example gene sets of the interferon
response. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
4-1 Activity of MYCASOs in a zebrafish model of T-cell acute lymphoblas-
tic leukemia. T-ALL was induced in zebrafish as described by Feng et
al.[6] Zebrafish were incubated with the indicated concentrations of
compounds for 2.5 days, at which time thymic fluorescence was mea-
sured as an indicator of tumor burden. (A) Thymic fluorescence fol-
lowing treatment with the indicated compounds in our pilot study.
(B) Representative fluorescent images of tumors from fish in our pilot
study. (C) Thymic fluorescence following treatment with the indicated
compounds in our second study. Red lines represent median values. *
indicates p value < 10-5, ** indicates p value < 10-6 as determined via
an unpaired student t-test. . . . . . . . . . . . . . . . . . . . . . . . . 115
17
4-2 MYCASO tolerability and toxicity in mice. Mice were treated with
MYCASOs formulated in a 0.9% saline solution via tail vein injection
at either the HI dose, 25 mg/kg every three days, or the low dose,
a one-time administration of 25 mg/kg followed by 5 mg/kg every
three days. (A) Body weights of mice over time. Mice were treated
for three weeks for a total of seven treatments and body weights were
determined at each treatment and presented as a percentage of starting
weight. (B) Tissue analysis of MYCASO treatment. After two weeks
of dosing for four treatments, select mice were sacrificed and liver tissue
was harvested for hematoxylin and eosin staining (H&E) and intestinal
tissue was harvested for MYC immunohistochemistry. . . . . . . . . . 118
4-3 Activity of MYCASOs in a murine xenograft model of disseminated
multiple myeloma. NSG mice were injected with luciferized MM1.S
cells and treated with vehicle control, MYCASO-3 at a dose of 25
mg/kg every three days, MYCASO-9 at a dose of 25 mg/kg every
three days, or MYCAO-13 at a one-time dose of 25 mg/kg followed
by 5 mg/kg every three days. (A) Tumor burden over time as mea-
sured by bioluminescence. MYCASO treatment had no effect on tumor
burden. (B) Overall survival of mice. MYCASO treatment had no ef-
fect on overall survival. (C) Relative weights of mice over time with
treatment. MYCASO-3 and MYCASO-13 treatments caused slight
decreases in weight. (D) Representative MYC immunohistochemistry
images from the livers and bone marrow of treated mice. MYC expres-
sion in the liver was low and unaffected by MYCASO treatment. MYC
expression in bone marrow was high due to MM1.S tumor engraftment
and unaffected by MYCASO treatment, suggesting poor delivery of
MYCASO molecules to the bone marrow compartment in vivo. . . . . 122
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4-4 Establishment of a murine orthotopic hepatocellular carcinoma xenograft
model. NSG mice were injected with one million luciferized SNU-398
cells. Luciferin was placed in mouse drinking water and biolumines-
cence was measured every week to monitor tumor burden. (A) Biolu-
minescence signal measured for seven weeks post-injection. The lucifer-
ized SNU-398 cells are able to engraft and grow tumors in NSG mice.
(B) Images of bioluminescent signals from injected mice. Luciferized
SNU-398 cells engraft in the liver and grow large tumors, constituting
an orthotopic model of hepatocellular carcinoma. . . . . . . . . . . . 128
4-5 In vivo effects of MYCASO-3 in a MYC-induced model of hepatocel-
lular carcinoma. (A) Schematic of HCC tumor model used to assess
MYCASO-3 effects. A plasmid expressing human MYC is co-injected
with a plasmid expressing the Sleeping Beauty transposase by hydro-
dynamic injection. Liver tumor formation is observed by three weeks
following perfusion, with large tumor masses observable by six weeks.
MYCASO-3 was dosed at 25 mg/kg in mice beginning four weeks af-
ter perfusion, and dosing was performed every three days for a pe-
riod of two weeks (a total of five doses). (B) Quantification of liver
mass as a percentage of total body mass following completion of the
study. Examples of harvested livers from a single control and a sin-
gle MYCASO-3 treated mouse are shown (vehicle-treated control mice,
n=3; MYCASO-3 treated mice, n=4). (C) 5’ RACE assessment from
RNA harvested from biopsied tumor samples from 3 control and 4
MYCASO-3 treated mice. Band depicts the major cleaved species ob-
servable in cell line studies. (D) MYC immunohistochemistry showing
MYC+ cells in livers of control and MYCASO-3 treated mice. (E)
Quantification of MYC+ cell staining in (D). MYC positivity grades
on a per cell basis was assigned using automated Aperio Digital Pathol-
ogy software. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
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5-1 qRT-PCR analysis of potential MYCASO o-target binding partner
transcripts. qRT-PCR for expression of potential o-target MYCASO
binding partnersTAF1A (A), INCENP (B), and PABPN1 (C) follow-
ing MYCASO treatment in HeLa cells (10 nM in Lipofectamine for 24
hours), HLF cells (10 mM unformulated for 120 hours), and CUTLL1
cells (10 mM unformulated for 72 hours) normalized to vehicle-treated
control. Values represent quadruplicate means +/- SD. Above each bar
graph are the sequences of the MYCASO and its potential off-target
binding partner; mismatches between the two are highlighted in red.
Transcripts seem to be particularly depleted following treatment with
the MYCASO that may serve as a potential binding partner, suggest-
ing off-target antisense activity. . . . . . . . . . . . . . . . . . . . . . 147
5-2 qRT-PCR analysis of dose- and time-proportional effects of MYCASO-
3 treatment on potential MYCASO off-target binding partner tran-
scripts. HeLa cells were transfected with 10 nM MYCASO-3 in Lipo-
fectamine 2000 for twenty-four hours. RNA was isolated and rela-
tive expression of transcripts was determined via qRT-PCR as de-
scribed in the methods. (A) Dose-proportional effects of MYCASO-3
treatment on potential MYCASO-3 off-target binding partner tran-
scripts. (B) Time-proportional effects of MYCASO-3 treatment on
potential MYCASO-3 off-target binding partner transcripts. (C) Time-
proportional effects of MYCASO-3 treatment on potential MYCASO-9
and MYCASO-13 off-target binding partner transcripts. Values repre-
sent quadruplicate means +/- SD. . . . . . . . . . . . . . . . . . . . . 149
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5-3 MYCASO-3-mediated cleavage of the TAF1A transcript. 5’ RACE
was carried out on HeLa cells after treatment for two hours with either
empty Lipofectamine 2000 vehicle or 10 nM MYCASO-3 formulated in
Lipofectamine 2000. Gene specific primers for the TAF1A transcript
were used. Vehicle-treated cells produce a band corresponding to the
size of the full-length TAF1A transcript, whereas MYCASO-3-treated
cells produce a fragment of the predicted size for cleavage of TAF1A
mRNA at the MYCASO-3 binding site. . . . . . . . . . . . . . . . . . 150
5-4 qRT-PCR analysis of dose-proportional effects of NT-ASO treatment
on potential off-target binding partner transcripts. HeLa cells were
transfected with the indicated doses of NT-ASO in Lipofectamine 2000
for twenty-four hours. RNA was isolated and relative expression of
transcripts was determined via qRT-PCR as described in the methods.
Values represent quadruplicate means +/- SD. . . . . . . . . . . . . . 151
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5-5 Transcriptomic analysis of MYCASO-3 treated cells. (A) RNA-sequencing
was performed on HeLa cells transfected with NT-ASO or MYCASO-3
(10 nM) for either 4 or 18 hours. Lipofectamine 2000 was used as a
delivery vehicle. mRNA reads that were mapped to MYC exons were
plotted for each sample, revealing a slight decrease in MYC -mapped
reads at 4 hours, and a pronounced effect at 18 hours, specifically with
MYCASO-3 treatment. (B) Volcano plots of gene expression differ-
ences comparing NT-ASO and MYCASO-3 treated cells with vehicle
after 4 and 18 hours. (C) Gene set enrichment analysis (GSEA) nor-
malized enrichment scores for MYC-associated gene sets (red and blue)
and the total C2 gene sets as part of MSigDB. Differential expression
analysis was performed with DESeq2 to generate MYCASO-3 specific
expression signatures and total ASO-treated signatures (NT-ASO and
MYCASO-3 samples) as described in Methods. (D) GSEA signatures
for two example gene sets of genes positively regulated by MYC (MYC
‘UP’). (E) GSEA signatures for two example gene sets of the interferon
response. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
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6-1 Pilot PRISM analysis of relative viability with MYCASO treatment
across a panel of cancer cell lines. The Broad Institute’s Profiling Rel-
ative Inhibition Simultaneously in Mixtures, or PRISM, assay was car-
ried out as previously described.[7] A panel of 100 cell lines was seeded
at a very low density in wells of a 12-well plate. Following seeding,
cells were treated with unformulated MYCASO, NT-ASO, or saline
vehicle control at the concentrations indicated. Every three days, cell
culture medium was replaced and cells were re-treated. After 7 or 14
days, cells were harvested, genomic DNA was isolated, and barcodes
were sequenced as described. Barcode frequency is presented as a heat
map, with blue representing lower frequency, or more cell death, and
white representing higher frequency, or more cell proliferation. Results
were normalized to the relative abundance of barcodes in the vehicle-
treated control samples, indicated as a heat map below the cell line
names, with green representing greater frequency. This pilot experi-
ment suggests that the PRISM assay can indeed be utilized to capture
a dynamic range of relative susceptibility to MYCASO treatment that
is both dose- and time-dependent. . . . . . . . . . . . . . . . . . . . . 166
B-1 Excellent concordance of mRNA expression is observed between repli-
cate RNA-seq samples. Transformed counts from RNA-seq samples
are compared between replicates. . . . . . . . . . . . . . . . . . . . . 174
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B-2 qRT-PCR analysis of potential MYCASO o-target binding partner
transcripts. qRT-PCR for expression of potential o-target binding
partners for MYCASO-3 (TAF1A, MTHFD1L, and COL16A1, top
row), MYCASO-9 (INCENP, RAB1B, and QARS, second row), and
MYCASO-13 (PABPN1, IFT140, and HIVEP2, bottom row) follow-
ing MYCASO treatment in HeLa cells (10 nM in Lipofectamine for 24
hours), HLF cells (10 mM unformulated for 120 hours), and CUTLL1
cells (10 mM unformulated for 72 hours) normalized to vehicle-treated
control. Values represent quadruplicate means +/- SD. Transcripts
seem to be particularly depleted following treatment with the MYC-
ASO that may serve as a potential binding partner, suggesting off-
target antisense activity. . . . . . . . . . . . . . . . . . . . . . . . . . 175
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Chapter 1
Background
1.1 The MYC Transcription Factor
One of the most commonly dysregulated genes across all human cancers codes
for the transcription factor MYC. The human MYC gene was identified in 1983.
Since then, there have been over 20,000 published articles on the function of MYC in
cancer alone. Despite the importance of this proto-oncogene and the immense interest
it garners throughout many different scientific disciplines, MYC-directed therapeutics
have yet to be realized. In this chapter we will introduce the biology of MYC, the role
MYC plays in cancer, various efforts towards developing drugs targeting MYC, and
the history and promise of antisense oligonucleotides, a technology we have harnessed
in a novel way towards the goal of developing MYC-targeting therapeutic modalities.
1.1.1 The Biology of MYC
The human MYC gene consists of 6 kilobases on chromosome 8 (cytogenetic band
8q24.21) (RefSeq NC_000008.11). The MYC pre-mRNA contains six distinct in-
trons, three exons, and eight alternative polyadenylation sites, and may be alterna-
tively spliced to produce eight different mRNA transcripts. Translation of the MYC
protein may be driven from two different promoters. The full-length functional MYC
protein acts as a transcription factor. MYC contains a basic helix-loop-helix DNA-
27
Figure 1-1: Crystal structure of the basic helix-loop-helix leucine zipper domains of
the MYC/MAX heterodimer bound to a DNA E-box sequence. Protein Database ID
1NKP.[1]
binding domain, which enables it to bind to E-boxes (canonical sequence: CACGTG)
throughout the genome to drive transcription of target genes. MYC also contains a
leucine zipper domain, enabling it to bind to other leucine zipper-containing tran-
scription factor proteins. A crystal structure of the basic helix-loop-helix leucine
zipper (bHLHZ) domains of the MYC/MAX heterodimer bound to a DNA E-box
sequence is shown in Figure 1-1.[1] In order to drive transcription of target genes,
MYC must bind to its obligate heterodimerization partner, the bHLH-leucine zip-
per transcription factor MAX. MYC may also bind to Miz1, a heterodimer that
purportedly represses transcription.[8] Binding of MYC/MAX heterodimers to gene
promoters leads to active transcription through a number of different mechanisms.[9]
The N-terminus of the MYC protein acts as a transactivation domain, recruiting hi-
stone acetyltransferase activity such as TRRAP, SAGA, P300, and CBP proteins,
chromatin remodeling machinery, and other chromatin regulators such as Mediator,
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Figure 1-2: Cellular processes control by MYC during normal conditions and during
tumorigenesis.[2]
with the result that MYC/MAX binding leads to histone acetylation and opening
up of the chromatin at target gene promoters, important first steps for transcrip-
tional activation.[9, 10, 11, 12] Furthermore, MYC plays a role in RNA Polymerase
II pause-release, stimulating promoter clearance and transcriptional elongation.[13]
Additionally, MYC drives the transcription of genes involved in ribosome biogene-
sis and protein synthesis and stimulates RNA Polymerase I and RNA Polymerase
III-driven transcription of rRNA and tRNA, resulting in an overall increase in pro-
tein synthesis.[12, 14] The result of these various activities of the MYC protein is an
overall increase in transcription and translational output.
MYC is often referred to as a ‘master transcriptional regulator.’ With greater
than 10,000 binding sites throughout the human genome, MYC coordinates a tran-
scriptional regulatory network that consists of approximately 15% of all genes.[15]
The MYC target gene network is extremely large and diverse. While it has been dif-
ficult to define the target genes regulated by MYC, and even more difficult to reach a
consensus within the field on the nature of these gene sets, it is generally agreed that
MYC specifically controls gene expression programs responsible for cell proliferation,
growth, metabolism, and evasion from apoptosis (Figure 1-2).[2, 15, 16]
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1.1.2 MYC Deregulation in Cancer
The MYC gene is one of the most commonly dysregulated genes across all hu-
man cancers. MYC deregulation can occur genetically, epigenetically, and post-
transcriptionally through a wide variety of non-redundant mechanisms (Figure 1-
3).[17] MYC is the most commonly amplified gene in cancer, with genomic copy-
number amplifications arising through genome doubling or tandem duplication lead-
ing to dramatically increased transcription and translation of MYC.[18] Pan-cancer
analyses of at least twelve cancer types have estimated the frequency of MYC ampli-
fication at approximately fourteen percent. Furthermore, MYC copy number often
correlates with disease prognosis, metastatic potential, therapeutic resistance, and
poor patient outcomes.
Another common mechanism of MYC dysregulation is translocation of the MYC
gene. MYC is commonly translocated to positions under the control of highly ac-
tive linage-specific enhancers. One well-studied example of this occurs in Burkitt’s
Lymphoma. In this disease, MYC is translocated to a region under the control of
the immunoglobulin heavy chain or light chain enhancers in a B cell population,
leading to constitutively high levels of MYC expression from the lineage-specific Ig
enhancers.[19, 20]
The activity of the endogenous MYC enhancer is sometimes observed to be in-
creased in malignancies. MYC is located in a gene desert, surrounded by MYC -
specific, lineage-specific enhancers. Genetic and epigenetic mechanisms may function
to dysregulate MYC expression. Two point mutations within the MYC gene desert
have been experimentally shown to influence MYC transcription and are associated
with increased cancer risk. Hyperacetylation and hypomethylation of lineage-specific
enhancers leading to hyperactivation of theMYC locus has been observed in a variety
of different cancers. Finally, duplication of enhancers has been observed in several
different cancer types, leading to enhanced transcription of MYC.
MYC deregulation may occur at the protein level, as well. The MYC protein has
a particularly short half-life of approximately twenty to thirty minutes.[21] A variety
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Figure 1-3: Mechanisms of MYC deregulation in cancer.[3]
31
of point mutations have been shown to enhance the stability of the MYC protein,
leading to higher levels of MYC protein within the cell. A missense point mutation
within MYC that changes threonine-58 to an alanine has been identified in a number
of different malignancies. Phosphorylation of Thr58 leads to MYC degradation, and
the T58A mutation has been shown to increase MYC protein stability, though this
result is not consistent and may be context-dependent. Furthermore, mutations in the
ubiquitin protein ligase complex subunit FBXW7 abrogate the ubiquitin-mediated
degradation of MYC protein, leading to increased MYC levels.
TheMYC gene resides downstream of many signaling pathways that are often dys-
regulated in cancer. Activation of these pathways often leads to increased MYC ex-
pression. For example, NOTCH1 interacts with a long-range MYC enhancer to drive
MYC expression, and activating mutations in NOTCH1 are observed in over sixty-
five percent of all T-cell leukemias, leading to increased MYC expression.[22] Other
pathways implicated in deregulated MYC expression in cancers include phosphat-
dylinositol 3-kinase-Protein Kinase B (PI3-Akt) signaling, mitogen-activated protein
kinase signaling (MAPK), the Janus kinase-signal transducer and activator of tran-
scription (JAK-STAT) signaling pathway, the estrogen receptor signaling pathway,
and the WNT/b-catenin pathway.
Through these widely varied mechanisms, MYC is among the most commonly
dysregulated genes across all cancers. While it is understood that dysregulated MYC
can dramatically alter cellular transcriptional programs, the precise mechanism for
its oncogenic activity remains an area of unresolved debate. Charles Lin et al. in-
troduced a model in 2012 based on the results of chromatin immunoprecipitation-
sequencing analyses in a variety of different cancer cells lines of oncogenic MYC as
a global transcriptional amplifier that non-specifically invades all active promoters
and enhancers.[23] Arianna Sabo et al. and Susanne Walz et al. published rebuttals
to this model in 2014 and proposed a different model in which MYC activates and
represses transcription of discrete gene sets, specifically the hallmark expression pro-
grams responsible for cancer cell proliferation, growth, metabolism, and evasion from
apoptosis.[24, 25] Nevertheless, the widespread pleiotropic transcriptional changes in-
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duced by deregulated MYC act to potently transform cells to an oncogenic phenotype.
Cancers with high levels of MYC have been experimentally shown to be ‘addicted’
to its expression, such that inhibition of dysregulated MYC expression leads to rapid
proliferative arrest and apoptosis of tumor cells.[26] It appears that the pathologic
levels of MYC present in these cancer cells are implicated in so many processes cru-
cial to the oncogenic phenotype (rapid growth and proliferation, high metabolism,
evasion from apoptosis) that reduction in the levels of MYC and MYC signaling is
non-compatible with cancer cell survival and leads to a rapid arrest of growth and
induction of apoptosis.
1.1.3 Drugging MYC
Due to the high prevalence of MYC dysregulation in human cancers and the
observation that cancers with high levels of MYC are addicted to its expression, efforts
aimed at developing MYC-directed therapeutics have been in motion for decades.
However, none of these efforts has yet resulted in a successful clinical application.
Here we review the efforts to date towards MYC-targeting therapies.
Many targeted cancer therapeutics rely on differences in structure between a mu-
tated onco-protein and the wild-type form to differentiate between pathological and
physiological in the targeting process. However, because MYC functions in cancers
through over-expression and hyper-activation, it is not possible to design a drug to dif-
ferentiate between physiologic and pathologic in such a setting. Concerns understand-
ably exist over whether administering a drug to inhibit MYC would lead to intolerable
and unacceptable toxicities through the drug’s action on MYC function in healthy tis-
sues. In 2008, Laura Soucek et al. addressed this issue utilizing a peptide construct
named Omomyc that dimerizes with the MYC protein and sequesters it into non-
functional complexes, effectively acting as a MYC dominant negative.[27, 28, 29, 30]
Through conditional expression of this peptide in transgenic mice, the authors showed
that MYC inhibition led to potent and rapid tumor regression. Furthermore, systemic
MYC inhibition exerted profound effects on normal regenerating tissues, including
the skin, testes, and intestines. These results are consistent with studies of MYC in
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healthy cells and tissues reporting that MYC is essential for growth and proliferation
of stem cell populations, but that differentiated cells seem to be less dependent on
MYC for their function.[31, 32, 33] However, these effects were well tolerated by mice
over extended periods and were rapidly and completely reversible. The high uncon-
trolled metabolic, growth, and proliferative activity of cancer cells seem to make them
particularly sensitive to MYC inhibition, whereas healthy stem cell populations that
grow and proliferate in a much slower, more controlled manner seem to be able to
tolerate MYC inhibition. These findings suggest that pharmacologic MYC inhibi-
tion may indeed be a viable cancer therapeutic strategy with an evident therapeutic
window.
The failure to develop MYC-directed therapeutics is due in part to the perceived
intractable or ‘undruggable’ nature of MYC, and transcription factors in general,
which function typically through interfacial protein-protein and protein-DNA inter-
actions that have historically been difficult to disrupt with small molecules.[34] To-
wards the goal of overcoming these historical limitations, small molecules have been
developed to block MYC/MAX dimerization.[35, 36, 37, 38, 39, 40] However, these
molecules exhibit low potency, display poor selectivity, and lack antitumor efficacy
in vivo. Importantly, none of them has exhibited activity promising enough to enter
clinical trials.
As an alternate MYC-targeting strategy, BET bromodomain inhibitors have been
employed to disrupt transcription of the MYC gene.[41, 42, 43] Members of the bro-
modomain and extraterminal (BET) subfamily of bromodomain proteins (BRD2,
BRD3, and BRD4) associate with acetylated chromatin and facilitate transcriptional
activation by mediating protein-protein interactions and increasing the effective mo-
larity of recruited transcriptional activators.[44] A major function of BRD4 is the
recognition of acetylated histones found in transcriptionally active regions of chro-
matin and the recruitment of transcriptional activators. BRD3 and BRD4 are known
to drive oncogenesis.[45] The first biologic validation of BRD4 as a therapeutic tar-
get was established by an RNAi screen in a mouse model of AML that revealed
that knockdown of BRD4 decreased disease progression.[43] Pharmacologic inhibi-
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tion of bromodomains is thought to selectively target malignant cells by disrupt-
ing chromatin-mediated signal transduction and thus reducing transcription at onco-
gene loci, most notably MYC.[41, 43, 46, 47] Furthermore, MYC drives transcription
at target genes through recruitment of co-activators such as the positive transcrip-
tion elongation factor complex b (P-TEFb) that also interact with BET proteins.[13]
Studies of BET inhibition in several cancer models demonstrate that downregulation
of MYC expression is associated with robust anti-proliferative effects with demon-
strations of therapeutic efficacy in murine tumor models. However, tumor-bearing
mice are not cured and relapse is characterized, in part, by reinforced expression of
MYC.[48, 49, 50, 51, 52]
An alternative strategy for targeting MYC aims to stabilize the G-quadruplex
of the MYC mRNA. A G-quadruplex is a tertiary structure formed in nucleic acid
molecules by sequences that are rich in guanine, and the MYC promoter region forms
such a structure.[53] The G-quadruplex sterically blocks and displaces transcription
factors from the MYC promoter and inhibits MYC transcription. Efforts towards
developing small molecules to bind and stabilize the MYC G-quadruplex to inhibit
transcription have been undertaken by several groups.[54, 55, 56, 57] Notably, CX-
3543, or Quarfloxin, is the only G-quadruplex stabilizer to have reach clinical trials,
having undergone Phase II trials for neuroendocrine tumors and chronic lymphocytic
leukemia.[58] However, it was also shown to function by disrupting nucleolin bound to
G-quadruplexes in ribosomal DNA, suggesting that the molecule may inhibit MYC
expression by a more indirect route.[59, 60, 61] Development was discontinued by
Cyclene, although Quarfloxin was licensed to TetraGene in 2013, and the future of
the drug is unclear at this time.
Further alternative strategies undertaken for targeting MYC include developing a
small protein to bind to the E-box binding sites of MYC target genes [62]; searching for
novel interactions between MYC and other chromatin-associated proteins that form
potentially druggable surfaces; targeting downstream processes that drive oncogene-
sis, such as ribosome biogenesis and spliceosome function; designing drugs to block
the interaction of the unique MBII domain with cofactors as a strategy to selectively
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target the oncogenic properties of MYC but not its function in normal healthy cell
proliferation [9]; and designing small molecules to bind and sequester MYC’s obli-
gate heterodimerization partner MAX (unpublished work). These strategies present
certain limitations, including lack of specificity, and require discoveries in medicinal
chemical synthesis and molecular biology such that development of these proposed
therapeutics had not yet been realized.
A final strategy for targeting MYC involves specific targeting of the MYC mRNA
transcript utilizing antisense oligonucleotide technology.
1.2 Antisense Oligonucleotides
1.2.1 Introduction to Antisense Oligonucleotides
Bennett and Swayze provide the following definition for antisense oligonucleotides
(ASOs): “oligonucleotides that are 8 to 50 nucleotides in length that, in toto or in
part, bind to RNA through Watson-Crick base pairing and upon binding to RNA,
modulate the function of the targeted RNA.”[63] The definition of ASOs is typi-
cally limited to single-stranded molecules, and we will adopt that restriction here.
The modification of gene expression using synthetic single-stranded DNA to inhibit
mRNA translation was demonstrated for the first time by Paterson et al. in 1977
in a cell-free system.[64] Soon after that Zamecnik and Stephenson showed that in
chicken fibroblast tissue culture containing Rous sarcoma virus, addition of a syn-
thetic 13-mer oligodeoxynucleotide complementary to the 3’ terminal sequence of the
Rous sarcoma virus could inhibit viral replication and transformation of fibroblasts
into sarcoma cells.[65, 66] These seminal papers and thousands that have followed
have paved the way for enormous progress towards the development of ASOs as new
class of drugs.[5] Since then, advancements have been made in chemical modification
of ASOs to improve stability and activity, in ASO synthesis to decrease cost and
increase access, in human genome sequencing and understanding of the underlying
biology of diseases to expand the list of targets, in ASO delivery techniques, and in
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understanding of ASO mechanism, pharmacology, and pharmacodynamics. Here we
will review some of those advancements, particularly those pertinent to the develop-
ment of MYC-targeting ASOs.
1.2.2 Mechanisms of Antisense Oligonucleotide Activity
Antisense oligonucleotides can modulate the function of target RNA through a
variety of different mechanisms (Figure 1-4). ASOs that bind to mRNA and recruit
RNase H to induce transcript cleavage are the best-understood class of ASOs and
account for the majority of ASO drugs in development.[63] RNase H is a family of
enzymes present in all mammalian cells that recognizes RNA/DNA heteroduplexes
and cleaves the RNA strand, releasing an intact DNA strand.[67, 68] RNase H1 has
been implicated in mediating target RNA cleavage directed by ASOs composed of
deoxynucleotides, though other RNase H activity is thought to play a role as well.[69]
The RNase H mechanism has proven to be a robust antisense mechanism and is
broadly exploited as both a research tool and a potential human therapeutic.
Sterically blocking translation of an mRNA is the prototypical antisense mecha-
nism and is often referred to as translation or hybridization arrest.[63] Such ASOs
are typically designed to bind near the translation initiation region of the target
mRNA and are thought to block the scanning of the 40S ribosomal subunit along the
transcript, block the assembly of the 40S and 60S ribosomal subunits, or block the
movement of the ribosome down the transcript. The sequence limitations for an ASO
utilizing this mechanism are severely limiting, and translation arrest is not widely
used as a therapeutic strategy.
An additional antisense mechanism functions by interfering in RNA intermedi-
ary metabolism. Most mRNAs undergo a complex series of processing steps that
include splicing, polyadenylation, and addition of a 5’ cap.[70] It has been estimated
that approximately ninety percent of mRNA transcripts exhibit alternatively spliced
variants in human cells [71], and many transcripts contain alternate polyadenyla-
tion sites.[72, 73] Furthermore, there are many diseases caused by aberrant RNA
intermediary metabolism; such disease settings present opportunities for ASO-based
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Figure 1-4: Mechanisms of antisense oligonucleotide activity. In the absence of ASO,
normal gene and protein expression is maintained (1). The ASO is taken up by cel-
lular endocytosis and can hybridize with target mRNA in the cytoplasm. Formation
of an ASO/mRNA heteroduplex induces (2) activation of RNase H, leading to se-
lective degradation of bound mRNA or (3) steric interference of ribosomal assembly.
Alternatively, the ASO can enter the nucleus and regulate mRNA maturation by (4)
inhibition of 5’ cap formation, (5) inhibition of mRNA splicing, or (6) activation of
RNase H. All of these activities lead to inhibition of target protein expression.[4]
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therapeutics.[74] Numerous studies have demonstrated that ASOs are capable of bind-
ing to pre-mRNA and modulating RNA splicing both in vitro and in vivo by masking
splicing enhancer and repressor sequences.[75, 76, 77, 78, 79, 80, 81] ASOs have also
been employed to modulate polyadenylation site selection in a transcript.[82] These
results support the contention that antisense oligonucleotides represent a unique ther-
apeutic strategy for treatment of diseases of RNA intermediary metabolism.[63] In-
deed, an ASO functioning through modulation of splicing of the dystrophin pro-
tein was approved by the FDA in 2016 for the treatment of Duchenne Muscular
Dystrophy.[83, 84]
ASOs consisting of ribonucleotides may function through a mechanism that mim-
ics the natural pathway through which microRNAs regulate expression of gene prod-
ucts. [85, 86] This mechanism is not fully understood, but it is known that the ASO
is bound by the Argonaute 2 protein in the RISC complex, and a seed region six to
eight nucleotides in length at the 5’ end of the ASO hybridizes to a sequence that
occurs predominantly in the 3’-untranslated region of the target mRNA to induce
degradation of the target transcript and/or block protein translation. Because the
length of the hybridization sequence is so short, a single ASO acting in this fashion
may regulate hundreds of different mRNAs.[87]
ASOs have also been designed to be complementary to microRNAs, functioning
by binding to the microRNA and inhibiting its function.[88, 89, 90, 91, 92] While
the details of this mechanism are not fully understood, as our knowledge of the
contribution of microRNAs to disease increases, it is likely that microRNA agonists
and antagonists will become important therapeutic strategies.[63]
There are many different types of RNA molecules within a cell that carry out
many different physiological and pathological functions, and these RNAs may form a
variety of secondary and tertiary structures.[74, 93, 94, 95] ASOs may be utilized to
disrupt RNA structures. A well-characterized example is design of an ASO to bind to
the conserved stem-loop transactivator response RNA structure present in the 5’-end
of HIV transcripts, preventing its binding to the HIV protein Tat, thereby inhibiting
an important step in viral replication.[96, 97] This strategy has also been employed
39
to design ASOs for the treatment of triplet repeat disease, in which nucleotide re-
peats within protein-coding transcripts form pathologic structures that alter mRNA
function.[98, 99]
A novel approach for selectively decreasing the expression of a target RNA was re-
cently described.[100] The authors designed a bifunctional oligonucleotide containing
a sequence that targeted the U1 snRNA splicing factor and a sequence complementary
to the target RNA sequence, thus tethering U1 snRNPs to the targeted RNA. When
the target site was 3’ to a site near the conserved polyadenylation sequence, the com-
plex inhibited polyadenylation, resulting in degradation of the transcript. Although
the authors addressed some of the concerns regarding depletion of U1 snRNA with
the synthetic oligonucleotide, concerns about the long-term safety and specificity of
this approach remain. In addition to the nucleases mentioned above, numerous other
nucleases and natural RNA-degrading pathways that are present in cells, such as
nonsense-mediated decay, could potentially be harnessed to promote selective degra-
dation of RNAs.[63, 101]
Other approaches that have been developed to promote selective cleavage of RNA
include ribozymes and DNAzymes in which the oligonucleotide possesses inherent
catalytic activity.[102, 103, 104] Although ribozymes and DNAzymes have shown
promise in cell culture experiments, they have not proven to be as effective in vivo as
some other approaches and have largely been abandoned as a therapeutic strategy for
targeting RNA.[63] Approaches to attach chemical warheads such as metallonucleases
to oligonucleotides as a means to promote selective RNA degradation have shown
encouraging activity in cell-free assays.[105, 106] These approaches have proven to
be difficult synthetically and currently do not appear to offer an advantage over
simpler approaches that take advantage of endogenous nucleases present in cells.[63]
Additionally, ribonucleoprotein complexes such as telomerase that require RNA to
carry out their function are amenable to targeting with ASOs in a unique way.[107,
108]
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1.2.3 Chemical Modifications of Antisense Oligonucleotides
The very first antisense oligonucleotides utilized for laboratory manipulation of
protein expression were single-stranded unmodified deoxyribo-oligonucleotide molecules.
[64, 65, 66] The past forty years have seen significant development in the chemistry of
modifying antisense oligonucleotides (Figure 1-5).[109, 110] These chemical advance-
ments have brought enhanced ASO stability in vitro and in vivo and improved ASO
affinity for target mRNA. Scientifically and clinically relevant ASO modifications will
be reviewed here.
First-Generation Chemistry
First-generation modifications to ASOs consist of modifications to the oligonu-
cleotide backbone. Specifically, one of the non-bridging oxygen atoms in the phos-
phate group between two nucleotides is replaced with a sulfur atom to form a phos-
phorothioate linkage, with a methyl group to form a methyl phosphonate linkage, or
with an amine to form a phosphoramidate linkage. These modifications confer nucle-
ase resistance.[111] They also enhance binding to serum proteins in vivo; these two
properties confer a longer circulation half-life to ASOs with first-generation modifica-
tions. [112] The phosphorothioate substitution is the most commonly employed. This
modification is minimally disruptive: it is easy to synthesize, does not disrupt the
negatively charged backbone that aids in ASO delivery, and is capable of functioning
through all of the antisense mechanisms discussed above. However, it is important
to note that first-generation modifications produce various non-specific side effects in
vivo, such as immune stimulation and complement activation, predominantly caused
by their interactions with proteins. It is rare that an ASO synthesized today will not
contain first-generation modifications.
Second-Generation Chemistry
Second-generation ASOs incorporate 2’-alkyl ribose substituents. The most com-
monly employed modifications are the additions of 2’-O-Methyl and 2’-O-Methoxyethyl
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Figure 1. Structure of fi rst, second and third generation antisense oligonucleotides.
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Figure 1-5: Chemical modifications of antisense oligonucleotides. Structure of first,
second, and third generation antisense oligonucleotides.[5]
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moieties.[113] These modifications enhance nuclease resistance and increase binding
affinity for target mRNA. However, the useful effects of these modifications are damp-
ened by the fact that they render modified nucleotides unrecognizable by RNase
H.[114] To maintain RNase H-recruiting capability, chimeric ASOs were developed,
in which a central gap region consisting of deoxyribonucleotides is surrounded on
both sides by modified nucleotides, known as ‘gapmers.’ This design strategy allows
for the recruitment of RNase H by the central gap region for target-specific mRNA
degradation while the modified ASO ends protect from nuclease degradation and con-
fer enhanced binding affinity for target mRNA.[115] Second-generation modifications
are widely employed.
Third-Generation Chemistry
Third generation ASOs involve chemical modification of the nucleotide furanose
ring. These include insertion of bridging atoms between the 2’ and 4’ positions to form
a locked (one-atom insertion) or a bicyclic (two-atom insertion) nucleic acid, replace-
ment of ribose with a morpholine ring to form a morpholino ASO (together with
phosphoramidate linkage modifications), and replacement of the sugar-phosphate
backbone with peptide bonds to form a peptide nucleic acid.[4, 5, 63] These modifi-
cations function to improve stability, as they are essentially resistant to degradation
by nucleases and peptidases. They also function to dramatically enhance binding
affinity for target mRNA. For example, the locked nucleic acid (LNA) modification
offers unprecedented gains in affinity for complementary sequences.[116, 117] The 2’-
O,4’-C -methylene bridge modification serves to conformationally restrict the sugar
moiety, locking it into a C3’-endo pucker or northern conformation. Incorporation
of several LNA-modified nucleotides into an ASO forces the entire molecule to orga-
nize into an A-form geometry, the conformation adopted by DNA in a DNA/RNA
duplex. A constrained LNA-modified ASO thus experiences large entropic gains in
binding affinity compared to an unmodified ASO that is less conformationally re-
strained and more flexible, able to adopt several geometries.[118, 119, 120] Similar
to the second-generation modifications described above, third-generation modifica-
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tions abrogate RNase H recruitment, and these modifications are often deployed in a
gapmer design scheme. Third-generation modifications are widely utilized. Their ac-
tivity is being actively studied, and the mechanisms behinds observations of toxicity
are being actively investigated.[121, 122, 123]
1.2.4 Delivery of Antisense Oligonucleotides
Antisense oligonucleotides face many obstacles to successful delivery both in vitro
and in vivo.[124, 125] In vitro, ASOs must avoid degradation in the culture medium,
enter the cell despite their large size and hydrophilicity, escape the endosome, and
bind to the appropriate cellular machinery. In vivo, ASOs must survive the patient’s
bloodstream, including avoiding phagocytosis, opsonization, aggregation with serum
proteins and red blood cells, and enzymatic degradation by endogenous nucleases;
avoid clearance by the kidneys; pass through the capillary endothelium and into the
target organ; travel through the dense extracellular matrix, which has both a physical
barrier to transport and phagocytic cells; enter the cell; escape the endosome; bind
to the appropriate cellular machinery; and avoid interactions with non-target cells,
i.e., exhibit cellular specificity.
A significant advantage of antisense oligonucleotides is that, despite these chal-
lenges, they can be delivered into most cells without the aid of any delivery formu-
lation. This property endows many advantages in vitro and in vivo, eliminating the
need for costly and toxic transfection reagents and complex chemical synthesis meth-
ods that limit application and complicate experimental results. However, cellular
uptake of ASOs is incompletely understood and varies widely based on cell type and
ASO sequence. Understanding of the mechanisms behind ASO uptake and intracel-
lular trafficking are necessary to elucidate the rules governing cellular- and sequence-
specificity of ASO delivery, which will help guide more efficient and effective ASO
design.
Stanley Crooke et al. published a review in 2017 of the current understanding of
cellular uptake and trafficking of ASOs.[126] Many cell surface receptors have been
implicated in ASO uptake, including Stabilin 1 and 2 and other scavenger receptors,
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Toll-like receptors, and the low density lipoprotein receptor (LDL-r). Cellular up-
take is amenable to medicinal chemical efforts, and conjugation of ligands to ASOs
has been shown to significantly enhance uptake; for example, conjugation of N-acetyl
galactosamine (GalNac) to ASOs enables internalization by the asialoglycogprotein
receptor (ASGPR) to enhance delivery to hepatocytes.[127] Furthermore, many in-
tracellular proteins have been shown to bind ASOs, including several known nucleic
acid binding proteins such as the helicase proteins ku70 and ku80, chaperone proteins
such as heat shock protein 90 (hsp90), and annexin A2.[128, 129] Pathways of ASO
trafficking within the cell are being elucidated. The path an ASO takes within a cell
may be classified as either productive or non-productive based on whether the ASO
is able to exert its function. It appears that a relatively small fraction of ASOs enter
cells through productive pathways.[130, 131] There is evidence that uptake via non-
productive pathways results in ASO accumulation in late endosomes and lysosomes,
where the compounds are non-functioning.[132] Importantly, these results seem to be
context specific, influenced by cell type, cell physiologic state, chemical modifications
incorporated into the ASO, and ASO sequence.[125, 133, 134] Our understanding of
ASO uptake and trafficking has grown immensely in recent years. However, there is
still much progress to be made to further elucidate the mechanisms at work and to
achieve a level of understanding that aids in improved ASO design.
Due to the difficulties of ASO delivery and the large number of unknowns sur-
rounding the process, ASOs are often delivered in vitro and in vivo with the aid of
delivery formulations. Ideally, optimal delivery may be achieved by placing an ASO
within a carefully designed delivery vehicle that minimizes the above-mentioned ob-
stacles to delivery. Furthermore, one may intentionally design the properties of the
system to achieve the desired in vitro and in vivo behavior. Delivery systems have
been utilized clinically since 1990 to deliver various small molecule drugs.[135] Various
approaches have been used for creating antisense delivery systems: direct chemical
modifications of the ASO structure, peptides/polymers/aptamers conjugated directly
to the ASO for increased stability and targeting, and nanoparticles in which the ASO
is incorporated and safely transported to the target site.[124, 125, 135] An expan-
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sive literature in drug delivery has identified formulations from large collections of
lipids and polymers that successfully facilitate nucleic acid delivery to hepatocytes
[136, 137, 138], monocytes [139], and endothelial cells.[140] However, very little work
has been done on drug delivery to other cancer-relevant cell types, tissues, and or-
gans. In fact, unformulated and formulated ASOs alike are predominantly delivered
in vivo to the liver and, to a lesser extent, to the kidneys.[141, 142] This has severely
limited the application of ASOs and the diseases that are amenable to translation of
effective ASO therapeutics.
Greater understanding of the processes underlying ASO delivery in vitro and in
vivo and further efforts towards developing improved delivery formulation methods are
necessary for the successful advancement of antisense oligonucleotides as a therapeutic
class, especially for treatment of diseases in difficult-to-target organs and tissues.
1.2.5 Clinical Status of Antisense Oligonucleotides
The first antisense oligonucleotide drug to be approved by the FDA was Vitravene,
or Fomivirsen, a 21-mer modified with phosphorothioate linkages targeted against the
human cytomegalovirus IE2 transcript as a treatment for CMV in AIDS patients,
approved in 1998.[143] Approval of Vitravene was hailed as a major milestone for
the biotechnology industry and was widely anticipated to usher in a new era of an-
tisense therapeutics.[144] However, this potential was not realized and excitement
around antisense therapeutics died out. Vitravene was pulled from the market due
to development of better therapies, and no new ASO therapies had hit the market.
Furthermore, pharmaceutical companies were eliminating their research and develop-
ment programs in antisense technology. For a while, it seemed as though antisense
oligonucleotide therapeutics had been a brief and disappointing fad.
Fifteen years after that first approval, antisense oligonucleotides finally seem
ready to make a clinical impact. In 2013, Isis Pharmaceuticals (now Ionis Phar-
maceuticals) achieved FDA approval for Kynamro, or mipomirsen, an ASO targeted
against the apolipoprotein B-100 transcript for the treatment of homozygous familial
hypercholesterolemia.[145, 146, 147] In 2016, Sarepta Therapeutics achieved acceler-
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ated FDA approval for Exondys 51, or eteplirsen, an ASO targeted against dystrophin
for the treatment of Duchenne Muscular Dystrophy.[83, 84] Also in 2016, Ionis Phar-
maceuticals and Biogen received FDA approval for Spinraza, or nusinersen, an ASO
targeted against SMN2 as the first approved drug for the treatment of the rare neu-
romuscular disorder spinal muscular atrophy.[148]
Antisense oligonucleotide therapeutics seem to have overcome those initial hurdles
at last, and a vast literature investigating ASO activity, mechanism, specificity, ap-
plications, toxicity, etc. attests to the effort invested in developing this drug class and
the growth the field has experienced. Capitalizing on this wealth of knowledge and on
recent clinical successes and renewed global interest in antisense technology, we be-
lieve that we are well poised to pursue the development of antisense oligonucleotides
targeted against the MYC proto-oncogene as prototypical cancer therapeutics.
1.2.6 Other Nucleic Acid-Based Strategies for Targeting MYC
We want to take a moment to mention other nucleic acid-based modalities that
have been explored as MYC-targeting agents. Notably, Dicerna Pharmaceuticals
developed a liposome-encapsulated siRNA targeted against MYC.[149] siRNA func-
tions through the RNA interference, or RNAi, pathway.[150] In the RNAi mecha-
nism, double-stranded RNA molecules approximately twenty nucleotides in length
are bound by the RISC protein complex, which separates the two RNA substrate
strands and loads one onto the complex member Argonaute 2.[151, 152, 153, 154, 155]
This haloenzyme binds to mRNA complementary to the loaded RNA strand and in-
duces cleavage of the target mRNA.[156, 157] RNAi is a well-studied mechanism,
and siRNAs are commonly employed for studies of gene expression modulation in the
lab and as investigational therapeutics.[158, 159, 160] Dicerna’s anti-MYC siRNA
formulation demonstrated potent activity in vitro and in vivo in a variety of differ-
ent cancer models and entered phase I and II clinical trials in 2014 in patients with
advanced solid tumors, hematological malignancies, pancreatic neuroendocrine tu-
mors, and advanced hepatocellular carcinoma (ClinicalTrials.gov NCT02110563 and
NCT02314052). However, Dicerna discontinued development of its MYC-targeting
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siRNA in 2016 because preliminary results did not meet the company’s expectation
for further development.[161]
Triplex-forming oligonucleotides (TFOs) are ASOs that bind to double-stranded
DNA to inhibit transcription of the target mRNA.[162] TFOs designed to target
the MYC promoter are associated with growth arrest and induction of apoptosis in
leukemia and lymphoma cell lines.[163, 164, 165] Tetraplex-forming oligonucleotides
have also been explored for their ability to inhibit transcription initiation of MYC,
such as G-quadruplex-forming oligonucleotides that bind to the MYC promoter,
which inhibit the growth of Burkitt lymphoma cells in vitro.[166]
An additional approach involves the use of decoy oligonucleotides, which compete
with DNA for transcription factor binding. Double-stranded decoy oligonucleotides
containing the MYC consensus E-box binding site decreased the proliferation of breast
tumor cells and neuroblastoma cells in vitro.[167] Decoy oligonucleotides have also
been designed to mimic transcription factor binding sites within the MYC promoter,
such as the binding site for b-catenin, which reducedMYC expression and significantly
inhibited the growth of colon cancer cells in vitro.[168, 169]
While alternative nucleic acid-based approaches present novel and promising po-
tential strategies for targeting MYC, none has achieved clinical success to date.
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Chapter 2
MYC-Targeting Antisense
Oligonucleotides
2.1 Introduction
A MYC-targeting drug could potentially have a broader impact in cancer treat-
ment than any other therapy in use today, yet such an entity has yet to be realized,
highlighting the need for new approaches and ways of thinking. Due to the diffi-
culty of targeting MYC transcription [48, 49, 50, 51] and the MYC protein product
[34], inhibition of translation through targeting of MYC mRNA represents a promis-
ing strategy for MYC inhibition. Indeed, antisense oligonucleotides (ASOs) targeted
against MYC have been employed to modulate its expression in the laboratory for
nearly as long as the oncogenic role of the protein has been known. The first reported
use of a MYC-targeting ASO was in 1986, when Erica L. Wickstrom et al. at the
University of South Florida published an abstract stating that an unmodified single-
stranded deoxyribo-oligonucleotide molecule targeted against the first 15 bases of the
MYC mRNA coding sequence knocked down MYC protein expression and inhibited
the growth of HL-60 promyelocytic leukemia cells, work which was published in a jour-
nal in 1988.[170, 171] In 1987, Reino Heikkila et al. at the NIH published an article
stating that this same molecule inhibited mitogen-induced MYC protein expression
and prevented S phase entry in human T lymphocytes.[172] In 1988, additional work
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confirmed these findings.[173, 174]
The next steps forward in MYC-targeted ASO development came in 1996. Carlo
Leonetti et al. at the Regina Elena Cancer Institute in Rome synthesized a deoxyribo-
oligonucleotide of the same sequence with a phosphorothioate backbone, a common
ASO modification that enhances stability.[175] This molecule inhibited the growth of
human melanoma cells in vitro through induction of apoptosis and led to inhibition of
tumor growth, reduction of metastases, and improved survival in a murine melanoma
xenograft model.
In 2000, this molecule entered clinical trials under Inex Pharmaceuticals as INX-
3280 for the treatment of solid tumors and lymphoma. However, during those inter-
vening years, the company discovered that the observed anti-cancer efficacy of the
molecule was due not to anti-MYC antisense activity, but instead to immune stim-
ulatory activity of a CpG motif within the molecule.[176] Their 1999 annual report
stated, “We have clearly demonstrated that the dominant effect of oligonucleotides is
to provoke the body’s immune system to mount in a very unique way an attack against
cancer.”[177] While the molecule continued to be developed for cancer treatment, it
was functioning predominantly in an antisense- and MYC-independent fashion (INX-
3280 was discontinued in 2002 during Phase II trials for lymphoma and solid tumors).
Indeed, recognition that what was thought to be on-target antisense activity is actu-
ally off-target, non-antisense activity became something of a pattern.[178]
In 2003, AVI BioPharma (now Sarepta) synthesized a MYC-targeting antisense
molecule utilizing third-generation chemistry.[179] The molecule, named AVI-4126,
was a phosphorodiamidate morpholino oligomer (PMO) that targeted the translation
initiation codon of immature MYC pre-mRNA. In a PMO molecule, the deoxyribose
moiety of DNA is replaced with a 6-membered morpholine ring, and the phosphodi-
ester backbone is replaced with phosphorodiamidate linkages. PMOs offer the advan-
tage of nuclease resistance.[63] The mechanism of action of PMO molecules does not
involve RNase H, as the endogenous enzyme cannot recognize the PMO structure,
but rather involves both steric blockade of translation machinery and interference
with splicing in pre-mRNA, thereby preventing translation of the appropriate mature
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mRNA. AVI’s molecule led to a significant reduction in tumor burden in a murine
prostate cancer model. They conducted a phase I safety study of the PMO in humans
that showed no toxicity or serious adverse events, and the commonly observed side
effects associated with phosphorothioate-based antisense oligonucleotides were not ob-
served. Phase Ib studies showed distribution of AVI-4126 to tumors in prostate and
breast cancer patients following unformulated intravenous injection.[180] In 2007, the
molecule inhibited lung metastasis and decreased tumor burden in a murine lung
cancer model.[181] This study revealed that AVI-4126 directs mis-splicing of MYC
pre-mRNA in vivo. There are no additional reported data on this molecule in cancer,
and the latest reports indicate that all trials have been discontinued.
In 2009, Richard V. Giles et al. synthesized an anti-MYC PMO targeted against
the first intron and the first few translated codons of MYC pre-mRNA.[182] This
molecule inhibited splicing ofMYC pre-mRNA and inhibited translation of functional
MYC protein in a number of human leukemia and lymphoma cell lines.
Clearly these PMOs exhibit potential as modulators of MYC expression, yet they
have failed to advance in the clinic.
The molecules presented here represent the furthest advances that have been made
toward developing MYC-targeted antisense therapeutics.
Antisense technology represents a promising tool for targeting MYC. There has
been active research in this area for the past few decades, yet a clinically relevant
molecule has yet to be realized. Antisense is experiencing a very exciting time as
a field, with huge strides being made in understanding underlying principles of the
biology, chemistry, and physics of ASO activity, and with ASOs at last receiving FDA
approval for use in the clinic.[110, 124, 126, 183] We propose to develop novel MYC-
targeting antisense oligonucleotides by exploring additional chemical, strategic, and
analytical approaches, learning from the limitations and failures of past attempts.
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2.2 MYC-Targeting Antisense Oligonucleotide
Design
2.2.1 Experimental Design
Rationale
Our objective was to create antisense oligonucleotides that potently and selectively
knock down MYC expression to serve as probes to interrogate MYC biology and
pathology, and to function as prototypical therapeutics for treating human cancers.
We aimed to overcome the limitations of previous attempts towards this objective
by (1) utilizing second- and third-generation chemical modifications to improve ASO
performance, (2) expanding our target, and (3) rigorously establishing mechanism
and on-target activity while thoroughly investigating off-target phenomena.
We designed our novel MYC-targeting antisense oligonucleotides (MYCASOs) to
be 16 nucleotides long, a size shown to be optimal both for sequence-specific target
knockdown and for cellular penetration.[184] We incorporated three chemical modi-
fications to improve MYCASO activity. First, all cytosine bases were replaced with
5-methylcytosine to prevent activation of TLR9 innate immune receptors.[185, 186,
187, 188] Second, phosphodiester bonds were replaced with phosphorothioate linkers
in the oligonucleotide backbone. This common modification dramatically improves
biostability by protecting from endo- and exonuclease activity and by enhancing ASO
binding to serum proteins.[189] Finally, the first and last three nucleotides on the
MYCASO strand were comprised of locked nucleic acid (LNA) stabilized sugars.
These sugars contain a methylene bridge connecting the 2’ oxygen and 4’ carbon
of the ribose ring (a 2’-O,4’-C -methylene-b-D-ribofuranosyl nucleotide). Incorpo-
ration of these modified nucleotides dramatically improves ASO target affinity by
reducing entropy loss during target hybridization, and enhances plasma stability and
bioavailability in vivo through increased nuclease resistance.[63, 190] The remaining
nucleotides contained an unmodified deoxyribose sugar. MYCASOs have a ‘gap-
mer’ design scheme shown both to efficiently hybrize to the target transcript and to
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recruit RNase H in a well-established mechanism that acts to both inhibit mRNA
translation and induce degradation of the transcript itself.[63, 69] ASO molecules
may inhibit translation of target mRNA via a number of different mechanisms.[63]
RNase H binds DNA/RNA heteroduplexes and cleaves the RNA while leaving the
DNA unchanged.[67, 68] Thus ASOs that engage RNase H are able to bind and induce
degradation of multiple target transcripts while remaining intact, thereby multiplying
the molecular-scale activity and increasing the potency of the molecule. Due to the
very short half-life of both MYC mRNA and protein [21, 191], we chose to utilize
RNase H-mediated target degradation, hypothesizing that this multiplicity of activity
would better allow the ASO to keep up with the rapid rate of MYC turnover.
We sought to create a library of MYCASOs to screen for MYC protein knockdown.
ASO development against MYC, and indeed against most targets, has historically fo-
cused on targeting the translation initiation region (TIR) of the mRNA, overlapping
the start codon.[171, 179, 182] This approach is particularly useful for ASO molecules
that do not induce target degradation but instead remain bound to the mRNA and
inhibit its translation; proximity of the ASO to the TIR sterically blocks the transla-
tion machinery from binding the mRNA.[63] However, it has become clear that ASO
activity is highly dependent on both sequence and target mRNA structure [192], thus
restricting ASO binding to the TIR severely limits the number of ASO candidates.
Because we intended to design ASOs to engage RNase H1 to degrade MYC mRNA,
we reasoned that an ASO targeted anywhere along the coding region of the mRNA
could result in transcript cleavage, fragment degradation via nucleases, and ultimately
decreased translation of MYC protein. Thus we expanded our target to include the
entirety of the coding region of the full length mature human MYC mRNA. We hy-
pothesized that by significantly expanding our target sequence in this way, we would
increase our chances of identifying a potent and selective MYC-targeting antisense
molecule.
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Materials and Methods
Chemists at Enzon Pharmaceuticals (now Belrose Pharmaceuticals) synthesized
a library of antisense oligonucleotides specifically targeted against the coding region
of full-length mature human MYC mRNA. MYCASO sequences were determined
by Enzon Pharmaceuticals using a proprietary computational algorithm designed to
maximize MYC homology and minimize off-target activity. In addition, a control
oligonucleotide of randomized bases not known to target any known mRNA tran-
scripts was synthesized. As described above, the ASO library consisted of single-
stranded 16-mers modified with 5-methylcytosine modifications, a phosphorothioate
backbone, and locked nucleic acid modified sugars in a ‘gapmer’ design scheme.
Synthesis of MYCASO oligonucleotides was performed as previously described.[193]
Briefly, the phosphoramidite approach was done on an OligoPilot automated synthe-
sizer (GE Healthcare). Oligos were then cleaved from the solid support, purified by
filtration followed by ion-exchange high-performance liquid chromatography. Mate-
rial was then desalted by ultrafiltration and lyophilized, and powder was stored at
-20∘C. Sequences and characteristics of all MYCASOs are listed in Table C.1.
2.2.2 Results
In collaboration with chemists at Enzon Pharmaceuticals, we designed and syn-
thesized 23 distinct antisense oligonucleotides specifically targeted against the cod-
ing region of full-length mature human MYC mRNA, named MYCASO-1 through
MYCASO-23. The target regions of these molecules span the entire length of MYC
mRNA, as depicted in the schematic in Figure 2-1. MYCASO sequences and target
sites along the MYC mRNA are given in Table 2.1 and were determined by Enzon
Pharmaceuticals using a proprietary computational algorithm designed to maximize
MYC homology and minimize off-target activity. They also synthesized a control
oligonucleotide of randomized bases not known to target any known mRNA tran-
scripts, named NT-ASO. As described above, the ASO library consists of single-
stranded 16-mers modified with 5-methylcytosine modifications, a phosphorothioate
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Figure 2-1: MYCASO target sites are distributed along the MYC mRNA.
# Sequence MYC	mRNA	target	NT	position
1 AGTTCCTGTTGGTGAA 589-604
2 TCACCATGTCTCCTCC 889-904
3 TTCACCATGTCTCCTC 890-905
4 GGTTCACCATGTCTCC 892-907
5 TACAGTCCTGGATGAT 955-970
6 CATACAGTCCTGGATG 957-972
7 TGTTGGTGAAGCTAAC 583-598
8 CTGTTGGTGAAGCTAA 584-599
9 GGTACAAGCTGGAGGT 1087-1102
10 GTGAGGAGGTTTGCTG 1431-1446
11 TGTGAGGAGGTTTGCT 1432-1447
12 TAGTTGTGCTGATGTG 1481-1496
13 GTAGTTGTGCTGATGT 1482-1497
14 GACACTGTCCAACTTG 1545-1560
15 TCAGGACTCTGACACT 1555-1570
16 CTCAGGACTCTGACAC 1556-1571
17 ATCTGTCTCAGGACTC 1562-1577
18 GATCTGTCTCAGGACT 1563-1578
19 TGATCTGTCTCAGGAC 1564-1579
20 AGGATAACTACCTTGG 1742-1757
21 GACAGGATGTATGCTG 1769-1784
22 GGACAGGATGTATGCT 1770-1785
23 GCTGTTCAAGTTTGTG 1855-1870
NT CGCAGATTAGAAACCT
Table 2.1: MYCASO Sequences and Target Sites. Sequences of the ASO molecules in
the MYCASO library are given from 5’ to 3’. Bold bases are LNA-modified deoxyri-
bonucleotides, all others are unmodified deoxyribonucleotides. All linkages between
nucleotides are phosphorothioate. ASO target sites are given as nucleotide positions
along the MYC mRNA, NCBI reference sequence NM_002467.4.
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backbone, and locked nucleic acid modified sugars in a ‘gapmer’ design scheme.
2.2.3 Discussion
With MYC deregulated in up to 50% of all cancer cases, sitting at the intersec-
tion of numerous pathways frequently implicated in oncogenesis, and often playing a
role in the development of cancer drug resistance, there is an acute need for MYC-
directed therapeutics.[15, 18, 194] While many attempts have been made to directly
or indirectly inhibit MYC function with varying success [34, 35, 41, 42, 43], target-
ing MYC translation utilizing antisense therapy remains a relatively unexplored area,
with past attempts employing now-outdated chemistry and falling prey to significant
toxicities.[171, 172, 173, 175, 176] Thus, we have synthesized a library of 23 dis-
tinct antisense oligonucleotide molecules targeted against the human MYC mRNA
transcript. These novel compounds are modified with 5-methylcytosines to avoid
immune-related toxicity [185, 186, 187, 188], with a phosphorothioate backbone to
improve stability [189], and with locked nucleic acid modified sugars to dramatically
improve target affinity.[63, 190] Their ‘gapmer’ design scheme allows for high-affinity
recognition of MYC transcripts while also allowing for the recruitment of RNase H to
induce degradation of the transcript, a mechanism that will, we believe, allow MYC-
ASOs to keep up with high MYC turnover rates and significantly knock down MYC
protein expression.[63, 69] These molecules are also unique in that the library was
designed by scanning the entire coding region of the MYC mRNA using a proprietary
computational algorithm of Enzon Pharmaceutical’s to identify seed sequences that
maximize MYC homology and minimize off-target activity. The result is a library of
molecules targeting regions scattered across the MYC mRNA, greatly increasing the
likelihood that one of these ASOs will be a potent and selective inhibitor of MYC
translation.
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2.3 MYC-Targeting Antisense Oligonucleotide
Target Engagement
2.3.1 Experimental Design
Rationale
The very first antisense oligonucleotides used for laboratory manipulation of pro-
tein expression were single-stranded unmodified DNA molecules.[65, 66] The past 40
years have brought significant development in the chemistry of modifying antisense
oligonucleotides.[109, 110] Many of these modifications were introduced in order to
improve the affinity of the ASO for its target mRNA. Indeed, the success of ASO
molecules in the lab and the clinic today is due in part to their enhanced affinity for
their targets, allowing for lower treatment doses and improved activity over competing
nucleic acids endogenous to the relevant system.
The locked nucleic acid modification incorporated into MYCASO molecules is one
such modification intended to improve affinity. Indeed, LNAs offer unprecedented
gains in affinity for complementary sequences.[116, 117] The 2’-O,4’-C -methylene
bridge modification serves to conformationally restrict the sugar moiety, locking it
into a C3’-endo pucker or northern conformation.[63, 117] Incorporating several LNA-
modified nucleotides into an ASO forces the entire molecule to organize into an A-form
geometry, the conformation adopted by DNA in a DNA/RNA duplex. Unmodified
DNA is more conformationally unrestrained and flexible, able to adopt several geome-
tries including the more stable B-form.[118, 119, 120] Unmodified DNA binding to a
complementary RNA sequence requires a loss of entropy; a constrained LNA-modified
ASO thus experiences large entropic gains in binding affinity.[63]
We sought to investigate whether MYCASO molecules exhibited greater affinity
than unmodified DNA oligonucleotides for their target sequence.
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MYCASO unmodified DNA oligonucleotide RNA oligonucleotide
T*T*C*A*C*C*A*T*G*T*C*T*C*C*T*C TTCACCATGTCTCCTC GAGGAGACAUGGUGAA
G*G*T*A*C*A*A*G*C*T*G*G*A*G*G*T GGTACAAGCTGGAGGT ACCUCCAGCUUGUACC
G*T*A*G*T*T*G*T*G*C*T*G*A*T*G*T GTAGTTGTGCTGATGT ACAUCAGCACAACUAC
Table 2.2: Sequences of oligonucleotides used to determine MYCASO anity.
Oligonucleotide sequences are given from 5’ to 3’. Bold bases are LNA-modied
nucleotides. An * indicates a phosphorothioate linkage.
Materials and Methods
Due to expense of materials, this investigation was only carried out on three lead
MYCASO candidates: MYCASO-3, MYCASO-9, and MYCASO-13 (see Chapter 3).
For each MYCASO, two oligonucleotides were designed and ordered from Integrated
DNA Technologies (IDT): an unmodified DNA oligonucleotide of the same sequence,
and a complementary unmodified RNA oligonucleotide, representative of the target
sequence within MYC mRNA. Sequences of MYCASOs, unmodified DNA oligonu-
cleotides, and RNA oligonucleotides are listed in Table 2.2. To measure ASO binding,
DNA/RNA duplex formation was monitored using SYBR GreenER, a fluorescent dye
that experiences more than a thousand-fold enhancement of fluorescence upon bind-
ing to nucleic acid duplexes.[195] For each pairwise combination of MYCASOs, un-
modified DNA oligonucleotides, and RNA oligonucleotides, the oligonucleotides were
diluted in 10 mL SYBR Select Master Mix (Life Technologies) and nuclease-free water
to a final concentration of 2 mM for each individual oligonucleotide and a final volume
of 20 mL in a MicroAmp Optical 384-well plate (Applied Biosystems). The plate was
placed in an Applied Biosystems ViiA 7 RT-PCR instrument that ran the following
program: 95∘C for 5 min.; 95∘C to 20∘C at 0.1∘C/sec.; 20∘C to 95∘C at 0.1∘C/sec
with a fluorescence measurement every 5.35 sec. The instrument software produced a
melting curve for each sample plotted as temperature on the x-axis and the derivative
of the fluorescence vs. temperature curve on the y-axis. Melting curves were normal-
ized by fitting a third order polynomial to the regions of the curve outside of duplex
melting (25-40∘C and 85-95∘C) and subtracting the polynomial from the curve. All
samples were performed in quadruplicate.
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Figure 2-2: MYCASOs have increased binding anity for target mRNA sequences.
MYCASOs or corresponding unmodied DNA oligonucleotides were incubated with
complementary RNA oligonucleotides representative of the MYCASOMYC mRNA
target sites at 2 mM each in SYBR Select Master Mix. Mixtures were held at 95∘C
for 5 min., cooled to 20∘C at 0.1∘C/sec., and then heated to 95∘C at 0.1∘C/sec.
with a fluorescence measurement taken every 5.35 sec. Melting curves were obtained
by plotting the derivative of the fluorescence vs. time plots vs. time; curves were
normalized by fitting a third order polynomial to the regions of the curves outside
of duplex melting (25-40∘C and 85-95∘C) and subtracting the polynomials from the
curves. Black data points represent unmodified DNA/RNA mixtures, and red data
points represent MYCASO/RNA mixtures. All samples were performed in quadru-
plicate. The shift in Tm between the DNA/RNA duplex and the MYCASO/RNA
duplex for each molecule is given above the melting curves, and all Tm’s and DTm’s
are presented in the table below.
2.3.2 Results
Figure 2-2 shows overlays of MYCASO/RNA melting curves with unmodified
DNA/RNA melting curves for MYCASO-3, MYCASO-9, and MYCASO-13. For each
compound, the melting temperature (Tm) of the MYCASO/RNA duplex is higher
than the Tm of the corresponding unmodified DNA/RNA duplex, as expected. Un-
expectedly, the MYCASO/RNA melting curves are bimodal. This bimodal pattern
appeared in replicate melting curves as well as cooling curves, suggesting two inde-
pendent Tm’s in the MYCASO/RNA duplexes. Bimodal curves were not seen for
other oligonucleotide combinations. No duplex formation occurred in samples with
non-complementary oligomers or in samples with a single oligonucleotide.
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2.3.3 Discussion
A unique feature of our MYCASO molecules is that they contain nucleotides
modified with locked nucleic acid stabilized sugars. These modified sugars were in-
cluded because they have been shown to offer unprecedented gains in affinity for
mRNA targets when incorporated into ASOs; this is achieved by conformationally
restricting the sugar moieties and forcing the ASO strand into the A-form geometry
adopted upon binding to complementary mRNA, thereby offering enormous entropic
gains in binding affinity.[63, 116, 117] Here we confirmed for a select group of rep-
resentative molecules that MYCASOs do indeed bind to their complementary MYC
mRNA sequences with increased affinity over unmodified DNA oligonucleotides, as
evidenced through an increase in the Tm of MYCASO/RNA duplexes over unmodi-
fied DNA/RNA duplexes, suggesting greater duplex stability (Figure 2-2). The Tm
increases observed with MYCASOs are comparable to gains seen with other LNA-
modified ASOs.[190, 196, 197]
An unexpected result of the melting curve analysis was the bimodal shape of the
melting curves for MYCASO/RNA duplexes. This phenomenon occurred for all three
MYCASOs tested and was replicable in repeat melting and cooling curve analyses.
We believe that the two peaks represent the differential melting of RNA duplexed
with two distinct regions of a MYCASO molecule: (1) the unmodified nucleotides
in the center of the molecule, or the ‘gap,’ and (2) the LNA-modified nucleotides on
either end. We propose that during melting, the MYCASO/RNA duplex behaves
as if it were three independent duplexes: the first is an LNA/RNA duplex, followed
by DNA/RNA, and ending with LNA/RNA again. We hypothesize that these three
duplexes melt at least partially independently of each other. As LNA/RNA duplex
stability is much greater than DNA/RNA stability, those duplexes would be expected
to exhibit higher Tm’s. Thus the MYCASO/RNA duplex goes through three stages
during melting: (1) fully bound duplex, (2) an arrangement in which the LNA/RNA
duplexes at the ends of the molecules are still bound, but the DNA/RNA center has
melted, giving a duplex–single-stranded oligonucleotides–duplex arrangement, and
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Figure 2-3: Proposed schematic of MYCASO/RNA duplex melting. We propose that
during melting, the MYCASO/RNA duplex behaves as if it were three independent
duplexes and goes through three distinct stages: (1) fully bound duplex, (2) an ar-
rangement in which LNA/RNA remains duplexed and DNA/RNA is melted, (3) fully
melted single oligonucleotide strands. This pattern of duplex melting would account
for the bimodal melting curves observed with MYCASO/RNA melting. Black lines
correspond to DNA nucleotides, orange lines to LNA nucleotides, and grey lines to
RNA.
(3) fully melted single oligonucleotide strands (Figure 2-3). The first melting event,
melting of the ‘gap’ region, consists of melting of a sequence of DNA/RNA duplex
that is shorter than the full length duplex, and thus would be expected to have a
Tm equal to or lower than the unmodified DNA/RNA duplex Tm, as is observed.
The second melting event, melting of LNA/RNA duplex, is expected to occur at a
higher temperature than unmodified DNA/RNA duplex, and thus would correspond
to the second of the peaks seen in the bimodal curves. We performed an additional
experiment in which the rate of temperature increase during oligonucleotide duplex
melting was decreased to 1∘C/min. Under these conditions, the peak observed at a
lower temperature shifted closer to the higher temperature peak and in some cases
completely disappeared underneath it. We hypothesize that the slower rate of tem-
perature increase allowed partially melted MYCASO/RNA structures to equilibrate
with other structures, and perhaps the structural rigidity of the flanking LNA/RNA
duplexes forced the DNA/RNA gap to maintain a duplex structure until reaching
the Tm of the LNA/RNA regions. To our knowledge, this is the first report of such
a phenomenon. We believe the scheme depicted in Figure 2-3 could hold true for
all LNA-modified ASOs with a gapmer design, and perhaps as well for gapmers with
alternate modifications, though the increases in affinity offered by other modifications
are not as great as with the LNA, so it might be difficult to experimentally observe
the independent melting events. Melting curve analyses of ASO/RNA duplexes are
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not typically performed using a double-stranded nucleic acid intercalating agent as a
reporter, as was done here; instead, absorbance at 260 nm is often used to monitor du-
plex formation.[190, 197, 198] Perhaps the differential melting of gapmer ASO/RNA
duplexes is not observable using other methods.
2.4 Conclusions
Antisense oligonucleotide technology is a promising yet underutilized tool that
can be employed to target the elusive yet massively important oncogene MYC ; ther-
apeutic modulation of MYC protein expression using antisense technology has not
yet been fully realized. Our objective was to create antisense oligonucleotides that
potently and selectively knock down MYC expression to serve as probes to interrogate
MYC biology and pathology, and to function as prototypical therapeutics for treating
human cancers. We aimed to overcome the limitations of previous attempts towards
this objective by (1) utilizing second- and third-generation chemical modifications
to improve ASO performance, (2) expanding our target, and (3) rigorously estab-
lishing mechanism and on-target activity while thoroughly investigating off-target
phenomena. Towards (1) and (2), we synthesized a library of 23 distinct MYC-
targeting antisense oligonucleotides, named MYCASOs. These compounds contain
several chemical modifications to improve stability and potency, every attention has
been given to minimizing antisense and non-antisense off-target activity, and their
target sites span the length of the MYC mRNA coding region. We believe that these
unique attributes will allow for discovery of a novel, potent, and selective inhibitor of
MYC protein expression. We have shown that MYCASOs bind to their MYC mRNA
target sequences with increased affinity over unmodified ASOs, promising evidence
for target engagement.
Next, we will investigate MYCASO activity in vitro in cancer cell lines.
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Chapter 3
MYC-Targeting Antisense
Oligonucleotide Activity in Cancer
Cell Lines
3.1 Introduction
MYC is among the most commonly dysregulated genes across all cancers. It is the
most commonly translocated gene, often ending up under the control of an unrelated
distal enhancer that drives expression of MYC at supraphysiological levels.[17, 18]
MYC is also commonly amplified; pan-cancer analyses of at least twelve cancer types
estimate that the frequency of MYC amplification across human cancers is 14%.
Increased enhancer activity at the endogenous MYC locus also contributes to dysres-
gulted MYC expression, often mediated through hyperacetylation, hypomethylation,
or duplication of lineage-specific enhancers that surround MYC. MYC is often indi-
rectly dysregulated, sitting downstream of many pathways that are commonly dereg-
ulated in cancers, such as the PI3-Kinase, MAP Kinase, and JAK/STAT pathways.
Indeed, MYC is believed to be dysregulated in upwards of 50% of all human cancers.
[199]
Because MYC is so frequently implicated in cancer development, progression, and
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drug resistance, a MYC-directed therapeutic has the potential to have a very broad
impact. To test this hypothesis, we sought to investigate the activity of MYCASOs in
a variety of different MYC-expressing human cancer cell lines from distinct lineages.
The first is HeLa, a cervical adenocarcinoma in which integration of the HPV-18
virus genome upstream of MYC amplifies its expression.[200] The second is MM1.S,
a multiple myeloma cell line harboring an IgH/MYC translocation that results in
dramatically increased expression of the MYC gene driven by the IgH promoter.[201]
Third is CUTLL1, a T-cell lymphoma line harboring a TCR/NOTCH1 rearrangement
in which activated Notch1 transcriptionally upregulates MYC expression.[202] The
final cell line is HLF, a non-differentiated hepatoma shown to be highly dependent on
MYC in the Broad Institute Achilles dataset.[203, 204] We carried all four of these
cell lines through our investigation of MYCASO activity as a rigorous test of the
potential of these molecules.
3.2 Screening the MYC-Targeting Antisense
Oligonucleotide Library in MYC-expressing
Human Cancer Cell Lines
3.2.1 Experimental Design
Rationale
It is traditional when developing an antisense molecule to screen a small library
of ASOs targeted against the mRNA of interest in order to identify one or several
hits.[189, 205] Theoretically, any ASO designed to specifically bind to the target
mRNA should be active, yet realistically the efficacy of any given ASO molecule is
not predictable. The reasons why certain ASO molecules are active and others are not
are unclear and remains an active area of research within the field.[206] Contributing
factors are likely sequence-specific and may include the three-dimensional structure
of the region of mRNA targeted by the ASO and its accessibility for ASO binding
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and RNase H recruitment, the cell surface receptors that bind to and internalize
ASOs, and the various intracellular trafficking pathways an ASO may take.[4, 126]
Furthermore, ASO toxicity is not fully understood, likely sequence-specific, and un-
predictable, and screening in batches increases the likelihood of identifying a non-toxic
ASO candidate.[122, 123, 207]
We designed a library of 23 distinct MYC -targeting LNA/DNA gapmer ASOs
designed to specifically target the humanMYC mRNA. This library effectively ‘scans’
the target mRNA. Because we aim to engage RNase H to cleave the target mRNA,
an ASO targeted anywhere along the transcript may lead to MYC knockdown. By
scanning the entire target region we are increasing our chances of identifying an active
compound through increased sequence variability and diversity of target sequences
and structures.
We sought to screen our MYCASO library for a readout of on-target activity:
MYC protein knockdown as measured via immunoblot. We also included vehicle-
treated samples to control for vehicle-mediated effects on MYC levels and non-
targeting control NT-ASO-treated samples to control for a generalized cellular re-
sponse to ASOs.
We chose to investigate MYCASO activity in four different human cancer cell
lines representing distinct lineages and MYC statuses in order to rigorously test the
performance of these molecules in several different contexts. These cell lines are HeLa
(cervical adenocarcinoma), MM1.S (multiple myeloma), CUTLL1 (T-cell lymphoma),
and HLF (non-differentiated hepatoma).
Materials and Methods
Cell Culture HeLa cells (ATCC) were grown in Dulbecco’s Modified Eagle’s Med-
ium (DMEM, + 4.5 g/L D-glucose, + L-Glutamine, Sigma) supplemented with 10%
FBS. HLF cells (Broad Institute CCLE) were grown in DMEM supplemented with 5%
FBS. CUTLL1 and MM1.S cells were grown in RPMI 1640 (+ L-Glutamine, Sigma)
supplemented with 10% FBS. Cells were maintained in an incubator at 37∘C and 5%
CO2. Cells were maintained in Corning TC-treated T-25, T-75, and T-175 flasks.
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HeLa and HLF cells were harvested by discarding used media, washing with PBS,
adding 0.25% trypsin (Sigma) to just cover the vessel surface, placing cells at37∘C
to detach, quenching trypsin with fresh media, and collecting the cell suspension.
Semi-adherent MM1.S cells were harvested by both collecting media containing cells
in suspension and detaching adherent cells using trypsin. Suspension CUTLL1 cells
were harvested by collecting media. For passaging, cells were spun at 200xg for 3
minutes, resuspended in fresh medium, and seeded in new flasks. Cells were split 1:4
or 1:5 every 2-3 days.
MYCASO Treatments MYCASO powders were suspended in 0.5% saline to a
concentration of 5 mM as confirmed spectroscopically. The day before treatment,
HeLa and HLF cells were seeded at a density of 100,000 cells/mL and CUTLL1 and
MM1.S cells at 250,000 cells/mL, and cells were allowed to adhere and/or recover
overnight. For gymnotic treatments, the saline solution was added directly to cell
culture media for a final MYCASO concentration of 10 mM. For transfection, MYC-
ASOs were mixed with Lipofectamine 2000 in serum-free Opti-MEM (Sigma) and
added to cell culture medium at a final concentration of 10 nM MYCASO and 2.5 mL
Lipofectamine / 1 mL medium.
Immunoblotting Cells were plated in Corning TC-treated 6-well dishes at 2 mL/
well, allowed to recover overnight, treated as described above, and harvested after a
treatment time of 24 hours (HeLa, transfection), 72 hours (CUTLL1, MM1.S, and
HeLa, gymnotic), or 120 hours (HLF). Harvested cells were placed on ice, centrifuged
at 500xg at 4∘C for 5 min., washed with cold PBS, centrifuged again, resuspended in
cold RIPA buffer (Sigma) containing Halt Protease Cocktail Inhibitor (Sigma), and
placed on ice. After 45 min., cells were centrifuged at 13,000xg at 4∘C for 15 min.
Protein concentration in the supernatant was determined via BCA assay. Westerns
were performed using the ThermoFisher Bolt system. 40 mg protein in Bolt Sample
Buffer with 5% beta-mercaptoethanol was loaded per lane into Bolt 4-12% Bis-Tris
gels. Gels were submerged in Bolt MES running buffer and run at 165 V for 35
66
min. Gels were transferred onto nitrocellulose membranes at 10 V for 60 min. in
Bolt Transfer Buer. Membranes were blocked in Odyssey Blocking Buer for 30
min. at room temperature. Primary antibody incubation was done overnight in
Odyssey Blocking Buer at 4∘C. Secondary antibody incubation was done for 1 hr.
at room temperature. Membranes were washed 3 times in TBS-T between antibodies.
Primary antibodies: c-MYC (Santa Cruz N-262, 1:500); alpha-tubulin (Sigma T5168,
1:4,000). Secondary antibodies: LI-COR IRDye 800CW goat anti-rabbit (1:7,000);
LI-COR IRDye 680RD goat anti-mouse (1:7,000). Membranes were imaged on a
LI-COR Odyssey CLx using Image Studio software.
3.2.2 Results
MYCASO treatment resulted in decreased MYC protein expression compared to
vehicle- and NT-ASO-treated controls at 10 nM after 24 hours when delivered to
HeLa cells using the transfection reagent Lipofectamine 2000 (Figure 3-1). Many
cell types are able to take up ASO molecules in the absence of transfection reagents
or other delivery formulations.[126] Using gymnotic (unformulated) delivery treat-
ment, MYCASO treatment resulted in decreased MYC protein expression compared
to vehicle- and NT-ASO-treated controls at 10 mM after 72 hours in HeLa, CUTLL1,
and MM1.S cells, and after 120 hours in HLF cells (Figure 3-1). Importantly, treat-
ment with the non-targeting NT-ASO at the same concentration did not result in
MYC protein knockdown in any of the cell lines.
3.2.3 Discussion
MYCASOs are able to potently decrease MYC protein expression in all four MYC-
expressing cancer cell lines. Compared to transfection, gymnotic treatment required
higher doses and longer time points, and resulted in weaker MYC knockdown. When
MYCASOs were transfected into HeLa cells, nearly every molecule resulted in over
70% MYC protein knockdown. With unformulated gymnotic treatment, the level of
MYC protein knockdown was much more variable among the MYCASO molecules.
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Figure 3-1: Screening of MYCASO library in MYC-expressing human cancer cell
lines. Immunoblots for c-MYC and b-tubulin in MYC-expressing cancer cell lines
after treatment with the full MYCASO library. HeLa cells (Lipo) were treated with
10 nM MYCASO in Lipofectamine for 24 hours. HeLa cells (gymnotic), CUTLL1
cells, and MM1.S cells were treated with 10 mM unformulated MYCASO for 72 hours.
HLF cells were treated with 10 mM unformulated MYCASO for 120 hours. The bar
graph shows average percent knockdown of MYC for unformulated treatment across
all four cell lines. Highlighted MYCASOs (3, 9, and 13) were chosen for further study
due to their superior knockdown activity and non-overlapping seed sites along the
MYC mRNA.
68
Taken together, these data suggest that cellular uptake/delivery is a significantly
factor in ASO activity. ASO uptake is incompletely understood, highly variable across
different cell lines, and, as demonstrated here, sequence-dependent. Our observations
underscore the need to further elucidate the mechanisms of ASO uptake, including
identification of cell surface receptors that recognize and internalize ASO molecules,
the productive and non-productive pathways an ASO may travel inside a cell, and the
sequence specificity of these various parts. Increased understanding of these processes
will allow for smarter and more efficient ASO design.
Importantly, treatment with the non-targeting ASO did not result in MYC protein
knockdown in any of the cell lines, suggesting that the MYC knockdown observed with
MYCASO treatment is due to on-target ASO binding and inhibition of translation
rather than a generalized response to ASO treatment.
The molecules exhibiting the greatest average MYC knockdown activity with gym-
notic treatment across the four cell lines were MYCASO-3, MYCASO-9, MYCASO-
12, and MYCASO-13 (Figure 3-1, bar graph). Because MYCASO-12 and MYCASO-
13 target overlapping sites on the MYC mRNA, we chose to pursue further study of
MYCASOs using three lead candidates: MYCASO-3, MYCASO-9, and MYCASO-
13, highlighted in red in Figure 3-1.
3.3 Characterization of Lead MYC-Targeting
Antisense Oligonucleotides
3.3.1 Experimental Design
Rationale
Our full MYCASO library consisted of 23 distinct MYC-targeting molecules and
a non-targeting control. Due to cost limitations, we synthesized these compounds
in preliminary milligram quantities for the screening experiments described above.
We chose to scale up and continue characterization of MYCASOs with the non-
targeting control NT-ASO and three lead compounds: MYCASO-3, MYCASO-9,
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and MYCASO-13.
Characterization of antisense molecules in the literature is inconsistent and typi-
cally unsatisfying, and we believe this might partially explain why failure to translate
these molecules to clinical utility is so common. Therefore we sought to charac-
terize MYCASOs similarly to small molecules being investigated for drug develop-
ment. Our first step after selection of lead candidates was to test for dose- and
time-responsiveness in the activity of our molecules. We opted to look at MYC ex-
pression at two levels: protein expression, as determined via immunoblot, and mRNA
expression, as determined via quantitative reverse transcription PCR. Because MYC-
ASOs are designed to function by binding to MYC mRNA and recruiting RNaseH to
degrade the transcript, we predicted that both MYC mRNA and MYC protein levels
should decrease with MYCASO treatment. This activity should be both dose- and
time-dependent. We chose to continue studies using the same four human cancer cell
lines from distinct lineages and harboring distinct MYC statuses for the sake of rig-
orously testing the performance of MYCASOs in different contexts. These cell lines
are HeLa (cervical adenocarcinoma), MM1.S (multiple myeloma), CUTLL1 (T-cell
lymphoma), and HLF (non-differentiated hepatoma). Because HeLa cells are easily
transfected and transfection allows for greater MYC knockdown at much shorter time
points and 1,000-fold lower doses, we chose to continue studies using Lipofectamine
transfection of HeLa cells to save on time and compound usage. MM1.S, CUTLL1,
and HLF cell lines were treated with unformulated MYCASOs.
Materials and Methods
Cell Culture HeLa cells (ATCC) were grown in Dulbecco’s Modified Eagle’s Med-
ium (DMEM, + 4.5 g/L D-glucose, + L-Glutamine, Sigma) supplemented with 10%
FBS. HLF cells (Broad Institute CCLE) were grown in DMEM supplemented with 5%
FBS. CUTLL1 and MM1.S cells were grown in RPMI 1640 (+ L-Glutamine, Sigma)
supplemented with 10% FBS. Cells were maintained in an incubator at 37∘C and 5%
CO2. Cells were maintained in Corning TC-treated T-25, T-75, and T-175 flasks.
HeLa and HLF cells were harvested by discarding used media, washing with PBS,
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adding 0.25% trypsin (Sigma) to just cover the vessel surface, placing cells at37∘C
to detach, quenching trypsin with fresh media, and collecting the cell suspension.
Semi-adherent MM1.S cells were harvested by both collecting media containing cells
in suspension and detaching adherent cells using trypsin. Suspension CUTLL1 cells
were harvested by collecting media. For passaging, cells were spun at 200xg for 3
minutes, resuspended in fresh medium, and seeded in new flasks. Cells were split 1:4
or 1:5 every 2-3 days.
MYCASO Treatments MYCASO powders were suspended in 0.5% saline to a
concentration of 5 mM as confirmed spectroscopically. The day before treatment,
HeLa and HLF cells were seeded at a density of 100,000 cells/mL and CUTLL1 and
MM1.S cells at 250,000 cells/mL, and cells were allowed to adhere and/or recover
overnight. For gymnotic treatments of HLF, CUTLL1, and MM1.S cells, the saline
solution was added directly to cell culture media for a final MYCASO concentration
of 0.5 to 20 mM. For transfection of HeLa cells, MYCASOs were mixed with Lipofec-
tamine 2000 in serum-free Opti-MEM (Sigma) and added to cell culture medium at
a final concentration of 0.5 to 20 nM MYCASO and 2.5 mL Lipofectamine / 1 mL
medium.
Immunoblotting Cells were plated in Corning TC-treated 6-well dishes at 2 mL/
well, allowed to recover overnight, treated as described above, and harvested after a
treatment time of 1 to 120 hours. Harvested cells were placed on ice, centrifuged at
500xg at 4∘C for 5 min., washed with cold PBS, centrifuged again, resuspended in
cold RIPA buffer (Sigma) containing Halt Protease Cocktail Inhibitor (Sigma), and
placed on ice. After 45 min., cells were centrifuged at 13,000xg at 4∘C for 15 min.
Protein concentration in the supernatant was determined via BCA assay. Westerns
were performed using the ThermoFisher Bolt system. 40 mg protein in Bolt Sample
Buffer with 5% beta-mercaptoethanol was loaded per lane into Bolt 4-12% Bis-Tris
gels. Gels were submerged in Bolt MES running buffer and run at 165 V for 35
min. Gels were transferred onto nitrocellulose membranes at 10 V for 60 min. in
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Bolt Transfer Buer. Membranes were blocked in Odyssey Blocking Buer for 30
min. at room temperature. Primary antibody incubation was done overnight in
Odyssey Blocking Buer at 4∘C. Secondary antibody incubation was done for 1 hr.
at room temperature. Membranes were washed 3 times in TBS-T between antibodies.
Primary antibodies: c-MYC (Santa Cruz N-262, 1:500); alpha-tubulin (Sigma T5168,
1:4,000). Secondary antibodies: LI-COR IRDye 800CW goat anti-rabbit (1:7,000);
LI-COR IRDye 680RD goat anti-mouse (1:7,000). Membranes were imaged on a
LI-COR Odyssey CLx using Image Studio software.
qRT-PCR Cells were seeded in Corning TC-treated 6-well dishes at 2 mL/well,
allowed to recover overnight, treated as described above, and harvested after a treat-
ment time of 1 to 120 hours. Harvested cells were placed on ice, centrifuged at 500xg
at 4∘C for 5 min., washed with cold PBS, and centrifuged again. RNA was isolated
using a QIAGEN RNeasy Mini Kit and eluted in RNAse-free water. RNA concentra-
tion of samples was determined spectroscopically using a Thermo Scientific NanoDrop
8000. cDNA synthesis was carried out using the SuperScript VILO cDNA synthesis
kit (ThermoFisher): 1 mg RNA, 4 mL of 5X VILO Reaction Mix, and 2 mL of 10X
SuperScript Enzyme Mix were diluted in DEPC-treated water to a final volume of
20 mL in 8-strip PCR tubes. Samples were placed in a thermal cycler that ran the
following program: 25∘C for 10 min., 42∘C for 60 min., 85∘C for 5 min. Following
cDNA synthesis, samples were placed on ice. Each qRT-PCR reaction consisted of
0.1 mL cDNA, 10 mL SYBR Select Master Mix, 1 mL of each primer at 10 mM, and
nuclease-free water to a total volume of 20 mL in a MicroAmp Optical 384-well plate
(Applied Biosystems). The following PCR protocol was run on an Applied Biosys-
tems ViiA 7 qRT-PCR instrument: 50∘C for 2 min., 95∘C for 2 min., 40 cycles of 95∘C
for 15 sec. followed by 60∘C for 1 min with a SYBR Green fluorescence measurement
made after every cycle, followed by a melting curve measurement. Ct thresholds were
determined automatically by the instrument software. For each sample, MYC Ct
values were normalized to GAPDH Ct values and converted to transcript abundance
relative to vehicle-treated controls. The following primers were used for qRT-PCR
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experiments:MYC forward: 5’-GCTGCTTAGACGCTGGATTT-3’;
MYC reverse: 5’-CTCCTCCTCGTCGCAGTAGA-3’;
GAPDH forward: 5’-GAAGGTGAAGGTCGGAGTCA-3’;
GAPDH reverse: 5’-TTGAGGTCAATGAAGGGGTC-3’.
3.3.2 Results
Treatment with MYCASO-3, MYCASO-9, and MYCASO-13 resulted in MYC
mRNA and protein knockdown in both dose- and time-responsive manners in HeLa,
CUTLL1, HLF, and MM1.S cell lines (Figure 3-2). Generally, treatment with NT-
ASO at the same dose and time points did not result in MYC mRNA knockdown.
However, there were a few exceptions. Treatment of MM1.S cells with NT-ASO at
the highest dose of 20 mM resulted in a significant decrease inMYC mRNA. Similarly,
there was a dose-dependent decrease in MYC mRNA in HeLa cells upon treatment
with higher doses of NT-ASO. There was also a decrease in MYC mRNA in HeLa
cells after treatment with NT-ASO at 10 nM for 24 hours. In all of these cases,
MYC mRNA levels dropped below those of vehicle-treated controls but remained
above those of MYCASO-treated samples. None of these observed decreases in MYC
mRNA levels were reflected at the protein level, as there was no change in MYC
protein levels upon treatment with NT-ASO at all dose and time points. Quantitation
of MYC protein knockdown from immunoblots is given in Table C.2.
3.3.3 Discussion
MYCASO treatment resulted in MYC mRNA and protein knockdown, as ex-
pected based on the rational design of MYCASOs intended to bind MYC mRNA
and recruit RNase H to degrade MYC transcripts, resulting in decreased protein pro-
duction. This activity was both dose- and time-dependent at both the mRNA and
protein levels.
Importantly, MYC protein levels remained unchanged with NT-ASO treatment at
the same dose and time points, suggesting that the observed MYC knockdown activity
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Figure 3-2: Knockdown ofMYC mRNA and protein expression with MYCASO treat-
ment. (A) Dose-proportional knockdown of MYC protein expression with MYCASO
treatment. (B) Time-proportional knockdown of MYC protein expression with MYC-
ASO treatment. (C) Dose-proportional decrease of MYC mRNA with MYCASO
treatment. Values represent quadruplicate means +/- SD. (D) Time-proportional
decrease in MYC mRNA with MYCASO treatment. Values represent quadruplicate
means +/- SD. For dose-proportional studies, HeLa cells were treated with 0, 0.5, 1,
5, 10, and 20 nM MYCASO in Lipofectamine for 24 hours. CUTLL1, MM1.S, and
HLF cells were treated with 0, 0.5, 1, 5, 10, and 20 mM unformulated MYCASO for
72 hours (CUTLL1 and MM1.S) or 120 hours (HLF). For time-proportional studies,
HeLa cells were treated with 10 nM MYCASO in Lipofectamine for 0, 1, 2, 4, 8,
12, and 24 hours. CUTLL1 and HLF cells were treated with 10 mM unformulated
MYCASO for 24, 48, 72, 96, and 120 hours. MM1.S cells were treated with 10 mM
unformulated MYCASO for 24, 48, and 72 hours.
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is specic to MYC-targeting compounds and is due to on-target activity rather than
a generalized cellular response to ASO treatment.
Treatment with NT-ASO did not typically result in MYC mRNA knockdown.
However, at higher doses and later time points in some cell lines there was an observed
decrease in MYC mRNA below control levels but still above the knockdown observed
with MYCASO treatment. These decreases in MYC mRNA levels are perhaps a
reflection of ASO-related toxicity caused by treatment with high doses of ASO for long
time periods. Because MYC sits at the intersection of so many signaling pathways
within the cell, MYC levels are sensitive to a large array of perturbations.[15] This
toxicity is perhaps exaggerated with transfection, which mediates delivery of greater
amounts of ASO into the cell compared to unformulated delivery, which is perhaps
why NT-ASO treatment of HeLa cells shows the greatest MYC knockdown activity.
All future experiments were carried out at the 10 nM dose for HeLa cells and the 10
mM dose for CUTLL1, HLF, and MM1.S cells, so we were not concerned about the
decreases in MYC mRNA seen at higher doses. Additionally, there was no decrease
in MYC protein levels with NT-ASO treatment at any dose or time points in any
of the cell lines, suggesting that the cells were still able to produce MYC protein
at typical levels despite a decrease in MYC mRNA. Because MYC protein levels
remain constant, and the MYC protein is the functional unit, we did not believe the
decreases in MYC mRNA levels observed with some NT-ASO treatments were cause
for concern in the present study. However, these observations do suggest that there
is some ASO-related toxicity occurring with these molecules that is not related to a
compound’s ability to bind and degrade MYC mRNA. We will explore this concept
later.
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3.4 Mechanism of Action of MYC-Targeting
Antisense Oligonucleotides
3.4.1 Experimental Design
Rationale
As mentioned above, characterization of antisense molecules in the literature is
inconsistent and typically unsatisfying, and we sought to characterize MYCASOs
similarly to small molecules being investigated for drug development with the hope
that more rigorous analysis would lead to greater understanding and a greater likeli-
hood of successful clinical translation. Part of this analysis involves establishing the
mechanism of action. MYCASOs were designed in a ‘gapmer’ scheme, with modified
LNA nucleotides on both ends and a central gap region consisting of unmodified DNA
nucleotides. The gap region allows for recruitment of RNase H, an endogenous cel-
lular enzyme that recognizes DNA/RNA heteroduplexes and selectively cleaves the
RNA strand.[63] Reports of gapmer ASOs typically cite the literature claiming RNase
H-mediated degradation of target mRNA as evidence for mechanism, but we believe
that this practice is dangerous and that thorough establishment of mechanism for our
molecules will preempt the downfalls many ASOs have faced before when off-target
activity was discovered far along the path to clinical translation.
Towards this goal, we conducted two experiments: (1) a 5’ Rapid Amplification of
cDNA Ends (RACE) assay to detect MYC mRNA cleavage products, and (2) rescue
of MYCASO-mediated MYC mRNA knockdown through knockdown of RNase H1.
Cellular RNase H recognizes the heteroduplex of a DNA-based ASO bound to its
target mRNA and cleaves the mRNA.[67, 68] The RNA-cleaving behavior of RNase
H has been extensively studied, and the enzyme cleaves the target mRNA within the
ASO binding region.[208] Thus ASO-mediated RNase H-driven cleavage results in
target mRNA fragments of predictable size. The 5’ RACE assay has been regularly
employed in the literature to reliably detect these fragments.[206, 209, 210] The assay
allows for capture and amplification of mRNA fragments with a known 3’ end but an
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unknown 5’ end, which is ideal for identifying the products of ASO-mediated mRNA
cleavage. A schematic of the 5’ RACE assay for use in our system is depicted in Fig-
ure 3-3 A. Following ASO treatment of a cell population, total RNA is isolated and a
gene specific primer is utilized to capture fragments and generate cDNA (GSP1-RT in
Figure 3-3 A). The next step in the assay is a ‘tailing’ reaction, in which the terminal
deoxynucleotidyl transferase enzyme (TdT) adds a string of cytosines on to the end
of the cDNA, generating single-stranded DNA fragments that now have known 5’ and
3’ ends. These fragments are used as template in a PCR reaction with a gene specific
primer (GSP2) and a primer that recognizes the dC tail of the cDNA fragments (the
5’ RACE abridged anchor primer, AAP). Often, target mRNA fragments are present
at such a low abundance that very little PCR product is present after this step, so
a second PCR step is carried out using a nested gene specific primer (GSP3) and
a primer that recognizes the other end of the previously generated PCR products
(the 5’ RACE abridged universal anchor primer, AUAP). Finally, this PCR product
is run on a gel for visualization of the amplified mRNA fragments. If RNase H is
cleaving ASO/mRNA duplexes at the site of ASO binding, fragments corresponding
to the expected length will be observable. Furthermore, these PCR products may be
sequenced to identify the exact cleavage site within the target mRNA. The 5’ RACE
assay provides visual and sequence confirmation of ASO-mediated mRNA cleavage
and thus is able to confirm on-target activity and suggest an RNase H-mediated mech-
anism of target transcript degradation. (Note: we have included 5’ RACE sequencing
results obtained from an additional cell line, SNU-398. We performed experiments in
this hepatocellular carcinoma cell line before deciding that HLF was a more appro-
priate model for a liver cancer based on the data from the Broad Institute Achilles
dataset identifying its dependence on MYC.)
For the second part of establishing the mechanism of MYCASOs, we consulted a
paper published in 2004 by Wu et al. at Isis (now Ionis) Pharmaceuticals that first
established the role of RNase H1 in ASO-mediated mRNA degradation.[69] We be-
lieve that this paper elegantly and thoroughly demonstrates an RNase H1-mediated
mechanism of ASO activity, and we sought to re-create their results with MYCASOs.
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Figure 3-3: 5’ RACE assay to detectMYC mRNA cleavage with MYCASO treat-
ment. (A) Schematic of 5’ RACE assay. Gene specific primers (GSPs) are used
to capture and amplify MYC mRNA fragments from total cellular RNA for visu-
alization on an agarose gel and sequencing. Lead MYCASOs are depicted in red.
(B) 5’ RACE PCR products following MYCASO treatment. MYCASO-treated sam-
ples contain fragments consistent with mRNA cleavage at MYCASO binding sites,
whereas vehicle- and NT-ASO-treated cells produce no fragments. HeLa cells were
treated with 10 nM MYCASO in Lipofectamine for 24 hours. CUTLL1, MM1.S, and
HLF cells were treated with 10 mM unformulated MYCASO for 72 hours (CUTLL1
and MM1.S) or 120 hours (HLF). (C) MYCASO-mediated cleavage sites of MYC
mRNA as determined via sequencing of 5’ RACE PCR products. MYC mRNA is
represented in black, MYCASO binding sites are indicated below the mRNA in grey
or red, with the red representing the indicated MYCASO sequence. Each sequenced
5’ end is indicated with an arrow; the most abundant cleavage site(s) for each MYC-
ASO treatment is emphasized with a tall arrow. PCR products were obtained from
MM1.S and SNU-398 cells treated with 10 mM unformulated MYCASO for 72 hours.
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Wu et al. employed siRNA and ASO molecules to knock down expression of en-
dogenous RNase H1 in a cellular system (RNase H1 knockout is lethal). We believe
that the key experiment illustrating RNase H1-mediated target mRNA cleavage was
quantification of target mRNA following treatment with a range of investigational
ASO concentrations under various levels of RNase H1 knockdown. To achieve this,
the authors treated cells with a range of anti-RNASEH1 siRNA/ASO and a range of
investigational ASO simultaneously, and then performed qRT-PCR to measure the
level of target mRNA. They demonstrated that with knockdown of RNase H1, ASO
efficacy decreased. This is the experiment we sought to re-create with MYCASOs. We
chose to employ their most potent anti-RNASEH1 ASO in our experiments. We chose
to carry out our experiments in HeLa cells for ease of delivery of the anti-RNASEH1
ASO using Lipofectamine transfection, and to save on time and materials. Finally,
we chose to focus on one molecule, MYCASO-3, again to save on time and materials.
Materials and Methods
Cell Culture HeLa cells (ATCC) were grown in Dulbecco’s Modified Eagle’s Med-
ium (DMEM, + 4.5 g/L D-glucose, + L-Glutamine, Sigma) supplemented with 10%
FBS. HLF cells (Broad Institute CCLE) were grown in DMEM supplemented with
5% FBS. CUTLL1, MM1.S, and SNU-398 cells were grown in RPMI 1640 (+ L-
Glutamine, Sigma) supplemented with 10% FBS. Cells were maintained in an incu-
bator at 37∘C and 5% CO2. Cells were maintained in Corning TC-treated T-25, T-75,
and T-175 flasks. HeLa and HLF cells were harvested by discarding used media, wash-
ing with PBS, adding 0.25% trypsin (Sigma) to just cover the vessel surface, placing
cells at 37∘C to detach, quenching trypsin with fresh media, and collecting the cell
suspension. Semi-adherent MM1.S and SNU-398 cells were harvested by both collect-
ing media containing cells in suspension and detaching adherent cells using trypsin.
Suspension CUTLL1 cells were harvested by collecting media. For passaging, cells
were spun at 200xg for 3 minutes, resuspended in fresh medium, and seeded in new
flasks. Cells were split 1:4 or 1:5 every 2-3 days.
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MYCASO Treatments MYCASO powders were suspended in 0.5% saline to a
concentration of 5 mM as confirmed spectroscopically. The day before treatment,
HeLa, HLF, and SNU-398 cells were seeded at a density of 100,000 cells/mL and
CUTLL1 and MM1.S cells at 250,000 cells/mL, and cells were allowed to adhere
and/or recover overnight. For gymnotic treatments of HLF, CUTLL1, MM1.S, and
SNU-398 cells, the saline solution was added directly to cell culture media for a final
MYCASO concentration of 10 mM. For transfection of HeLa cells, MYCASOs were
mixed with Lipofectamine 2000 in serum-free Opti-MEM (Sigma) and added to cell
culture medium at a final concentration of 10 nM MYCASO and 2.5 mL Lipofectamine
/ 1 mL medium.
5’ Rapid Amplification of cDNA Ends (RACE) Cells were seeded in Corn-
ing TC-treated 6-well dishes at 2 mL/well, allowed to recover overnight, treated as
described above, and harvested after a treatment time of 24 hours (HeLa cells), 72
hours (CUTLL1, MM1.S, and SNU-398 cells), or 120 hours (HLF cells). Harvested
cells were placed on ice, centrifuged at 500xg at 4∘C for 5 min., washed with cold
PBS, and centrifuged again. RNA was isolated using a QIAGEN RNeasy Mini Kit
and eluted in RNase-free water. RNA concentration of samples was determined spec-
troscopically using a Thermo Scientific NanoDrop 8000. The 5’ RACE assay was
carried out as described by Invitrogen using their 5’ RACE kit. A thermal cycler was
used for all incubations.
First Strand cDNA Synthesis In 8-strip PCR tubes, 5 mg total RNA and 2.5
pmol gene specific primer 1 (GSP1-RT: 5’-TGTTTCAACTGTTCTC-3’) were diluted
to 15.5 mL in DEPC-treated water, incubated for 10 min. at 70∘C, then chilled for
1 min. on ice. Next, 2.5 mL 10X PCR buffer, 2.5 mL 25 mM MgCl2, 1 mL 10 nM
dNTP mix, and 2.5 mL 0.1 M DTT were added to the sample, followed by a 1 min.
incubation at 42∘C. 1 mL SuperScript II RT was added to the reaction, followed by
incubation at 42∘C for 50 min., then 70∘C for 15 min. 1 mL RNase mix was then
added, followed by incubation at 37∘C for 30 min. The cDNA reaction was purified
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using a Qiagen PCR purication kit and eluted in nuclease-free water.
TdT Tailing of cDNA The following components were added to an 8-strip
PCR tube: 6.5 mL DEPC-treated water, 5 mL 5X tailing buffer, 2.5 mL 2 mM dCTP,
and 10 mL cDNA sample. Reactions were incubated for 2.5 min. at 94∘C, then chilled
for 1 min. on ice. 1 mL TdT was added, followed by incubation for 10 min. at 37∘C,
then 10 min. at 65∘C.
PCR of dC-tailed cDNA The following components were added to an 8-strip
PCR tube: 32 mL nuclease-free water, 5 mL 10X PCR buffer, 3 mL 25 mM MgCl2,
1 mL 10 mM dNTP mix, 2 mL 10 mM nested gene specific primer 2 (GSP2: 5’-
CCTCTGCTTGGACGGACAGGA-3’), 2 mL 10 mM Abridged Anchor Primer (AAP:
5’-GGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG-3’), 5 mL dC-tailed cDNA.
0.25 mL Taq DNA polymerase (5 units/mL) was added immediately before mixing the
reaction and placing in a thermal cycler pre-equilibrated to 95∘C to run the following
PCR protocol: 95∘C for 2 min.; 30 cycles of 95∘C for 15 sec., 58∘C for 15 sec., and
68∘C for 1 min.; and final extension at 68∘C for 5 min.
Nested Amplification For improved visualization of PCR products, a second
PCR reaction was carried out using another nested gene specific primer (GSP3: 5’-
CTGGTCACGCAGGGCAAAAA-3’) and the 5’ RACE abridged universal anchor
primer (AUAP: 5’-GGCCACGCGTCGACTAGTAC-3’). The PCR products from
the previous step were diluted 1:100 in TE buffer. The following components were
added to an 8-strip PCR tube: 34 mL nuclease-free water, 5 mL 10X PCR buffer, 3
mL 25 mM MgCl2, 1 mL 10 mM dNTP mix, 1 mL 10 mM GSP3, 1 mL 10 mM AUAP,
5 mL diluted primary PCR product. 0.25 mL Taq DNA polymerase (5 units/mL) was
added immediately before mixing the reaction and placing in a thermal cycler pre-
equilibrated to 95∘C to run the following PCR protocol: 95∘C for 2 min.; 30 cycles of
95∘C for 15 sec., 57∘C for 15 sec., and 68∘C for 1 min.; and final extension at 68∘C
for 5 min.
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Gel Visualization of PCR Products 10 mL PCR product were loaded onto
an E-Gel 1.2% with Ethidium Bromide Agarose Gel (Invitrogen). Gels were run using
an E-Gel iBase Power System (Invitrogen) set to program 1 for 20 min. 5 mL of E-Gel
1 kb Plus DNA Ladder (Invitrogen) was loaded into one lane per gel.
Sequencing of 5’ RACE Products 5’ RACE PCR products from MM1.S and
SNU-398 cells were cloned into pCR4-TOPO plasmid for sequencing using the TOPO
TA Cloning Kit (Invitrogen). 4 mL 5’ RACE PCR products were mixed with 1 mL
Salt Solution and 1 mL TOPO vector and incubated for 30 min. at room tempera-
ture. The mixtures were then placed on ice and transformed into DH5a competent
cells. 2 mL of the reaction mixture were added to 50 mL bacteria, which was incu-
bated on ice for 30 min. Samples were heat shocked at 42∘C for 45 sec., and placed
back on ice for 2 min. 250 mL of S.O.C. media were added to the cells, and the
mixture was placed in a shaker at 37∘C for 1 hr. The cell mixture was then spread on
an agar plate containing 100 mg/mL Ampicillin and placed at 37∘C overnight. The
next day, individual bacterial colonies were picked from the agar plate and sequenced
using four different primers: M13 reverse: 5’-CAGGAACAGCTATGAC-3’; T3: 5’-
GCAATTAACCCTCACTAAAGG-3’; T7: 5’-TAATAGCACTCACTATAGGG-3’;
and M13 (-21) forward: 5’-TGTAAAACGACGGCCAGT-3’. For each sample, the
cleanest sequence read among all four primers was used; if none provided a clean
read-through of the fragment end, the sample was discarded from analysis. Data
from both MM1.S and SNU-398 cells were pooled. MYC mRNA cleavage sites as de-
termined via sequencing were mapped to the MYC mRNA (NCBI reference sequence
NM_002467.4).
Anti-RNASEH1 ASO The most potent anti-RNASEH1 ASO sequence from Wu
et al.’s 2004 paper, ISIS 194178, was ordered from TriLink. The ISIS 194178 sequence
is 5’-TGCAGGCTATTTTCCACACC-3’. The first and last 5 nucleotides are 2’-O-
Methyl modified DNA nucleotides, and the remaining nucleotides are unmodified
DNA nucleotides. All cytosines contain a 5-Methyl modification. Finally, all inter-
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nucleoside bonds are phosphorothioate.
MYCASO and Anti-RNASEH1 H1 ASO Co-Transfections MYCASO pow-
ders were suspended in 0.5% saline to a concentration of 5 mM as confirmed spectro-
scopically. The anti-RNASEH1 ASO ISIS 194178 was suspended in PBS to a con-
centration of 5 mM as confirmed spectroscopically. The day before treatment, HeLa
cells were seeded at a density of 250,000 cells/mL and allowed to adhere overnight.
For transfection of HeLa cells, MYCASO-3 and ISIS 194178 were mixed with Lipo-
fectamine 2000 in serum-free Opti-MEM (Sigma) and added to cell culture medium
at a final concentration of 0 to 10 nM MYCASO-3, 0 to 50 nM ISIS 194178, and 2.5
mL Lipofectamine / 1 mL medium.
qRT-PCR HeLa cells were seeded in Corning TC-treated 6-well dishes at 2 mL/well,
allowed to recover overnight, treated as described above, and harvested after a treat-
ment time of 24 hours. Harvested cells were placed on ice, centrifuged at 500xg at 4∘C
for 5 min., washed with cold PBS, and centrifuged again. RNA was isolated using
a QIAGEN RNeasy Mini Kit and eluted in RNAse-free water. RNA concentration
of samples was determined spectroscopically using a Thermo Scientific NanoDrop
8000. cDNA synthesis was carried out using the SuperScript VILO cDNA synthesis
kit (ThermoFisher): 1 mg RNA, 4 mL of 5X VILO Reaction Mix, and 2 mL of 10X
SuperScript Enzyme Mix were diluted in DEPC-treated water to a final volume of
20 mL in 8-strip PCR tubes. Samples were placed in a thermal cycler that ran the
following program: 25∘C for 10 min., 42∘C for 60 min., 85∘C for 5 min. Following
cDNA synthesis, samples were placed on ice. Each qRT-PCR reaction consisted of
0.1 mL cDNA, 10 mL SYBR Select Master Mix,1 mL of each primer at 10 mM, and
nuclease-free water to a total volume of 20 mL in a MicroAmp Optical 384-well plate
(Applied Biosystems). The following PCR protocol was run on an Applied Biosys-
tems ViiA 7 qRT-PCR instrument: 50∘C for 2 min., 95∘C for 2 min., 40 cycles of 95∘C
for 15 sec. followed by 60∘C for 1 min with a SYBR Green fluorescence measurement
made after every cycle, followed by a melting curve measurement. Ct thresholds were
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determined automatically by the instrument software. For each sample, MYC and
RNase H1 Ct values were normalized to GAPDH Ct values and converted to tran-
script abundance relative to appropriate controls. The following primers were used
for qRT-PCR experiments: MYC forward: 5’-GCTGCTTAGACGCTGGATTT-3’;
MYC reverse: 5’-CTCCTCCTCGTCGCAGTAGA-3’;
RNASEH1 forward: 5’- AAGCCCGGAAGTTTCAGAAG-3’;
RNASEH1 reverse: 5’- TTCATGTCCATCTCCATCCA-3’;
GAPDH forward: 5’-GAAGGTGAAGGTCGGAGTCA-3’;
GAPDH reverse: 5’-TTGAGGTCAATGAAGGGGTC-3’.
3.4.2 Results
We observed MYC transcript fragments in RNA isolated from MYCASO-treated
cells but not in vehicle-treated or NT-ASO-treated cells (Figure 3-3 B). The sizes
of the 5’ RACE PCR products correspond to the expected sizes of MYC mRNA
cleavage products generated via cleavage at MYCASO binding sites. Interestingly,
the size of the predominant MYC mRNA fragment from MYCASO-3 treatment is
smaller than expected. In fact, it appears to be the same size as the fragment from
MYCASO-9 treatment. Sequencing of 5’ RACE products is consistent with cleavage
of MYC mRNA at MYCASO binding sites: Figure 3-3 C shows sequenced 5’ ends
of MYC transcript fragments depicted as arrows along the MYC mRNA relative to
MYCASO binding sites. With sequencing we also observe fragments that appear to
be cleaved outside of the MYCASO target regions. The larger arrows represent the
most highly represented cleavage sites among the sequencing data; again we see that
the predominant fragment from MYCASO-3 treatment lines up with the MYCASO-9
binding site.
We see that treatment of HeLa cells with the well-established antisense oligonu-
cleotide targeted against RNase H1 from Wu et al., ISIS 194178, knocks down RNase
H1 expression in a dose-dependent manner (Figure 3-4 A). Knocking down the expres-
sion of RNase H1 abrogated MYCASO-3-mediated knockdown of the MYC transcript
(Figure 3-4 B).
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Figure 3-4: Knockdown of RNase H1 rescues MYCASO-mediated downregulation
of MYC mRNA. (A) qRT-PCR for RNASEH1 in HeLa cells following treatment
with an anti-RNASEH1 ASO (ISIS 194178) in Lipofectamine for 24 hours normal-
ized to vehicle-treated control. (B) qRT-PCR for MYC in HeLa cells following co-
transfection with the indicated doses of anti-RNASEH1 ASO and MYCASO-3 in
Lipofectamine for 24 hours normalized to appropriate controls. With decreased lev-
els of RNase H1, MYCASO-mediated knockdown of MYC mRNA levels is rescued.
Values represent quadruplicate means +/- SD.
85
3.4.3 Discussion
MYC transcript fragments are present in MYCASO-treated samples and not in
vehicle- or NT-ASO treated samples, and their sizes suggest cleavage of the MYC
transcript at the sites of MYCASO binding, consistent with the mechanism of RNase
H. However, there are some notable exceptions to the expected results. The size of
the predominant MYC mRNA fragment from MYCASO-3 treatment is smaller than
expected and appears to be the same size as the fragment from MYCASO-9 treat-
ment. Additionally, treatment with MYCASO-9 and occasionally with MYCASO-3
sometimes produces a minor fragment that is the same size as the fragment from
MYCASO-13 treatment. In fact, we often observe multipleMYC transcript fragments
from MYCASO treatment. These fragments may be classified as either background
(if they also appear in vehicle- and NT-ASO-treated controls), or MYCASO-specific.
The MYCASO-specific fragments we observe are the three sizes expected from cleav-
age at MYCASO-3, MYCASO-9, and MYCASO-13 binding sites, yet the appearance
of these fragments does not always correspond to the treatment. Furthermore, the
abundance of these fragments changes with treatment time. For example, the ma-
jor fragment present after treatment of HeLa cells with MYCASO-3 for 2 hours is
the expected size for cleavage at the site of MYCASO-3 binding; at 24 hours, this
fragment becomes less abundant while the fragment corresponding to cleavage at the
MYCASO-9 binding site becomes more abundant. These observations suggest that
perhaps MYCASO-mediated cleavage products are degraded by nucleases down to
smaller, potentially more stable products. This is consistent with reports of 5’ to 3’
degradation of ASO-cleavage products.[209] This is also consistent with our sequenc-
ing data, which revealed MYC mRNA fragments with 5’ ends anywhere downstream
of MYCASO binding, suggesting 5’ to 3’ degradation. The three MYCASO-specific
fragments we observe may represent the most stable degradation products of MYC
transcript fragments cleaved at MYCASO-3, MYCASO-9, and MYCASO-13 binding
sites, and a fragment may be degraded from larger products down to smaller ones
over time. If this were the case, it appears that the MYCASO-3 cleavage product
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is relatively unstable compared to the MYCASO-9 and MYCASO-13 cleavage prod-
ucts, which appear to last longer in the cell. Another interpretation of these results is
that RNase H cleavage of the MYC mRNA may occur at a site outside of MYCASO
binding, perhaps at a more accessible location along the mRNA. This is consistent
with sequencing results, which show 5’ ends of products at multiple sites outside of
MYCASO binding regions. MYCASO-3, MYCASO-9, and MYCASO-13 may be ef-
ficacious because they bind to particularly open sites on the MYC mRNA and/or
because the duplexes they form with the MYC transcript are particularly accessible
to RNase H. This is consistent with studies of ASO efficacy.[206] It may be possi-
ble that while RNase H recognizes the MYCASO-3/MYC mRNA duplex, it may in
fact cleave at the MYCASO-9 binding site simply because it is accessible to cleavage
and/or situated nearby in three-dimensional space. While the details of the mech-
anism behind these observations are unclear, it is certain that MYCASOs mediate
cleavage of the MYC mRNA, consistent with an RNase H-mediated mechanism of
target degradation.
As an added note, we are hesitant to rely too heavily on the relative abundance
of MYC mRNA fragments revealed through sequencing of 5’ RACE products, as
we believe the cloning procedure utilized to prepare products for sequencing may be
biased towards smaller fragments.
Knockdown of RNase H1 abrogates MYCASO-3-mediated MYC mRNA knock-
down, suggesting that RNase H1 plays a role in MYCASO-mediated MYC transcript
degradation. We did not achieve complete knockdown of RNase H1, and the rescue of
MYCASO-mediated MYC mRNA knockdown was only partial. This is explainable
through the activity of the remaining RNase H1 in the cell, or through the activity
of other RNase H enzymes, as was observed by Wu et al.[69]
Overall, these data suggest that the decrease inMYC transcript and protein levels
we observe with MYCASO treatment is indeed achieved at least in in part through
the well-established antisense mechanism of RNase H1-mediated cleavage of MYC
mRNA upon MYCASOs binding to their target.
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3.5 Phenotypic Consequences of MYC-Targeting
Antisense Oligonucleotide Treatment
3.5.1 Experimental Design
Rationale
MYC is an essential gene, sitting at the intersection of many signaling path-
ways and controlling expression of a vast array of genes responsible for cell growth,
metabolism, protein synthesis, and cell proliferation.[15] Many tumors and cancer cell
lines have been shown to be ‘addicted’ to MYC, such that removal or inhibition of
MYC results in tumor regression, rapid proliferative arrest, and apoptosis.[26] These
data are promising for development of MYC inhibitors as cancer therapeutics. How-
ever, when this idea was first proposed there was concern over the toxicity of such a
therapy. The MYC driving cancer growth is often identical to the MYC functioning
in healthy cells, and concerns over what a MYC-directed therapeutic would do to
healthy tissue were well founded. Towards the goal of determining the viability of
MYC inhibition as a cancer therapy, Laura Soucek et al. designed a peptide that
acts as a dominant negative MYC, binding and sequestering MYC into nonfunctional
heterodimers, named Omomyc.[27] The group created a mouse model for inducible
systemic expression of Omomyc to model systemic MYC inhibition. They found that
MYC inhibition triggered rapid regression of tumors.[30] MYC inhibition also exerted
profound effects on normal regenerating tissues. Studies of MYC in healthy cells and
tissues have revealed that MYC is essential for growth and proliferation of stem cell
populations, but differentiated cells seem to be less dependent on MYC for their
function.[31, 32, 33] Consistent with these findings, Soucek et al. observed toxicity in
stem cell populations with MYC inhibition. However, these effects were well tolerated
by mice over extended periods and rapidly and completely reversible. The high un-
controlled metabolic, growth, and proliferative activity of cancer cells seems to make
them particularly sensitive to MYC inhibition, whereas healthy stem cell populations
that grow and proliferate in a much slower, more controlled manner seem to be able to
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tolerate MYC inhibition. These findings suggest that pharmacologic MYC inhibition
may indeed be a viable cancer therapeutic strategy.
With these findings in mind, we expect that MYC inhibition mediated by MYC-
ASO treatment will result in profound viability effects in cancer cells. We have shown
that MYCASOs are able to knock down MYC mRNA and protein expression in can-
cer cell lines. We expect that this sustained inhibition of MYC activity will result
in proliferative arrest and induction of apoptosis. To test this hypothesis, we investi-
gated the effects of MYCASOs on the viability and proliferation of cancer cell lines.
As with MYC mRNA and protein knockdown, we sought to investigate the dose-
and time-responsiveness of the phenotypic effects of MYCASOs. To accomplish this
task, we employed two different assays: (1) an ATP-dependent luminescence-based
readout of viability, the ATPlite assay, and (2) a flow cytometry-based cell counting
method, the Guava ViaCount assay. The ATPlite assay utilizes cellular ATP levels
as a marker for cell viability, as ATP is present in all metabolically active cells, and
its concentration declines rapidly when cells die. The reagents used in the assay lyse
cells and react with cellular ATP to produce light. The emitted light is proportional
to the ATP concentration within a certain range. Therefore luminescence measure-
ments may be used as readouts of relative viability. The Guava ViaCount reagent
contains dyes to differentially stain alive and dead cells, which are then detected on
a single cell basis using a Guava flow cytometer. This assay gives a readout of num-
bers of alive and dead cells. The Guava ViaCount assay is particularly useful for
monitoring cell numbers over time, and we employed it as an orthogonal assay to
the ATPlite viability assay to observe how MYCASO treatment affects the growth of
cancer cells over time. As we have done throughout the chapter, we employed four dif-
ferent cancer cell lines representing distinct lineages and MYC statuses to rigorously
test the performance of our compounds: HeLa (cervical adenocarcinoma), MM1.S
(multiple myeloma), CUTLL1 (T-cell lymphoma), and HLF (non-differentiated hep-
atoma). Because HeLa cells are easily transfected and transfection allows for greater
MYC knockdown at much shorter time points and 1,000-fold lower doses, we chose to
continue studies using Lipofectamine transfection of HeLa cells to save on time and
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compound usage. MM1.S, CUTLL1, and HLF cell lines were treated with unformu-
lated MYCASOs.
As mentioned earlier in this chapter, MYC sits at the intersection of many differ-
ent pathways within the cell and is highly sensitive to a great number of perturbations.
We are seeking to rigorously investigate MYCASOs and determine whether all ob-
served activity is due to on-target or off-target effects. Towards this goal, we would
like to investigate whether any observed viability effects that come with MYCASO
treatment are indeed due to MYC knockdown, or if they are caused by off-target tox-
icities. Therefore we carried out a MYC viability rescue experiment. Our goal was
to re-introduce MYC protein to rescue MYCASO-mediated MYC knockdown and
resultant viability effects. Because MYCASOs have such a high affinity for the MYC
mRNA, we chose to design a mutant MYC construct with silent mutations within
the MYCASO binding sites, thereby abrogating MYCASO binding to the exogenous
MYC mRNA while still allowing for the expression of wild type MYC protein. Our
next step was to introduce this construct into cancer cells. We chose to generate a
HeLa cell line that had stably integrated the mutant MYC construct into its genome
using lentiviral transduction techniques. We designed the cell line to constitutively
overexpress the mutant MYC construct. Following generation of this cell line, we
compared it to the parental wild type HeLa cell line during MYCASO treatment to
observe whether the MYCASO-resistant MYC expressed in our generated line would
confer a rescue of viability effects.
Materials and Methods
Cell Culture HeLa cells and HEK293T cells (ATCC) were grown in Dulbecco’s
Modified Eagle’s Medium (DMEM, + 4.5 g/L D-glucose, + L-Glutamine, Sigma) sup-
plemented with 10% FBS. HLF cells (Broad Institute CCLE) were grown in DMEM
supplemented with 5% FBS. CUTLL1 and MM1.S cells were grown in RPMI 1640
(+ L-Glutamine, Sigma) supplemented with 10% FBS. Cells were maintained in an
incubator at at 37∘C and 5% CO2. Cells were maintained in Corning TC-treated
T-25, T-75, and T-175 flasks. HeLa, HLF, and HEK293T cells were harvested by dis-
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carding used media, washing with PBS, adding 0.25% trypsin (Sigma) to just cover
the vessel surface, placing cells at37∘C to detach, quenching trypsin with fresh me-
dia, and collecting the cell suspension. Semi-adherent MM1.S cells were harvested
by both collecting media containing cells in suspension and detaching adherent cells
using trypsin. Suspension CUTLL1 cells were harvested by collecting media. For
passaging, cells were spun at 200xg for 3 minutes, resuspended in fresh medium, and
seeded in new flasks. Cells were split 1:4 or 1:5 every 2-3 days.
MYCASO Treatments MYCASO powders were suspended in 0.5% saline to a
concentration of 5 mM as confirmed spectroscopically. The day before treatment,
HeLa and HLF cells were seeded at a density of 100,000 cells/mL and CUTLL1 and
MM1.S cells at 250,000 cells/mL, and cells were allowed to adhere and/or recover
overnight. For gymnotic treatments of HLF, CUTLL1, and MM1.S cells, the saline
solution was added directly to cell culture media for a final MYCASO concentration
of 0.5 to 20 mM. For transfection of HeLa cells, MYCASOs were mixed with Lipofec-
tamine 2000 in serum-free Opti-MEM (Sigma) and added to cell culture medium at
a final concentration of 0.5 to 100 nM MYCASO and 2.5 mL Lipofectamine / 1 mL
medium.
ATPlite Viability Assays ATPlite substrate was reconstituted in buffer as de-
scribed by PerkinElmer and diluted 1:1 in PBS. Cells were plated in white-bottom
96-well plates (PerkinElmer), allowed to recover overnight, and treated as described
above for 1 to 120 hours. Following treatment, 100 mL diluted ATPlite solution was
added to each well, plates were placed on an orbital shaker at 500 rpm for 2 min., and
luminescence was read using a PerkinElmer EnVision microplate reader. Lumines-
cence values were normalized to vehicle-treated controls. Each sample was performed
in quadruplicate
Guava Viacount Growth Over Time Assays Growth over time assays were
carried out using Guava ViaCount Reagent and a Guava easyCyte HT flow cytome-
ter (Millipore). Cells were plated in Corning TC-treated 48-well plates, allowed to
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recover overnight, and treated as described above. At each timepoint following treat-
ment, cells were harvested and mixed 1:1 with Guava ViaCount Reagent. 100mL
sample were plated in a clear 96-well plate, and the plate was loaded onto the flow
cytometer. Each timepoint was performed in triplicate. The ViaCount program in the
Guava software was used to count cells. Gating for live and dead cells was performed
manually for each cell line.
Generation of a Mutant MYC -Overexpressing Cell Line
Plasmid Design A mutant MYC cDNA construct was designed containing
17 silent mutations in the MYCASO-3, MYCASO-9, and MYCASO-13 seed sites
and a T58A mutation, shown to impair MYC degradation by the proteasome.[211,
212] The full sequence of the cDNA and a list of the introduced mutations can be
found in Appendix A. The construct was synthesized by Genewiz. The cDNA was
cloned into the pLenti6.3/V5-DEST plasmid using Gateway Cloning. First, mu-
tant MYC cDNA was amplified using custom primers containing Gateway attB
sequences on either end to generate an attB-PCR product (forward primer: 5’-
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCCCTCAACGTTAGCT-
TCACCA-3’; reverse primer: 5’-GGGGACCACTTTGTACAAGAAAGCTGGGTCT-
TACGCACAAGAGTTCCGTAGCTGT-3’). The reverse primer includes a stop codon
to prevent translation of C-terminal tags encoded in destination vectors. Next, a
Gateway BP recombination reaction was carried out to generate an entry clone: 100
fmol mutant MYC attB-PCR product, 300 ng pDONR221 plasmid, and 4 mL 5X
BP Clonase Reaction Buffer were diluted to 16 mL in TE buffer. 4 mL BP Clonase
enzyme mix were added, and the reaction was incubated at room temperature for
1 hr. After completion of the reaction, 1 mL reaction mix was mixed into 50 mL
DH5a competent cells (Invitrogen) on ice. The cell mixture was placed on ice for 30
min., heat-shocked at 42∘C for 45 sec., and placed back on ice for 2 min. 500 mL of
S.O.C. media were added to the cells and they were placed in a shaker at 37∘C for
45 min. The cell mixture was then spread on an agar plate containing 50 mg/mL
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Kanamycin and placed at37∘C overnight. The next day, individual bacterial colonies
were picked from the agar plate and sequenced using the M13 (-21) forward primer
(5’-TGTAAAACGACGGCCAGT-3’) for inclusion of the mutant MYC sequence in
the pDONR221 plasmid. A positive clone was grown up in 2 mL L.B. media con-
taining 50 mg/mL Kanamycin shaking at 37∘C overnight, then scaled up to 50 mL
the next day and placed at 37∘C shaking overnight again. The next day, the plasmid
was isolated from bacterial cells using a Qiagen Plasmid Midi Kit. Next, a Gateway
LR recombination reaction was carried out to generate the final expression clone: 300
ng mutant MYC entry clone, 300 ng pLenti6.3/V5-DEST plasmid, and 4 mL 5X LR
Clonase Reaction Buffer were diluted to 16 mL in TE buffer. 4 mL LR Clonase enzyme
mix were added, and the reaction was incubated at room temperature overnight. The
next day, DH5a competent cells were transformed with the reaction mixture as de-
scribed above and the bacterial cell mixture was spread on an agar plate containing
100 mg/mL Ampicillin and placed at 37∘C overnight. Individual colonies were picked
and sequenced for inclusion of the mutantMYC construct in the pLenti6.3/V5-DEST
plasmid using the CMV-forward primer (5’-CGCAAATGGGCGGTAGGCGTG-3’)
and the WPRE-reverse primer (5’-CATAGCGTAAAAGGAGCAACA-3’). A posi-
tive clone was grown up in L.B. media containing 100 mg/mL Ampicillin as described
above, and the plasmid was isolated from bacterial cells using a Qiagen Plasmid Midi
Kit. This plasmid will be referred to as pLenti.MYC.
Lentiviral Production HEK293T cells were plated in a 10 cm dish and co-
transfected with 600 ng pMD2.G (envelope plasmid), 1 mg psPAX2 (packaging plas-
mid), and 5 mg pLenti.MYC using Xfect Transfection Reagent (Clontech). After 48
hours, virus-containing media was collected, filtered through a 0.45-mM filter (Milli-
pore), and concentrated using Lenti-X Concentrator (Clontech).
Lentiviral Transduction HeLa cells were plated in a 24-well dish at 60,000
cells/well. The next day, 10 mL of concentrated virus were added per well. Polybrene
(Millipore) was added to half of the wells to a final concentration of 8 mg/mL. The
93
plate was spun at 250xg for 1 hour at room temperature, then placed in an incubator
at 37∘C and 5% CO2. After 24 hours cells were harvested, pooled, and plated in fresh
media. After 24 hours, Blasticidin was added to the media at a final concentration
of 1 mg/mL. Cells were maintained in DMEM with 10% FBS + 1 mg/mL Blasticidin,
refreshed every 2-3 days. This cell line will be referred to as HeLa.pLenti.MYC
Immunoblotting HeLa wild type and HeLa.pLenti.MYC cells were plated in Corn-
ing TC-treated 6-well dishes at 2 mL/well, allowed to recover overnight, treated as
described above, and harvested after a treatment time of 24 hours. Harvested cells
were placed on ice, centrifuged at 500xg at 4∘C for 5 min., washed with cold PBS,
centrifuged again, resuspended in cold RIPA buffer (Sigma) containing Halt Protease
Cocktail Inhibitor (Sigma), and placed on ice. After 45 min., cells were centrifuged
at 13,000xg at 4∘C for 15 min. Protein concentration in the supernatant was deter-
mined via BCA assay. Westerns were performed using the ThermoFisher Bolt system.
40 mg protein in Bolt Sample Buffer with 5% beta-mercaptoethanol was loaded per
lane into Bolt 4-12% Bis-Tris gels. Gels were submerged in Bolt MES running buffer
and run at 165 V for 35 min. Gels were transferred onto nitrocellulose membranes
at 10 V for 60 min. in Bolt Transfer Buffer. Membranes were blocked in Odyssey
Blocking Buffer for 30 min. at room temperature. Primary antibody incubation was
done overnight in Odyssey Blocking Buffer at 4∘C. Secondary antibody incubation
was done for 1 hr. at room temperature. Membranes were washed 3 times in TBS-T
between antibodies. Primary antibodies: c-MYC (Santa Cruz N-262, 1:500); alpha-
tubulin (Sigma T5168, 1:4,000). Secondary antibodies: LI-COR IRDye 800CW goat
anti-rabbit (1:7,000); LI-COR IRDye 680RD goat anti-mouse (1:7,000). Membranes
were imaged on a LI-COR Odyssey CLx using Image Studio software.
3.5.2 Results
As expected, MYCASO treatment was accompanied by a dramatic decrease in cell
viability as approximated by ATP-dependent luminescence in all four cancer cell lines.
This decrease in viability was both dose-proportional and time-proportional (Figure
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Figure 3-5: Cell viability eects of MYCASO treatment. (A) Dose-proportional ef-
fect of MYCASO treatment on cellular viability as approximated by ATP-dependent
luminescence normalized to vehicle-treated control. HeLa cells were treated with the
indicated doses of MYCASO in Lipofectamine for 24 hours. CUTLL1, MM1.S, and
HLF cells were treated with the indicated doses of unformulated MYCASO for 72
hours (CUTLL1 and MM1.S) or 120 hours (HLF). Values represent quadruplicate
means +/- SD. (B) Time-proportional eect of MYCASO treatment on cellular via-
bility as approximated by ATP-dependent luminescence normalized to vehicle-treated
control. HeLa cells were treated with 10 nM MYCASO in Lipofectamine for the in-
dicated time periods. CUTLL1, MM1.S, and HLF cells were treated with 10mM
unformulated MYCASO for the indicated time periods. Values represent quadrupli-
cate means +/- SD.
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Figure 3-6: Growth over time with MYCASO treatment. Cell numbers over time
with vehicle, NT-ASO, and MYCASO treatment. Cells were stained using the Guava
ViaCount reagent and counted by a Guava ow cytometer. HeLa cells were treated
with 10 nM MYCASO in Lipofectamine. CUTLL1, MM1.S, and HLF cells were
treated with 10 mM unformulated MYCASO. Values represent triplicate means +/-
SD.
3-5 A and B). Plots of cell numbers over time as determined via the orthogonal
flow cytometry-mediated cell counting Guava ViaCount assay are given in Figure 3-
6 and confirm that MYCASO treatment is accompanied by a dramatic decrease in
cell viability. MYCASO-treated cells grow more slowly at first compared to vehicle-
treated and NT-ASO treated cells and then begin to decrease in number over time.
Importantly, cell viability does not seem to be significantly altered by treatment with
the NT-ASO control.
To determine if the observed viability effects are a result of decreased MYC ex-
pression, we generated a HeLa cell line that stably, constitutively overexpresses a
MYC construct containing silent mutations in the MYCASO seed sites, designed
to abrogate MYCASO binding to the mutant MYC transcript while still producing
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wild-type MYC protein. This cell line is named HeLa.pLenti.MYC. Overexpression
of this mutant MYC partially rescued MYCASO-mediated MYC protein knockdown
(Figure 3-7 A). This was accompanied by a partial rescue of the decrease in cell vi-
ability observed with MYCASO treatment at 10 nM and at a high dose of 100 nM
(Figure 3-7 B).
3.5.3 Discussion
As expected, MYCASO treatment was accompanied by a dramatic decrease in cell
viability that is both dose- and time-proportional. Using flow cytometry-mediated
cell counting, we observed that MYCASO-treated cells grow more slowly at first
compared to vehicle-treated and NT-ASO treated cells and then begin to decrease in
number over time, suggesting that MYC inhibition first slows growth of cancer cells,
perhaps through proliferative arrest, and then results in cancer cell death, most likely
via apoptosis. Importantly, cell viability does not seem to be significantly altered by
treatment with the NT-ASO control, suggesting that observed viability effects are
mediated through MYC inhibition.
To further investigate this hypothesis, we generated a HeLa cell line that sta-
bly, constitutively overexpresses a MYC construct containing silent mutations in the
MYCASO seed sites, designed to abrogate MYCASO binding to the mutant MYC
transcript while still producing wild-type MYC protein. We observed that overex-
pression of this mutant MYC partially rescued MYCASO-mediated MYC protein
knockdown, suggesting that while the mutations introduced to the MYC mRNA
partially decrease MYCASO binding, MYCASOs still retain the ability to bind the
mutant construct and inhibit MYC protein expression, albeit to a lesser extent than in
the parental cell line. This partial rescue of MYC protein expression was accompanied
by a partial rescue of MYCASO-mediated viability effects. This rescue was evident
both at the typical MYCASO dose of 10 nM and at a significantly increased dose of
100 nM, suggesting that the HeLa.pLenti.MYC cells are able to translate MYC pro-
tein and maintain cell viability even at overwhelming doses of MYCASO. The rescue
of MYCASO-mediated viability effects observed with mutant MYC overexpression
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Figure 3-7: Rescue of MYCASO-mediated MYC protein knockdown and viability
eects. (A) Rescue of MYCASO-mediated MYC protein knockdown. Immunoblot for
c-MYC and b-tubulin following MYCASO treatment (10 nM in Lipofectamine for 24
hours) in HeLa cells (pLenti.MYC -) and in a HeLa-derived cell line stably expressing
a MYC construct containing silent mutations in MYCASO seed sites designed to
abrogate MYCASO binding (pLenti.MYC +). (B) Rescue of MYCASO-mediated
viability effects. Cellular viability as approximated by ATP-dependent luminescence
following MYCASO treatment (10 nM (left) or 100 nM (right) in Lipofectamine for
24 hours) in HeLa and mutant MYC over-expressing cells normalized to vehicle-
treated control. Expression of the mutant MYC construct leads to partial rescue of
MYCASO-mediated viability effects. Values represent triplicate means +/- SD.
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suggests that these viability effects are at least partially caused through inhibition of
MYC, suggesting on-target activity of MYCASOs, and that MYCASOs are indeed
able to inhibit the growth of cancer cells and induce apoptosis. The fact that the
observed rescue effect is only partial is most likely due to two factors. The first is
that MYCASOs clearly can still bind the mutant MYC construct and inhibit transla-
tion of functional MYC protein, so MYC is still not expressed at typical levels in the
mutant cell line. The second is likely toxicity of MYCASO molecules contributing to
the decrease in cell viability with treatment. This toxicity will be explored later.
We would like to take a moment to discuss our choices for the rescue experi-
ment. The HeLa.pLenti.MYC line was arrived at after much trial and error. Our
first attempt at a rescue experiment involved transfection of a Doxycycline-inducible
mutant MYC construct into HeLa cells. However, this transient rescue proved incon-
sistent as MYCASOs also need to be transfected into HeLa cells, and in our hands
co-transfection of the plasmid and ASO molecules resulted in inconsistent delivery of
the separate components that was difficult to control for, and we felt that this was
too unreliable of a method to rely on. We decided instead to utilize a stable system,
and we generated cell lines that had stably integrated a Dox-inducible mutant MYC
construct into their genomes. We generated these cell lines from CUTLL1, HLF,
and HeLa parental lines. However, these systems proved unreliable as well, as the
timing of Dox administration, induction of mutant MYC expression, time of treat-
ment, and duration of treatment were difficult to determine. Because the cell is so
sensitive to MYC levels and perturbations of the MYC axis, we believe that transient
induction of MYC expression presents too great of a disturbance to the cell, and
additionally that this transiently-expressed MYC may not even function normally in
such a scenario, which is essential for the rescue experiment. Keeping this in mind,
we decided that constitutive expression of the mutant MYC construct would be the
cleanest system for this experiment. We chose the pLenti6.3/V5-DEST vector for the
lentiviral transduction of the mutant MYC construct, which drives high expression
of the inserted gene from the CMV promoter, and which has performed robustly and
consistently in our hands. We attempted to transduce this vector into CUTLL1 and
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HLF cells, but we were unsuccessful. This was not surprising to us, as we expect that
forced overexpression of exogenous MYC would not be conducive to many cell type.
Despite this, we were successful in generating a HeLa cell line that had integrated
the mutant MYC construct into the genome from pooled samples of transduced cells.
Interestingly, this cell line looked slightly different and grew slightly faster than the
parental cell line, which is not surprising given that it is expressing MYC at higher
levels. It is important to note that it has been widely observed that when exogenous
MYC is introduced into cells, expression of MYC from the endogenous locus is shut
down [213, 214, 215], so it is likely that the HeLa.pLenti.MYC line is expressing only
the mutant MYC construct, which we believe is desirable for our rescue experiments.
As we observed, MYCASOs were still able to bind to the mutant MYC transcript
and inhibit MYC protein expression, but MYCASO activity was still significantly
abrogated sufficiently to allow for observation of a rescue of viability effects.
3.6 Transcriptional Consequences of MYC-Targeting
Antisense Oligonucleotide Treatment
3.6.1 Experimental Design
Rationale
MYC is often referred to as a master regulator transcription factor. It has greater
than 10,000 binding sites throughout the human genome, coordinates a regulatory net-
work that consists of approximately 15% of all genes, and sits downstream of many sig-
naling pathways.[15] MYC binding to the genome leads to the recruitment of histone
acetyltransferase activity and the chromatin remodeling SWI-SNF complex.[10, 11]
Deregulation and overexpression of MYC leads to amplification of transcription and
causes global alterations in chromatin structure.[216] The mechanism of these changes
remains an area of open debate. In 2012, Charles Lin et al. published a study employ-
ing chromatin immunoprecipitation-sequencing (ChIP-seq) analysis to identify MYC
binding sites in tumor cell lines with differential MYC expression.[23] The authors
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presented a model of MYC as a global transcriptional amplifier that invades all active
promoters and enhancers when expressed at high levels. In 2014, Arianna Sabo et
al. and Susanne Walz et al. published rebuttals, presenting an alternate model in
which MYC activates and represses the transcription of discrete gene sets.[24, 25]
Despite this remaining an open question, the field has traditionally referred to ‘MYC
target gene sets’ and ‘MYC gene signatures’ as fairly consistent and reliable tran-
scriptional consequences of MYC expression. MYC inhibition functions as a potent
cancer therapeutic through inhibition of the massive amounts of transcription medi-
ated by MYC. We therefore sought to investigate the transcriptional consequences
of MYCASO-mediated MYC inhibition, hypothesizing that we would observe knock-
down of ‘signature’ MYC genes.
We chose to utilize total mRNA sequencing (RNA-seq) analysis for an unbiased
readout of the transcriptional profile of MYCASO-treated cells. We performed these
experiments in HeLa cells, as many of our experiments up to this point have been
performed in this cell line. Because HeLa cells are treated with Lipofecamine trans-
fection of MYCASOs, we included empty Lipofectamine treatments to control for any
transfection reagent-related toxicities. We also included NT-ASO-treated samples to
control for general ASO-related toxicities. Due to cost limitations, we decided to test
only one MYCASO molecule, MYCASO-3. Finally, we chose two time points for
our analysis: four hours and eighteen hours. At the four hour time point, we have
observed that MYC mRNA is significantly knocked down, yet MYC protein level has
not yet changed and there have been no viability effects. We chose this time point to
investigate effects of MYCASO molecules at the mRNA level, before there has been
significant knockdown of MYC protein to alter the transcriptional profile of the cells.
At eighteen hours, there has been sustained MYC mRNA and protein knockdown,
but there is not yet any significant viability effect. We chose this time point to inves-
tigate the effects of sustained MYC protein knockdown, which, as described above,
we predict will significantly alter the transcriptome in a semi-predictable way.
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Materials and Methods
Cell Culture HeLa cells (ATCC) were grown in Dulbecco’s Modified Eagle’s Med-
ium (DMEM, + 4.5 g/L D-glucose, + L-Glutamine, Sigma) supplemented with 10%
FBS. Cells were maintained in an incubator at 37∘C and 5% CO2. Cells were main-
tained in Corning TC-treated T-25, T-75, and T-175 flasks. Cells were harvested
by discarding used media, washing with PBS, adding 0.25% trypsin (Sigma) to just
cover the vessel surface, placing cells at 37∘C to detach, quenching trypsin with fresh
media, and collecting the cell suspension. For passaging, cells were spun at 200xg for
3 minutes, resuspended in fresh medium, and seeded in new flasks. Cells were split
1:4 or 1:5 every 2-3 days.
MYCASO Treatments MYCASO powders were suspended in 0.5% saline to a
concentration of 5 mM as confirmed spectroscopically. The day before treatment,
HeLa cells were seeded at a density of 100,000 cells/mL allowed to adhere overnight.
For transfection of HeLa cells, MYCASOs were mixed with Lipofectamine 2000 in
serum-free Opti-MEM (Sigma) and added to cell culture medium at a final concen-
tration of 10 nM MYCASO and 2.5 mL Lipofectamine / 1 mL medium.
RNA-seq Analysis HeLa cells were seeded in Corning TC-treated 6-well dishes at
2 mL/well, allowed to recover overnight, treated as described above, and harvested
after treatment times of 0, 4, and 18 hours. Harvested cells were placed on ice, cen-
trifuged at 500xg at 4∘C for 5 min., washed with cold PBS, and centrifuged again.
For each sample, 10 mL cells were mixed with 10 mL trypan blue dye, loaded onto a
Countess cell counting chamber slide, and counted using a Countess II Automated
Cell Counter. Each sample was adjusted to contain 400,000 cells. RNA was iso-
lated using a QIAGEN RNeasy Mini Kit and eluted in RNAse-free water, and ERCC
synthetic spike-ins were added per the manufacture’s instructions (Ambion). RNA
samples were quantified using a Qubit 2.0 Fluorometer (Life Technologies, Carlsbad,
CA, USA) and RNA integrity was checked with an Agilent TapeStation (Agilent Tech-
nologies, Palo Alto, CA, USA). RNA library preparations and sequencing reactions
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were conducted at GENEWIZ, LLC. (South Plainfield, NJ, USA). RNA sequencing
library preparation was carried out using the NEBNext Ultra RNA Library Prep
Kit for Illumina by following manufacturer’s recommendations (NEB, Ipswich, MA,
USA). Briefly, mRNA were first enriched with Oligod(T) beads. Enriched mRNAs
were fragmented for 15 minutes at 94∘C. First strand and second strand cDNA were
subsequently synthesized. cDNA fragments were end repaired and adenylated at
3’ ends, and universal adapter was ligated to cDNA fragments, followed by index
addition and library enrichment with limited cycle PCR. Sequencing libraries were
validated on the Agilent TapeStation (Agilent Technologies, Palo Alto, CA, USA),
and quantified by using a Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA) as well
as by quantitative PCR (Applied Biosystems, Carlsbad, CA, USA).
The sequencing libraries were multiplexed and clustered on two lanes of a flowcell.
After clustering, the flowcell was loaded on the Illumina HiSeq instrument according
to manufacturer’s instructions. The samples were sequenced using a 2x150 Paired
End (PE) configuration. Image analysis and base calling were conducted by the
HiSeq Control Software (HCS). Raw sequence data (.bcl files) generated from Illumina
HiSeq were converted into fastq files and de-multiplexed using Illumina’s bcl2fastq
2.17 software. One mis-match was allowed for index sequence identification.
To visualize reads at the MYC locus, paired-end FASTQs were aligned using
HISAT2 v2.0.5 using default parameters. The index used was constructed from all
contigs from hg19 (Feb. 2009, GRCh37 (GCA_000001405.1)) and ERCC sequences
obtained from ThermoFisher. Deeptools v2.5.3 was used to convert bams to bed-
graphs with RPKM normalization and 100 bp bins. The coordinates of the MYC
locus were obtained from the RefGene database, and the Sushi v1.14.0 Bioconductor
package was used to plot pileup in this region.
For differential expression analysis, transcripts were quantified from raw paired-
end FASTQs using Salmon 0.8.2 with automatic library type detection and default pa-
rameters. The index used was built from RefMrna sequences obtained from hg19 (Feb.
2009, GRCh37 (GCA_000001405.1)) and from ERCC sequences obtained from Ther-
moFisher (https://assets.thermofisher.com/TFS-Assets/LSG/manuals/ERCC92.zip).
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Transcript-level counts were imported and merged to gene-level counts via the Txim-
port v1.4.0 Bioconductor package using a transcript-to-gene key generated from the
UCSC RefGene database. ERCC transcripts were excluded from the analysis at this
stage. DESeq2 v1.14 was used with single-factor design formula (“˜ condition”) to
find differentially expressed genes.
To generate MYCASO-3 and ASO signatures, transcripts were quantified and
merged to the gene-level as described above. Prior to analysis with DESeq2 v1.14,
zero-hour samples were excluded and a three factor design formula was used to test
for expression changes attributable to the presence of a MYCASO-3 while controlling
for treatment time as well as the presence of any ASO (MYCASO-3 or NT-ASO).
We also used this approach to test for expression changes attributable to ASOs in
general while controlling for time and the presence of MYC-targeted ASO. For each
of these comparisons, all genes and their associated Wald statistic were exported for
use with the GSEA Preranked function.
3.6.2 Results
Excellent concordance of mRNA expression was observed between replicate sam-
ples (Figure B-1). At each time point we observed a decrease in sequencing reads
that map to MYC exons specifically in MYCASO-3 treated cells (Figure 3-8 A and
B). This loss of MYC mRNA was slight but detectable after four hours of treat-
ment, and reached approximately 50% of total reads at the eighteen hour time point.
In both NT-ASO and MYCASO-3 treated cells, significant effects on other tran-
scripts were observed (Figure 3-8 B). However, much broader effects on the tran-
scriptome were observed at the eighteen hour time point, with dramatic effects on
hundreds of transcripts in both the NT-ASO and MYCASO-3 treated cells. After
four hours of NT-ASO treatment we detected a total of 771 genes downregulated and
308 genes upregulated, while after eighteen hours 4319 genes were downregulated and
4047 genes were upregulated (Log2 fold change <-0.2/>0.2, p value < 0.01). With
MYCASO-3 treatment, 355 genes were downregulated at four hours, including MYC
itself (p = 8.09e-16); 166 genes were upregulated. After eighteen hours of treatment
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Figure 3-8: Transcriptomic analysis of MYCASO-3 treated cells. (A) RNA-
sequencing was performed on HeLa cells transfected with NT-ASO or MYCASO-3
(10 nM) for either 4 or 18 hours. Lipofectamine 2000 was used as a delivery vehi-
cle. mRNA reads that were mapped to MYC exons were plotted for each sample,
revealing a slight decrease in MYC -mapped reads at 4 hours, and a pronounced ef-
fect at 18 hours, specifically with MYCASO-3 treatment. (B) Volcano plots of gene
expression differences comparing NT-ASO and MYCASO-3 treated cells with vehicle
after 4 and 18 hours. (C) Gene set enrichment analysis (GSEA) normalized enrich-
ment scores for MYC-associated gene sets (red and blue) and the total C2 gene sets
as part of MSigDB. Differential expression analysis was performed with DESeq2 to
generate MYCASO-3 specific expression signatures and total ASO-treated signatures
(NT-ASO and MYCASO-3 samples) as described in Methods. (D) GSEA signatures
for two example gene sets of genes positively regulated by MYC (MYC ‘UP’). (E)
GSEA signatures for two example gene sets of the interferon response.
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with MYCASO-3, 3975 genes were downregulated with MYC ranked 23 in signifi-
cance among downregulated genes (p = 5.18e-261); 4075 genes were upregulated with
MYCASO-3 including CDKN1A, known to be negatively regulated by MYC (p =
6.32e-240).[217] MYC mRNA levels were relatively unaffected by NT-ASO treatment
when compared to vehicle treated cells.
In order to reveal gene signatures that are affected by MYCASO-3 treatment
specifically and ASO treatment generally, we employed comprehensive gene set en-
richment analysis (GSEA) utilizing all curated gene sets available in the Molecular
Signatures Database (MSigDB ‘C2’, n = 3678 gene sets).[218] Global distributions
of gene set enrichment scores are shown in Figure 3-8 C. Among the library of gene
sets analyzed are 38 MYC-specific gene sets that have been experimentally defined
through functional assessments of genes up- or downregulated after selective pertur-
bation of MYC. We find that among the gene sets that are most highly negatively
enriched in MYCASO-3 treated cells are genes validated to be positively regulated by
MYC (MYC ‘UP’). 18 of 25 MYC ‘UP’ gene sets showed negative enrichment scores,
while only 5 of 25 did when all ASO (MYCASO-3 and NT-ASO) treated samples are
compared to vehicle control samples. All gene sets associated with negative regula-
tion by MYC (MYC ‘DOWN’) were conversely positively correlated with MYCASO-3
treatment. This pattern was not conserved when all ASO-treated samples were com-
pared to vehicle controls, revealing that the selective repression of MYC transcrip-
tional networks is specifically an effect of MYCASO-3 and not associated with general
consequences of ASO exposure (Figure 3-8 C). Notably, ASO-treated samples were
significantly associated with a global interferon response, as 9 of the top 12 enriching
gene sets were annotated as activated interferon signatures. Included in the MYC
‘UP’ signatures specifically enriched in MYCASO-3 treated samples are from stud-
ies from Coller et al. and Schuhmacher et al. (Figure 3-8 D) [219, 220]; exemplary
interferon signatures were annotated by Browne et al. and Zhang et al.[221, 222]
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3.6.3 Discussion
To better understand the global effects of MYCASO treatment specifically and
ASO treatment generally, we performed quantitative assessments of the global tran-
scriptome using total mRNA sequencing. HeLa cells were treated with MYCASO-3
or NT-ASO by transfection with lipid-based reagent formulation, and samples were
harvested at both four hours and eighteen hours post-transfection. Vehicle treated
cells were included as controls at both time points. At each time point we observed
a decrease in sequencing reads that map to MYC exons specifically in MYCASO-3
treated cells, as expected. This loss of MYC mRNA was slight but detectable after
four hours of treatment, and reached approximately 50% of total reads at the eighteen
hour time point. In both NT-ASO and MYCASO-3 treated cells, significant effects on
other transcripts were observed. However, much broader effects on the transcriptome
were observed at the eighteen hour time point, with dramatic effects on hundreds of
transcripts in both the NT-ASO and MYCASO-3 treated cells. With MYCASO-3
treatment, we observed downregulation of MYC at four hours (p = 8.09e-16) and at
eighteen hours (p = 5.18e-261). At the later time point MYC ranked 23 in signifi-
cance among downregulated genes, which is a promising result suggesting potent and
specific MYCASO-3 on-target performance. Importantly, MYC mRNA levels were
relatively unaffected by NT-ASO treatment when compared to vehicle treated cells.
Comprehensive gene set enrichment analysis revealed down-regulation of gene sets
regulated by MYC consistent with the literature. Importantly, this pattern was not
conserved when all ASO-treated samples were compared to vehicle controls, revealing
that the selective repression of MYC transcriptional networks is specifically an effect
of MYCASO-3 and not associated with general consequences of ASO exposure.
Notably, ASO-treated samples were significantly associated with a global inter-
feron response. This response to ASO exposure may be the driving force behind the
suggestions of ASO-related toxicity observed in this chapter.
These studies reveal that while global gene expression programs may be perturbed
non-specifically with ASO treatment, MYCASO treatment can have selective effects
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on both MYC and the MYC-associated gene expression programs required for cancer
cell proliferation and survival.
3.7 Conclusions
In the previous chapter, we described the synthesis of a library of LNA/DNA
antisense oligonucleotides targeted specifically against the full length of the human
MYC mRNA coding region and demonstrated their ability to engage with target
mRNA sequences. In this chapter, we examined the activity of these MYCASO
molecules in human cancer cell line models. We rigorously investigated activity and
mechanism in four different cancer cell lines representing distinct lineages and MYC
statuses, keeping in mind our commitment to developing a potent and selective MYC-
targeted prototypical therapeutic. The tested cell lines were HeLa (cervical ade-
nocarcinoma), MM1.S (multiple myeloma), CUTLL1 (T-cell lymphoma), and HLF
(non-differentiated hepatoma).
We found that when transfected into HeLa cells, MYCASOs potently down-
regulated MYC protein expression. Gymnotic unformulated delivery of MYCASOs
into HeLa, CUTLL1, MM1.S, and HLF cells also resulted in potent knockdown of
MYC protein expression, though activity was highly variable among the molecules,
highlighting the crucial role of cellular uptake/delivery and trafficking in the activity
of ASO molecules, and underlining the necessity for further work in this field.
We found that treatment with lead MYCASO molecules resulted in knockdown
of MYC mRNA and protein levels in both dose- and time-proportional manners.
Using a 5’ RACE assay we observed that MYCASO treatment resulted in cleavage
of MYC mRNA at the site of MYCASO binding, consistent with the mechanism of
RNase H these molecules were designed to employ, though interestingly visualization
and sequencing of cleavage products revealed MYC mRNA fragments with 5’ ends
distributed throughout the mRNA, with a predominance of cleavage sites located
within MYCASO binding sites, but not necessarily the MYCASO used in the given
treatment, suggesting potential new mechanisms of RNase H-mediated cleavage and
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interesting patterns of mRNA fragment degradation that may reflect on MYCASO
potency. We observed that with knockdown of RNase H1 activity, MYCASOs lost
their ability to decrease MYC mRNA, consistent with the intended MYCASO mech-
anism and historical ASO discoveries.
MYCASO treatment resulted in decreased cell viability that was both dose- and
time-proportional. MYCASO treatment at first slowed cell growth and then caused
cell death, suggesting that MYCASO-mediated MYC inhibition results in prolifera-
tive arrest and eventual apoptosis, consistent with the literature. MYCASO-mediated
viability effects were partially rescued with overexpression of a mutant MYC con-
struct designed to produce wild type MYC protein but abrogate MYCASO binding
to mRNA, confirming that MYCASO effects on viability are at least partially medi-
ated through MYC protein knockdown.
Finally, we utilized comprehensive RNA-seq transcriptomics to decipher global
MYCASO on- and off-target activity. Through this analysis we confirmed significant
knockdown of MYC expression with MYCASO treatment, and we observed selec-
tive down-regulation of MYC target gene sets. We also observed an up-regulation
of the interferon response with both MYCASO and NT-ASO treatment, as well as
suggestions of sequence-specific toxicity, which we will address later.
Overall, the data support on-target activity of MYCASO molecules as potent
and selective inhibitors of MYC protein expression through binding of MYC mRNA,
recruitment of RNase H, and transcript cleavage, resulting in knockdown of MYC
mRNA and protein levels. We see some suggestions of potential off-target activity and
toxicity, which we will investigate further later on. The next step in our path towards
developing prototypical MYC-targeting therapeutics is to investigate MYCASOs in
an in vivo setting.
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Chapter 4
MYC-Targeting Antisense
Oligonucleotide Activity in Animal
Models
4.1 Introduction
In previous chapters, we described the synthesis of a library of MYC -targeting
LNA/DNA-modified antisense oligonucleotides and demonstrated their ability to bind
and cleave MYC mRNA via a well-established RNase H-mediated mechanism [69],
potently down-regulating MYC mRNA and protein levels and causing profound tran-
scriptional changes and viability effects in a variety of different MYC-expressing hu-
man cancer cell lines. Our goal in developing these MYCASO molecules is to generate
prototypical MYC-directed therapeutics for the treatment of cancer. The next step
in the drug development process is in vivo validation of MYCASO compounds.
Due to difficulties that will be explained later, we tested MYCASOs in a variety of
different in vivo models. First, we will present data from a Zebrafish model of acute
lymphoblastic leukemia. The remainder of the in vivo studies were performed in
murine models, so next we present tolerability and toxicity studies of lead MYCASO
molecules performed in mice. Following this, we present data from MYCASO treat-
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ment in the following murine models: a disseminated multiple myeloma xenograft,
an orthotopic hepatocellular carcinoma xenograft, an orthotopic renal cell carcinoma
xenograft, and finally a MYC-driven hepatocellular carcinoma model.
4.2 Zebrafish Conditional Transgenic T-Cell Acute
Lymphoblastic Leukemia Model
4.2.1 Experimental Design
Rationale
Bolstered by our data showing MYCASO efficacy in CUTLL1 cells, we sought to
evaluate MYCASO activity in an in vivo T cell acute lymphoblastic leukemia model.
The zebrafish is a model organism commonly employed for biological investigation
and in vivo modeling. The zebrafish is a popular model organism for many reasons,
including small size, low cost, relatively quick reproduction time, large number of
offspring per reproduction, ease of genetic manipulations, and robust behavior.[223]
Importantly for us, it is possible to deliver a therapeutic agent to zebrafish simply
by soaking the zebrafish in a solution containing the molecule.[224] Furthermore, the
A. Thomas Look lab at the Dana Farber Cancer Institute has developed a robust
model of T cell acute lymphoblastic leukemia in zebrafish.[6] Importantly, this model
is MYC-driven, making it ideal for MYCASO studies.
More specifically, the Look lab zebrafish leukemia model is a compound trans-
genic fish, with Cre recombinase integrated into the genome under the control of
the heat-shock promoter and a loxP-dsRED2-loxP-EGFP-mMYC cassette integrated
into the genome under the control of the rag2 promoter (mMYC: mouse c-MYC).
This system allows for development of healthy zebrafish and maintenance of the line
under normal conditions. Heat shock treatment at three days post-fertilization leads
to Cre expression, rearrangement of the loxP loci, and expression of EGFP-mMYC.
Importantly, this occurs only in developing T cells expressing rag2. Overexpression
of MYC leads to development of T-cell acute lymphoblastic leukemia. Development
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of T-ALL is highly penetrant, occurring in 81% of sh. Because MYC is tagged with
EGFP, tumor burden can be visualized, monitored, and measured as uorescence in
the thymus.
This model is well suited for MYCASO studies. The disease is MYC-driven,
providing a relatively uncomplicated model for the study of MYC inhibition. Impor-
tantly, mouse and humanc-MYC are largely homologous [225], and all MYCASO
sequences were designed to target both human and mouse MYC with no mismatches.
As mentioned, we can deliver MYCASOs to zebrafish simply by soaking the fish in
an aqueous solution containing dissolved MYCASO. Finally, zebrafish T-ALLs are
remarkably similar to human T-ALLs [226], suggesting that this model will be a good
predictor of MYCASO activity in treatment of human disease. For these reasons, we
teamed up with the Look lab to evaluate MYCASO activity in this zebrafish model
of T-ALL.
Materials and Methods
See Feng et al. 2007, Langenau et al. 2005, and Langenau et al. 2003 for
details on the generation of transgenic zebrafish and the conditional induction of
T-ALL.[6, 226, 227]
Zebrafish were kept individually in wells of a clear 96-well plate in water. For the
first, pilot experiment, fish were incubated in water containing 50 mM MYCASO-3 or
MYCASO-13. 5 mM JQ1, dexamethasone, and DMSO treatments were included as
controls.[42, 228] For the second experiment, fish were incubated in water containing
50, 100, or 150 mM NT-ASO, MYCASO-3, or MYCASO-13. 5 mM JQ1 and DMSO
treatments were included as controls. After 2.5 days of treatment (5.5-8 days post-
fertilization), tumor burden was measured as thymic fluorescence.
4.2.2 Results
In the pilot experiment, treatment with both 50 mM MYCASO-3 and 50 mM
MYCASO-13 resulted in a significant decrease in thymic fluorescence compared to
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DMSO-treated controls (Figure 4-1 A). Pictures taken of the EGFP uorescence are
shown in Figure 4-1 B and show decreased thymic uorescence with MYCASO-3 and
MYCASO-13 treatments. In the second experiment, treatment with 100mM and 150
mM of MYCASO-3 and with 50 mM, 100 mM, and 150 mM of MYCASO-13 resulted
in a significant decrease in thymic fluorescence compared to DMSO-treated controls
(Figure 4-1 C). Treatment with 150 mM of NT-ASO also resulted in a decrease in
tumor burden.
4.2.3 Discussion
The zebrafish model presented here is ideal for studies of MYCASO activity be-
cause it is MYC-driven, the zebrafish disease imitates human T-ALL remarkably well,
and treatment of zebrafish with antisense oligonucleotides is a relatively easy and
straightforward process.[6, 224, 226] We observed that treatment with MYCASO-3
and MYCASO-13 decreased tumor burden in this model. In our pilot study, treat-
ment with both MYCASOs at 50 mM resulted in significantly decreased tumor burden.
However, the data from the second study are much messier. We were unable to recre-
ate the decrease in tumor burden observed with 50 mM MYCASO-3 treatment in
the first study. However, MYCASO-3 treatment decreased tumor burden at 100 mM
and 150 mM, and MYCASO-13 treatment decreased tumor burden again at 50 mM
as well as at the higher doses of 100 mM and 150 mM. The decrease in tumor burden
with MYCASO-3 and MYCASO-13 treatment was dose-proportional. The NT-ASO
control molecule decreased tumor burden when dosed at 150 mM, suggesting that
high doses of ASO molecules may lead to some kind of anti-tumor activity in this
model. Despite this observation, activity of MYCASO molecules at the lower doses
is suggestive of on-target activity and indicates that MYCASOs are able to decrease
tumor burden in a T-ALL model.
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Figure 4-1: Activity of MYCASOs in a zebrafish model of T-cell acute lymphoblastic
leukemia. T-ALL was induced in zebrafish as described by Feng et al.[6] Zebrafish
were incubated with the indicated concentrations of compounds for 2.5 days, at which
time thymic fluorescence was measured as an indicator of tumor burden. (A) Thymic
fluorescence following treatment with the indicated compounds in our pilot study. (B)
Representative fluorescent images of tumors from fish in our pilot study. (C) Thymic
fluorescence following treatment with the indicated compounds in our second study.
Red lines represent median values. * indicates p value < 10-5, ** indicates p value <
10-6 as determined via an unpaired student t-test.
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4.3 Tolerability and Toxicity in Mice
4.3.1 Experimental Design
Rationale
Murine models represent the gold standard for demonstrating in vivo efficacy for
cancer drug development.[229] Mice represent the most robust mammalian model
organism available to us in the lab. As a first step towards investigating MYCASO
efficacy in murine models, we performed a tolerability and toxicity study. For this
study we utilized C57BL/6J mice, the most widely used inbred strain. We tested
MYCASO-3, MYCASO-9, MYCASO-13, and NT-ASO compounds at two doses: 25
mg ASO/kg body weight every three days (high dose, ‘HI’), and a one-time dose of
25 mg ASO/kg body weight followed by 5 mg ASO/kg body weight every three days
(low dose, ‘low’). These doses were chosen based off of doses that have been well-
tolerated in published reports of other ASO molecules.[230, 231, 232] Tolerability and
toxicity were determined by monitoring body weight and general appearance of mice
over time. Tissue analysis was also performed after two weeks of dosing to look for
signs of toxicity in the liver (because ASOs are hepatotropic) and the intestine (due
to the rapid turnover of intestinal cells).
Materials and Methods
Thirty-six seven-week-old female C57BL/6J mice were obtained from The Jackson
Laboratory and housed in the Dana Farber Cancer Institute Vivarium. Mice were
divided into nine cohorts with four mice per cohort. Prior to treatment, body weights
of mice were measured. NT-ASO, MYCASO-3, MYCASO-9, and MYCASO-13 were
formulated in a 0.9% saline solution and administered via lateral tail vein injection.
The vehicle treatment was injection of saline solution alone. The nine cohorts were
dosed with vehicle or NT-ASO, MYCASO-3, MYCASO-9, or MYCASO-13 at the one
of two different doses: 25 mg ASO/kg body weight every three days (high dose, ‘HI’),
and a one-time dose of 25 mg ASO/kg body weight followed by 5 mg ASO/kg body
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weight every three days (low dose, ‘low’). Body weights were measured and mice were
observed for signs of overt toxicity at the time of treatment every three days. Body
weights were normalized to beginning body weights to monitor for weight loss with
treatment. Mice were treated for twenty-one days for a total of seven treatments.
The MYCASO-13 HI treatment group had to be sacrificed at day 12 after only four
treatments due to severe weight loss, dehydration, and jaundice.
After two weeks of treatment continued for a total of four treatments, represen-
tative mice from the vehicle-treated cohort, MYCASO-3 HI cohort, MYCASO-9 HI
cohort, and MYCASO-13 low cohort were sacrificed for tissue analysis. The Dana
Farber Cancer Institute Pathology Core Facility performed tissue analysis. Repre-
sentative slices of liver were obtained and underwent hematoxylin and eosin staining
to monitor for ASO-mediated hepatic toxicity. Representative slices of intestine were
obtained and underwent immunohistochemical staining for MYC protein to assess
MYCASO activity in healthy intestinal tissue.
This study was carried out under an approved protocol by the Animal Care and
Use Committee.
4.3.2 Results
Body weights of mice over time are shown in Figure 4-2 A. No significant weight
loss or overt toxicity was observed with NT-ASO treatment at both high and low
doses, with MYCASO-3 treatment at the low dose, with MYCASO-9 at both high
and low doses, and with MYCASO-13 treatment at the low dose. Slight toxicity was
observed with MYCASO-3 treatment at the high dose as determined via slight weight
loss. Severe toxicity was observed with MYCASO-13 treatment at the high dose as
determined via extreme weight loss and observed dehydration/jaundice.
Tissue analysis of liver and intestine from mice from the vehicle-treated cohort,
MYCASO-3 HI cohort, MYCASO-9 HI cohort, and MYCASO-13 low cohort is shown
in Figure 4-2 B. There is no observable hepatotoxicity with MYCASO treatment
as determined via hematoxylin and eosin (H&E) staining of liver tissue slices. Im-
munohistochemical staining for MYC protein in intestinal tissue slices revealed some
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Figure 4-2: MYCASO tolerability and toxicity in mice. Mice were treated with
MYCASOs formulated in a 0.9% saline solution via tail vein injection at either the
HI dose, 25 mg/kg every three days, or the low dose, a one-time administration of
25 mg/kg followed by 5 mg/kg every three days. (A) Body weights of mice over
time. Mice were treated for three weeks for a total of seven treatments and body
weights were determined at each treatment and presented as a percentage of starting
weight. (B) Tissue analysis of MYCASO treatment. After two weeks of dosing
for four treatments, select mice were sacrificed and liver tissue was harvested for
hematoxylin and eosin staining (H&E) and intestinal tissue was harvested for MYC
immunohistochemistry.
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decrease in MYC expression with MYCASO-3 and MYCASO-13 treatment.
4.3.3 Discussion
MYCASOs seem to be well tolerated and demonstrate minimal toxicity in mice.
Importantly, a high dose of MYCASO-13 treatment was very poorly tolerated, char-
acterized by severe weight loss and dehydration, necessitating early sacrifice of mice
treated at that dose. A high dose of MYCASO-3 also produced slight weight loss.
Otherwise, MYCASOs were well tolerated, suggesting that treatment with MYC-
ASOs at these doses is acceptable in future studies. MYCASO treatment did not
result in overt hepatotoxicity as determined via H&E staining of liver tissue. Treat-
ment with MYCASO-3 and MYCASO-13 resulted in a slight decrease in MYC ex-
pression in intestinal cells as determined via immunohistochemical staining for MYC
protein. This represents on-target activity of MYCASO molecules. Previous studies
have demonstrated that MYC knockdown in intestinal cells with systemic MYC in-
hibition is well-tolerated and rapidly and completely reversible [30], suggesting that
our observations are not cause for concern in future studies. Overall, MYCASOs
are well-tolerated and non-toxic in mice at the appropriate doses, and we feel pre-
pared to utilize MYCASO treatments in murine cancer models towards the goal of
demonstrating in vivo efficacy.
4.4 Murine Disseminated Multiple Myeloma
Xenograft Model
4.4.1 Experimental Design
Rationale
In the previous chapter we demonstrated MYCASO activity in a cancer cell line
model of multiple myeloma, MM1.S. The MM1.S cell line harbors an IgH/MYC
translocation that results in dramatically increased expression of the MYC gene
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driven by the IgH enhancers.[201] Due to the potent activity of MYCASOs in MM1.S
cells and the underlying biology producing a MYC-driven model, we chose to inves-
tigate MYCASO activity in an MM1.S xenograft murine model. More specifically,
we created luciferase-expressing MM1.S cells to be able to easily monitor tumor bur-
den in vivo. When injected into mouse tail veins, the MM1.S cell line develops into
disseminated multiple myeloma. Importantly, the study must be carried out in im-
munocompromised mice to avoid immune rejection of the human cell line. This model
has been utilized extensively for assessment of drug activity.[233, 234, 235] Due to the
disseminated nature of the disease, we believe this model is well suited for systemic
administration of MYCASOs via tail vein injection.
Materials and Methods
MM1.S murine xenografts were carried out as previously described.[233, 234, 235]
Briefly, the luciferase gene was stably integrated into the genome of the MM1.S cell
line. NSG male mice were obtained from The Jackson Laboratory and divided into
four treatment cohorts with eight mice per cohort. Two million luciferized MM1.S
cells were injected into mouse tail veins. Mice were treated with vehicle control,
MYCASO-3 at 25 mg ASO/kg bodyweight every three days, MYCASO-9 at 25 mg
ASO/kg bodyweight every three days, or MYCASO-13 once at 25 mg ASO/kg body-
weight followed by 5 mg ASO/kg bodyweight every three days. Treatments were
administered via tail vein injection. Mouse body weight was measured during treat-
ment to monitor for toxicity. Luciferin was provided in the drinking water, and tumor
burden was measured as bioluminescence during treatment. Mice were treated for 24
days. Overall survival was monitored as the primary endpoint. Mice were sacked
after 28 days, or when a clinical endpoint was reached, defined as changes in posture,
gait, or mobility that interfered with feeding behavior, such as hind limb paraly-
sis, consistent foot dragging, or spinal curvature. After mice were sacked, the Dana
Farber Pathology Core Facility performed tissue analysis. Liver and bone marrow
tissue slices were analyzed for MYC protein expression via immunohistochemistry.
The study was performed at the Dana Farber Cancer Institute under an approved
120
protocol by the Animal Care and Use Committee.
4.4.2 Results
Luciferized MM1.S cells injected into NSG mouse tail veins developed into dissem-
inated multiple myeloma in all four treatment cohorts, as measured by an increase in
bioluminescence over time as a readout of tumor burden (Figure 4-3 A). MYCASO
treatment had no effect on tumor burden compared to vehicle-treated controls. Ad-
ditionally, MYCASO treatment resulted in no significant change in overall survival
compared to vehicle-treated controls (Figure 4-3 B). The relative body weights of
mice during treatment are shown in Figure 4-3 C. Treatment with MYCASO-3 and
MYCASO-13 resulted in a small amount of weight loss compared to vehicle-treated
controls. Importantly, severe jaundice was observed with MYCASO-13 treatment
after the third dose. The fourth dose was skipped, and regular dosing was resumed
with the fifth dose. Representative MYC immunohistochemistry images are given
in Figure 4-3 D. MYC expression in mouse livers was sparse and was unaffected by
MYCASO treatment. MM1.S cells home to the bone marrow [233], thus MYC expres-
sion in mouse bone marrows was analyzed. As expected, staining for MYC expression
showed intense and uniform MYC in the bone marrow. MYC expression in the bone
marrow was unaffected by MYCASO treatment.
4.4.3 Discussion
A MM1.S xenograft murine model is an ideal model for assessing MYCASO activ-
ity in vivo due to the MYC-driven nature of the disease and the indications of MYC-
ASO activity in MM1.S cells in vitro demonstrated previously. Here we established
disseminated multiple myeloma in NSG mice with luciferized MM1.S cells. Tumor
engraftment and growth proceeded as expected. Mice were treated with MYCASOs
at doses determined to be well tolerated in the tolerability and toxicity study de-
scribed above. MYCASO treatment was relatively well tolerated by mice, except for
jaundice observed with MYCASO-13 treatment. Importantly in this study, MYC-
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Figure 4-3: Activity of MYCASOs in a murine xenograft model of disseminated
multiple myeloma. NSG mice were injected with luciferized MM1.S cells and treated
with vehicle control, MYCASO-3 at a dose of 25 mg/kg every three days, MYCASO-9
at a dose of 25 mg/kg every three days, or MYCAO-13 at a one-time dose of 25 mg/kg
followed by 5 mg/kg every three days. (A) Tumor burden over time as measured by
bioluminescence. MYCASO treatment had no effect on tumor burden. (B) Overall
survival of mice. MYCASO treatment had no effect on overall survival. (C) Relative
weights of mice over time with treatment. MYCASO-3 and MYCASO-13 treatments
caused slight decreases in weight. (D) Representative MYC immunohistochemistry
images from the livers and bone marrow of treated mice. MYC expression in the liver
was low and unaffected by MYCASO treatment. MYC expression in bone marrow
was high due to MM1.S tumor engraftment and unaffected by MYCASO treatment,
suggesting poor delivery of MYCASO molecules to the bone marrow compartment in
vivo.
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ASO treatment did not have an effect on tumor burden or overall survival. MYC
immunohistochemistry performed on mouse bone marrow following treatment may
provide an explanation as to why this is. MM1.S cells home to the bone marrow and
a large proportion of the tumor burden resides in the bone marrow niche. There was
no change in MYC expression in bone marrow tumors as determined by MYC IHC.
Because we have demonstrated the ability of MYCASOs to decrease MYC protein
expression in MM1.S cells in vitro and in mice intestinal tissue when administered
systemically in vivo, this finding suggests that in this study MYCASOs were not
delivered to MM1.S-derived tumors. The inability to deliver MYCASO molecules to
these tumors in vivo may be a result of tumor localization to the bone marrow, which
has historically been exceptionally difficult to target.[236, 237, 238] Thus we believe
that this study represents not a failure of MYCASO molecules to achieve MYC inhi-
bition and decrease tumor burden in an in vivo setting but rather an illustration of
the delivery challenges facing antisense oligonucleotide therapeutics. Moving forward,
we aim to demonstrate MYCASO activity in vivo in another setting with fewer deliv-
ery challenges, while keeping in mind the potential to expand MYCASO applications
with specialized nanoparticles or other optimized delivery modalities.[125, 239]
4.5 Murine Orthotopic Hepatocellular Carcinoma
Xenograft Model
4.5.1 Experimental Design
Rationale
Keeping in mind the delivery challenges inherent to ASO compounds [125, 239],
we elected to investigate MYCASO activity in a murine liver cancer model. ASOs
are widely known to be hepatotropic [141, 142] due to the large amount of blood flow
through the liver as well as the activity of macrophages in the reticuloendothelial sys-
tem that internalize ASOs and pass through the liver. We have observed MYCASO
activity in a variety of liver cancer cell lines, including HLF, HepG2, HEP3B, and
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SNU-398 cell lines. The SNU-398 cell line is derived from a hepatocellular carcinoma
and harbors mutations in p53 andb-catenin leading to deregulated Wnt pathway
signaling.[240] A consequence of deregulated Wnt signaling is deregulated MYC ex-
pression [17], thus these cells are MYC-dependent and may be susceptible to MYC-
ASO treatment. Indeed, we have observed that MYCASOs are able to induce cleavage
of MYC mRNA and decrease MYC protein expression in SNU-398 cells comparable
to what we have reported here for other cell lines. Therefore we sought to evaluate
MYCASO activity in an orthotopic SNU-398 xenograft murine model of hepatocel-
lular carcinoma.
Materials and Methods
Cell Culture SNU-398 cells (ATCC) were grown in RPMI 1640 (+ L-Glutamine,
Sigma) supplemented with 10% FBS. Cells were maintained in an incubator at 37∘C
and 5% CO2. Cells were maintained in Corning TC-treated T-25, T-75, and T-175
flasks. SNU-398 cells are semi-adherent and were harvested by both collecting media
containing cells in suspension and detaching adherent cells using trypsin: vessels were
washed with PBS, 0.25% trypsin (Sigma) was added to just cover the vessel surface,
cells were placed at 37∘C to detach, trypsin was quenched with fresh media, and the
cell suspension was collected. For passaging, cells were spun at 200xg for 3 minutes,
resuspended in fresh medium, and seeded in new flasks. Cells were split 1:4 or 1:5
every 2-3 days.
Establishment of a Murine Orthotopic Hepatocellular Carcinoma Xenograft
Model The luciferase gene was stably integrated into the genome of SNU-398 cells
as previously described.[241] To determine whether luciferized SNU-398 cells would
engraft, one million cells were injected via tail vein into three NSG mice (The Jackson
Laboratory). Every week post-injection luciferin was placed in mouse drinking water
and bioluminescence was measured as a readout of tumor burden.
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MYCASO Treatment of Tumor-Bearing Mice Mice were divided into treat-
ment cohorts, injected with one million luciferized SNU-398 cells, and treated with
vehicle control or MYCASO-3 at 25 mg ASO/kg bodyweight every three days admin-
istered via tail vein injection. Tumor burden was measured at every treatment time
via bioluminescent imaging. Mice were treated until clinical endpoint was reached,
defined as changes in posture, gait, or mobility that interfered with feeding behavior,
at which time mice were sacked.
5’ RACE Analysis of Mouse Tumors Once mice were sacked, livers were iso-
lated, tissue was lysed and homogenized, and RNA was isolated using a QIAGEN
RNeasy Mini Kit and eluted in RNase-free water. RNA concentration of samples
was determined spectroscopically using a Thermo Scientific NanoDrop 8000. The 5’
RACE assay was carried out as described by Invitrogen using their 5’ RACE kit. A
thermal cycler was used for all incubations.
First Strand cDNA Synthesis In 8-strip PCR tubes, 5 mg total RNA and 2.5
pmol gene specific primer 1 (GSP1-RT: 5’-TGTTTCAACTGTTCTC-3’) were diluted
to 15.5 mL in DEPC-treated water, incubated for 10 min. at 70∘C, then chilled for
1 min. on ice. Next, 2.5 mL 10X PCR buffer, 2.5 mL 25 mM MgCl2, 1 mL 10 nM
dNTP mix, and 2.5 mL 0.1 M DTT were added to the sample, followed by a 1 min.
incubation at 37∘C. 1 mL SuperScript II RT was added to the reaction, followed by
incubation at 42∘C for 50 min., then 70∘C for 15 min. 1 mL RNase mix was then
added, followed by incubation at 37∘C for 30 min. The cDNA reaction was purified
using a Qiagen PCR purification kit and eluted in nuclease-free water.
TdT Tailing of cDNA The following components were added to an 8-strip
PCR tube: 6.5 mL DEPC-treated water, 5 mL 5X tailing buffer, 2.5 mL 2 mM dCTP,
and 10 mL cDNA sample. Reactions were incubated for 2.5 min. at 94∘C, then chilled
for 1 min. on ice. 1 mL TdT was added, followed by incubation for 10 min. at 37∘C,
then 10 min. at 65∘C.
125
PCR of dC-tailed cDNA The following components were added to an 8-strip
PCR tube: 32 mL nuclease-free water, 5 mL 10X PCR buffer, 3 mL 25 mM MgCl2,
1 mL 10 mM dNTP mix, 2 mL 10 mM nested gene specific primer 2 (GSP2: 5’-
CCTCTGCTTGGACGGACAGGA-3’), 2 mL 10 mM Abridged Anchor Primer (AAP:
5’-GGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG-3’), 5 mL dC-tailed cDNA.
0.25 mL Taq DNA polymerase (5 units/mL) was added immediately before mixing the
reaction and placing in a thermal cycler pre-equilibrated to 95∘C to run the following
PCR protocol: 95∘C for 2 min.; 30 cycles of 95∘C for 15 sec., 58∘C for 15 sec., and
68∘C for 1 min.; and final extension at 68∘C for 5 min.
Nested Amplification For improved visualization of PCR products, a second
PCR reaction was carried out using another nested gene specific primer (GSP3: 5’-
CTGGTCACGCAGGGCAAAAA-3’) and the 5’ RACE abridged universal anchor
primer (AUAP: 5’-GGCCACGCGTCGACTAGTAC-3’). The PCR products from
the previous step were diluted 1:100 in TE buffer. The following components were
added to an 8-strip PCR tube: 34 mL nuclease-free water, 5 mL 10X PCR buffer, 3
mL 25 mM MgCl2, 1 mL 10 mM dNTP mix, 1 mL 10 mM GSP3, 1 mL 10 mM AUAP,
5 mL diluted primary PCR product. 0.25 mL Taq DNA polymerase (5 units/mL) was
added immediately before mixing the reaction and placing in a thermal cycler pre-
equilibrated to 95∘C to run the following PCR protocol: 95∘C for 2 min.; 30 cycles of
95∘C for 15 sec., 57∘C for 15 sec., and 68∘C for 1 min.; and final extension at 68∘C
for 5 min.
Gel Visualization of PCR Products 10 mL PCR product were loaded onto
an E-Gel 1.2% with Ethidium Bromide Agarose Gel (Invitrogen). Gels were run using
an E-Gel iBase Power System (Invitrogen) set to program 1 for 20 min. 5 mL of E-Gel
1 kb Plus DNA Ladder (Invitrogen) were loaded into one lane per gel.
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4.5.2 Results
Injection of luciferizied SNU-398 cells into NSG mouse tail veins resulted in an ex-
ponential increase in bioluminescence over the course of seven weeks, suggesting that
this cell line is able to engraft and grow tumors in mice (Figure 4-4 A). Furthermore,
bioluminescent imaging of mice revealed that the bioluminescent signal was generated
in the liver, indicating orthotopic engraftment of this hepatocellular carcinoma cell
line (Figure 4-4 B).
Despite successful engraftment of this cell line, MYCASO-3 treatment did not
result in any significant decrease in tumor burden or overall survival (data not shown).
In a few mice, MYCASO-3 treatment slowed tumor growth and decreased overall
tumor burden; but on the whole, no significant difference between treatment groups
was observed.
5’ RACE analysis performed on RNA isolated from treated mice did not reveal
any MYC mRNA fragments from either vehicle-treated or MYCASO-3-treated mice
(data not shown).
4.5.3 Discussion
We succeeded in creating an orthotopic hepatocellular carcinoma xenograft murine
model from luciferized SNU-398 cells. These cells have deregulated MYC expression
and were susceptible to MYCASO treatment in vitro, and they were able to engraft
in NSG mice and grow tumors in mouse livers. However, MYCASO-3 administration
via tail vein injection did not result in any significant change in tumor burden or
overall survival. A few mice did respond, with slower growing tumors and decreased
tumor burden overall. However, on the whole, no significant difference between treat-
ment groups was observed. 5’ RACE analysis carried out on RNA isolated from
treated mice did not reveal MYC transcript fragments in MYCASO-3-treated mice,
suggesting that MYCASO molecules were not being internalized by tumor cells, as
we observed with our disseminated multiple myeloma xenograft murine model, above.
Though ASOs are hepatotropic, it has been shown that delivery of any molecule to
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Figure 4-4: Establishment of a murine orthotopic hepatocellular carcinoma xenograft
model. NSG mice were injected with one million luciferized SNU-398 cells. Luciferin
was placed in mouse drinking water and bioluminescence was measured every week to
monitor tumor burden. (A) Bioluminescence signal measured for seven weeks post-
injection. The luciferized SNU-398 cells are able to engraft and grow tumors in NSG
mice. (B) Images of bioluminescent signals from injected mice. Luciferized SNU-398
cells engraft in the liver and grow large tumors, constituting an orthotopic model of
hepatocellular carcinoma.
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solid tumors is inhibited by the increased pressure within the tumor caused by rapid
growth of a solid mass without the appropriate growth of blood vessels to maintain
physiological hydrostatic, interstitial, and oncotic pressure.[242, 243, 244, 245] Thus
we hypothesize that this study represents not a failure of MYCASO molecules to
achieve MYC inhibition and decrease tumor burden in anin vivo setting, but rather
a demonstration of the delivery challenges inherent to treating solid tumors. Moving
forward, we aim to identify a model in which we can demonstrate MYCASO activity
in vivo in a setting with fewer delivery challenges.
4.6 Murine Conditional Transgenic Renal Cell
Carcinoma Model
4.6.1 Experimental Design
Rationale
Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of
the proximal convoluted tubule. MYC activity is increased in most cases of RCC,
the MYC gene is amplified in 5-10% of patients, MYC is overexpressed in 20% of
patients, and MYC is associated with a hereditary RCC syndrome.[246] Additionally,
systemically administered ASOs accumulate in the kidney, much like the liver, due to
high blood flow and the activity of the reticuloendothelial system.[141, 142] For these
reasons, we chose to pursue a murine RCC model to investigate in vivo MYCASO
activity. We collaborated with the Dean Felsher laboratory at Stanford to utilize their
MYC-driven conditional transgenic mouse model.[246] In this model, human MYC is
integrated into the mouse genome in the form of Tet-O-MYC, and the tetracycline
transactivating gene is integrated into the genome under the control of the kidney-
specific g-glutamyl transferase gene promoter. Transgenic mice conditionally express
MYC in the proximal convoluted tubule cells of the kidney when doxycycline (Dox)
is removed from their drinking water. Induction of MYC expression leads to rapidly
progressing RCC. We conducted a pilot study with the Felsher laboratory to evaluate
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MYCASO-3 activity in this RCC model
Materials and Methods
Conditional transgenic mice were developed as described.[246] Mice were divided
into two treatment cohorts. Dox was removed from drinking water, and mice were
treated with vehicle control or MYCASO-3 at 25 mg ASO/kg bodyweight every three
days administered via tail vein injection. Mice were treated until clinical endpoint
was reached, defined as changes in posture, gait, or mobility that interfered with
feeding behavior, at which time mice were sacked.
4.6.2 Results
MYCASO-3 treatment did not result in any significant change in overall survival
of mice with MYC-induced RCC compared to vehicle-treated controls.
4.6.3 Discussion
In the pilot study described here, we evaluated MYCASO-3 activity in a MYC-
driven and MYC-addicted murine model of renal cell adenocarcinoma.[246] MYCASO-
3 treatment did not result in any significant difference in overall survival compared
to vehicle treatment. Because this was a pilot study we did not perform any further
experiments to investigate why MYCASO-3 was not active in this model, though we
hypothesize that the results of this study reflect an inability of MYCASOs to reach
tumor cells, as observed in the previous two in vivo models. Instead of pursuing this
model further, we turned instead to another in vivo model with greater promise for
demonstrating MYCASO activity.
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4.7 Murine MYC Hyperperfusion Hepatocellular
Carcinoma Model
4.7.1 Experimental Design
Rationale
As described above, we believe that models of cancer in the mouse liver are ideal
systems for evaluating MYCASO activity in vivo due to the hepatotropic nature of
ASO compounds.[141, 142] We collaborated with the Xin Chen laboratory at Uni-
versity of California San Francisco to evaluate MYCASO activity in a MYC-driven
murine liver cancer model.[247] In this model, mice are hydrodynamically perfused
with two plasmids: one containing the humanMYC sequence surrounded by transpo-
son elements, and one containing the sequence encoding Sleeping Beauty transposase.
Hydrodynamic perfusion involves injection of a very high volume of liquid (approxi-
mately 10% of mouse body volume) into the mouse tail vein over a very short period
of time, typically five to ten seconds. This rapid increase in mouse blood volume
leads to compromising of capillary endothelial walls and hepatocyte cell membranes
as well as fluid backup into the liver, all resulting in leakage of the injected plasmids
out of the bloodstream and into hepatocyte cells. Ten to forty percent of hepatocytes
take up the plasmid DNA, leading to expression of the Sleeping Beauty transposase
and integration of the human MYC sequence into the genome in two to ten percent
of hepatocytes. Hyperperfusion is the most efficient non-viral in vivo gene delivery
method to date. Unregulated expression of MYC by these hepatocytes leads to devel-
opment of liver tumors. We were intrigued by this model as a system in which to test
MYCASO activity because it is purely MYC-driven, and because the tumors reside
in the liver, eliminating delivery concerns as much as possible. We collaborated with
the Chen laboratory to evaluate MYCASO-3 activity in this mouse model.
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Materials and Methods
MYCASO Treatment in a MYC-driven Murine Liver Tumor Model The
MYC-induced liver tumor murine model was performed as previously described.[247]
Briefly, 20 mg of plasmid encoding MYC surrounded by transposase elements were
mixed with 2 mg of plasmid encoding the Sleeping Beauty transposase in 2.5 mL PBS
and injected into the lateral tail vein of seven six- to eight-week old female FVB/N
mice (The Jackson Laboratory). Four weeks following plasmid hyperperfusion, four
mice were randomly selected to receive MYCASO-3 treatment. Mice were treated
with at total of five doses of MYCASO-3 at 25 mg ASO/kg bodyweight every three
days. Following the final dose, mice were euthanized and liver samples were harvested
for subsequent analysis. Partial liver specimens were flash frozen for 5’ RACE, and
remaining liver tissue was formalin fixed and paraffin embedded for MYC immuno-
histochemistry studies. MYC IHC was performed as previously described [42] using
a MYC-specific antibody (Epitomix, Y69) at 1:1000 with TSA (PerkinElmer) am-
plification. Slides were scanned and analyzed for quantitated MYC staining using
an Aperio Digital Pathology SlideScanner and Imagescope software. This study was
approved by the Committee for Animal Research at the University of California, San
Francisco.
5’ RACE Analysis of Mouse Tumors Liver tissue specimens were lysed and
homogenized, and RNA was isolated using a QIAGEN RNeasy Mini Kit and eluted
in RNase-free water. RNA concentration of samples was determined spectroscopically
using a Thermo Scientific NanoDrop 8000. The 5’ RACE assay was carried out as
described by Invitrogen using their 5’ RACE kit. A thermal cycler was used for all
incubations.
First Strand cDNA Synthesis In 8-strip PCR tubes, 5 mg total RNA and 2.5
pmol gene specific primer 1 (GSP1-RT: 5’-TGTTTCAACTGTTCTC-3’) were diluted
to 15.5 mL in DEPC-treated water, incubated for 10 min. at 70∘C, then chilled for
1 min. on ice. Next, 2.5 mL 10X PCR buffer, 2.5 mL 25 mM MgCl2, 1 mL 10 nM
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dNTP mix, and 2.5 mL 0.1 M DTT were added to the sample, followed by a 1 min.
incubation at 42∘C. 1 mL SuperScript II RT was added to the reaction, followed by
incubation at 42∘C for 50 min., then 70∘C for 15 min. 1 uL RNase mix was then
added, followed by incubation at 37∘C for 30 min. The cDNA reaction was purified
using a Qiagen PCR purification kit and eluted in nuclease-free water.
TdT Tailing of cDNA The following components were added to an 8-strip
PCR tube: 6.5 mL DEPC-treated water, 5 mL 5X tailing buffer, 2.5 mL 2 mM dCTP,
and 10 mL cDNA sample. Reactions were incubated for 2.5 min. at 94∘C, then chilled
for 1 min. on ice. 1 mL TdT was added, followed by incubation for 10 min. at 37∘C,
then 10 min. at 65∘C.
PCR of dC-tailed cDNA The following components were added to an 8-strip
PCR tube: 32 mL nuclease-free water, 5 mL 10X PCR buffer, 3 mL 25 mM MgCl2,
1 mL 10 mM dNTP mix, 2 mL 10 mM nested gene specific primer 2 (GSP2: 5’-
CCTCTGCTTGGACGGACAGGA-3’), 2 mL 10 mM Abridged Anchor Primer (AAP:
5’-GGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG-3’), 5 mL dC-tailed cDNA.
0.25 mL Taq DNA polymerase (5 units/mL) was added immediately before mixing the
reaction and placing in a thermal cycler pre-equilibrated to 95∘C to run the following
PCR protocol: 95∘C for 2 min.; 30 cycles of 95∘C for 15 sec., 58∘C for 15 sec., and
68∘C for 1 min.; and final extension at 68∘C for 5 min.
Nested Amplification For improved visualization of PCR products, a second
PCR reaction was carried out using another nested gene specific primer (GSP3: 5’-
CTGGTCACGCAGGGCAAAAA-3’) and the 5’ RACE abridged universal anchor
primer (AUAP: 5’-GGCCACGCGTCGACTAGTAC-3’). The PCR products from
the previous step were diluted 1:100 in TE buffer. The following components were
added to an 8-strip PCR tube: 34 mL nuclease-free water, 5 mL 10X PCR buffer, 3
mL 25 mM MgCl2, 1 mL 10 mM dNTP mix, 1 mL 10 mM GSP3, 1 mL 10 mM AUAP,
5 mL diluted primary PCR product. 0.25 mL Taq DNA polymerase (5 units/mL) was
added immediately before mixing the reaction and placing in a thermal cycler pre-
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equilibrated to 95∘C to run the following PCR protocol: 95∘C for 2 min.; 30 cycles of
95∘C for 15 sec., 57∘C for 15 sec., and 68∘C for 1 min.; and final extension at 68∘C
for 5 min.
Gel Visualization of PCR Products 10 mL PCR product were loaded onto
an E-Gel 1.2% with Ethidium Bromide Agarose Gel (Invitrogen). Gels were run using
an E-Gel iBase Power System (Invitrogen) set to program 1 for 20 min. 5 mL of E-Gel
1 kb Plus DNA Ladder (Invitrogen) were loaded into one lane per gel.
4.7.2 Results
Following hyperperfusion of MYC -expressing and Sleeping Beauty transposase-
expressing plasmids into mice, hepatocytes were rapidly transformed, with tumor
formation occurring within 3 weeks (Figure 4-5 A). We established tumors in a cohort
of seven mice, and four weeks following perfusion we began treatment with MYCASO-
3 at a 25 mg ASO/kg bodyweight dose every three days. Four mice were randomly
selected for MYCASO-3 treatment, with three mice used as vehicle-treated controls.
Mice were treated over the course of two weeks (a total of 5 injections). Following
treatment, all mice were euthanized and livers were harvested to assess pharmaco-
dynamic effects of MYCASO treatment. Notably, gross observation of MYCASO-3
treated tumors revealed dramatically lower tumor volume compared to controls (Fig-
ure 4-5 B). Quantification of liver size as a percentage of total body weight revealed a
decrease in liver size with MYCASO-3 treatment, though because the sample size was
so small this result is not statistically significant (Figure 4-5 B). RNA was harvested
from biopsied tumor material from each mouse and subject to 5’ RACE. All four mice
treated with MYCASO-3 showed specific cleavage ofMYC mRNA, while no apparent
cleavage product was detected in control mouse tumors (Figure 4-5 C). Quantified
assessments of MYC protein levels by MYC immunohistochemistry revealed dark,
MYC-positive staining in control mice. MYCASO-3 treated mice showed smaller
patches of MYC-positive tumors, with relatively less intense MYC expression when
assessed visually and digitally on a per cell basis (Figure 4-5 D and E).
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Figure 4-5: In vivo effects of MYCASO-3 in a MYC-induced model of hepatocellular
carcinoma. (A) Schematic of HCC tumor model used to assess MYCASO-3 effects. A
plasmid expressing human MYC is co-injected with a plasmid expressing the Sleeping
Beauty transposase by hydrodynamic injection. Liver tumor formation is observed
by three weeks following perfusion, with large tumor masses observable by six weeks.
MYCASO-3 was dosed at 25 mg/kg in mice beginning four weeks after perfusion,
and dosing was performed every three days for a period of two weeks (a total of five
doses). (B) Quantification of liver mass as a percentage of total body mass follow-
ing completion of the study. Examples of harvested livers from a single control and
a single MYCASO-3 treated mouse are shown (vehicle-treated control mice, n=3;
MYCASO-3 treated mice, n=4). (C) 5’ RACE assessment from RNA harvested from
biopsied tumor samples from 3 control and 4 MYCASO-3 treated mice. Band depicts
the major cleaved species observable in cell line studies. (D) MYC immunohisto-
chemistry showing MYC+ cells in livers of control and MYCASO-3 treated mice. (E)
Quantification of MYC+ cell staining in (D). MYC positivity grades on a per cell
basis was assigned using automated Aperio Digital Pathology software.
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4.7.3 Discussion
In collaboration with the Xin Chen laboratory at the University of California in
San Francisco, we induced MYC-driven tumors in the livers of FVB/N mice. Im-
portantly, this is the first murine model in which we were able to observe MYC-
ASO activity. MYCASO-3 treatment led to cleavage of MYC mRNA within tumors,
knockdown of MYC protein expression in tumors, and a decrease in tumor volume.
Taken together, our results suggest that MYCASO-3 can have direct, anti-MYC and
anti-tumor effects in vivo.
We recognize that the size of this study limits the power of our conclusions. Fur-
thermore, we recognize that no non-targeting control ASO was employed in this study,
leaving open the possibility that the anti-tumor effects observed with MYCASO-3
treatment were mediated in part through non-specific ASO activity. Nonetheless, we
assert that these results represent detectable MYC-specific and on-target anti-tumor
activity of MYCASOs in an in vivo context.
4.8 Conclusions
In this chapter, we investigated in vivo models for the study of MYCASO activity
against MYC-expressing tumors. We observed MYCASO efficacy in a zebrafish model
of T cell acute lymphoblastic leukemia. In this model we also observed suggestions
of toxicity as a result of a generalized response to antisense agents.
MYCASOs are well-tolerated by mice, with the notable exception of administra-
tion of MYCASO-13 at 25 mg ASO per kilogram mouse bodyweight, which resulted
in severe weight loss, dehydration, and jaundice. These data are consistent with
our observations that MYCASO-13 seems to be particularly toxic compared to other
MYCASO molecules, and further study is warranted to identify the toxicity of this
molecule.
With murine models of MYC-expressing cancers, we observed great difficulty in
the delivery of MYCASO molecules. We were unable to achieve delivery of MYCASOs
to the bone marrow for treatment of a disseminated multiple myeloma model, which
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is consistent with the historical difficulty of targeting ASO agents to this tissue.[236,
237, 238] We also encountered difficulty delivering MYCASOs to solid tumors in the
liver and kidney, consistent with reports of barriers to solid tumor delivery.[242, 243,
244, 245]
Despite these setbacks, we were able to demonstrate first signs of MYCASO anti-
tumor activity in vivo in a MYC-driven murine model of hepatocellular carcinoma.
Overall, our findings suggest that with proper delivery, MYCASO treatment in
vivo can result in cleavage of MYC mRNA, knockdown of MYC protein expression,
and reduced tumor burden.
These findings warrant future studies. Next steps for in vivo studies of MYCASO
molecules should involve scaling up the murine MYC hyperperfusion experiment to
increase the power of the study and achieve a statistically significant decrease in tumor
burden, perhaps with treatment with MYCASO-3, MYCASO-9, and MYCASO-13.
Additionally, MYCASO effects on overall survival should be investigated. NT-ASO
treatment should be included to control for a generalized ASO response, which our
data suggest is likely. Furthermore, we would be interested to investigate the biodis-
tribution of MYCASO molecules as well as thorough pharmacokinetic and pharmaco-
dynamic analyses. Finally, due to the difficulty we had in delivering these molecules
to most tumors, investigation of delivery formulations to improve MYCASO delivery
such as nanoparticles could expand the applications of these molecules.
Overall we have achieved proof of concept of MYCASO activity in vivo, a promis-
ing step for the advancement of MYCASO molecules as potential cancer therapeutics.
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Chapter 5
Off-Target Activity of
MYC-Targeting Antisense
Oligonucleotides
5.1 Introduction
Off-target activity is common to cancer therapeutics, which are often characterized
by significant side effects that are frequently severely debilitating. In fact, because
many therapies are indiscriminate inhibitors of cellular proliferation or target onco-
genic components that also perform essential functions in healthy cells, off-target
activity is almost inherent to cancer treatments. No exception to this rule, anti-
sense oligonucleotide off-target activity has been well documented.[4, 121, 248] We
have observed evidence of potential MYCASO toxicity and off-target activity, as has
been documented here in qRT-PCR analyses of MYC mRNA levels with NT-ASO
treatment, viability effects with NT-ASO treatment, incomplete rescue of MYCASO-
mediated viability effects with MYC overexpression, and gross toxicity observed in
mice treated with a high dose of MYCASO-13.
In this chapter, we investigate MYCASO off-target activity. Specifically, we take
a deep look at off-target antisense activity; that is, antisense-mediated knockdown of
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transcripts other thanMYC. All MYCASO sequences are specific toMYC mRNA, yet
because MYCASOs are 16-mers, there are likely to be transcripts within the cell that
contain sequences that are complementary to MYCASO sequences with only a few
mismatches. In fact, given that the human genome consists of three billion base pairs
and assuming random distribution of nucleotide bases, there will statistically be twelve
sequences that are fourteen nucleotides long, forty-four sequences that are thirteen
nucleotides long, and one hundred seventy-eight sequences that are twelve nucleotides
in length that are complementary to a given MYCASO compound. These sequences,
if translated into mRNA, will produce transcripts containing sites complementary
to MYCASOs with two, three, or four mismatches. The mismatch tolerance for
ASO binding and for RNase H recruitment suggest that such transcripts may be
bound by MYCASOs and potentially cleaved by RNase H.[249] In this chapter we
will investigate this possibility.
The literature in antisense development and characterization is notably lacking in
thorough analyses of ASO off-target effects. It is common for authors to investigate
the immune-stimulating properties of ASOs [250, 251, 252], to compare gene-specific
ASOs to non-targeting controls [174, 253, 254], and to investigate the effects of gene-
specific ASOs on a handful of other transcripts, for example investigating effects on
MYC-L with treatment with a MYC-N -specific ASO.[255] Results of experiments
such as these are used to support claims of ASO specificity. However, very few
thorough or unbiased examinations of ASO activity exist. We believe that such
an approach in developing an ASO for therapeutic application is novel, interesting,
safe, and smart. Here we undertake a complete transcriptomic analysis of MYCASO
activity towards the goals of achieving an unbiased assessment of MYCASO specificity
and identifying off-target activity to thoroughly investigate these prototypical MYC-
targeting cancer therapeutic molecules.
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5.2 Investigation of Effects of MYCASO Treatment
on Potential Off-Target Binding Partner
Transcripts
5.2.1 Experimental Design
Rationale
To first investigate potential MYCASO off-target antisense activity, we sought
to identify mRNA transcripts with sequences that are complementary to MYCASO
sequences with minimal mismatches, reasoning that these would be the most likely
off-target binding partners for MYCASOs. We utilized the NCBI nucleotide BLAST
tool to identify transcripts with the least number of mismatches from MYCASO-
3, MYCASO-9, MYCASO-13, and NT-ASO sequences that were also expressed in
HeLa cells as determined from the Human Protein Atlas.[256, 257] We selected three
transcripts for each ASO and assessed the levels of these transcripts with MYCASO
treatment compared to control treatments using qRT-PCR in HeLa, CUTLL1, and
HLF cells lines.
Materials and Methods
Cell Culture HeLa cells (ATCC) were grown in Dulbecco’s Modified Eagle’s Med-
ium (DMEM, + 4.5 g/L D-glucose, + L-Glutamine, Sigma) supplemented with
10% FBS. HLF cells (Broad Institute CCLE) were grown in DMEM with 5% FBS.
CUTLL1 (generously provided by J. Aster) cells were grown in RPMI 1640 (+ L-
Glutamine, Sigma) supplemented with 10% FBS. Cells were maintained at 37∘C and
5% CO2. HeLa and HLF cells were harvested by discarding used media, washing with
PBS, adding 0.25% trypsin (Sigma) to just cover the vessel surface, placing cells at
37∘C to detach, quenching trypsin with fresh media, and collecting the cell suspen-
sion. Suspension CUTLL1 cells were harvested by collecting media. For passaging,
cells were spun at 200xg for 3 minutes, resuspended in fresh medium, and seeded in
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new asks. Cells were split 1:4 or 1:5 every 2-3 days.
MYCASO Treatments Lyophilized MYCASO powders were suspended in 0.5%
saline to a concentration of 5 mM as confirmed spectroscopically. The day before
treatment, HeLa and HLF cells were seeded at a density of 100,000 cells/mL and
CUTLL1 cells at a density of 250,000 cells/mL; cells were then allowed to adhere
and/or recover overnight. For gymnotic treatments, the saline solution was added
directly to cell culture media for a final MYCASO concentration of 10 mM. For trans-
fection, MYCASOs were mixed with Lipofectamine 2000 in serum-free Opti-MEM
(Sigma) and added to cell culture medium at a final concentration of 0.5 to 100 nM
MYCASO and 2.5 mL Lipofectamine/1 mL medium.
Identification of Potential MYCASO Off-Target Binding Partner Tran-
scripts The NCBI nucleotide BLAST tool was utilized to identify potential MYC-
ASO off-target binding partner transcripts (https://blast.ncbi.nlm.nih.gov/Blast.cgi).
MYCASO-3, MYCASO-9, MYCASO-13, and NT-ASO sequences were searched within
the human genomic + transcript database. Results were given as genomic and tran-
script sequences in order of complementarity. A result was ignored if it corresponded
to a region of genomic DNA not known to encode mRNA or if the sequence was
present in the incorrect orientation for MYCASO binding. Hits were organized into
groups based on number of mismatches, and each sequence within a group was con-
sidered equivalent. Next, we searched hit sequences within the Human Protein Atlas
[256, 257] for mRNA expression in HeLa cells. Transcripts with Fpkm less than one
or not reported were thrown out. From the remaining sequences we chose three tran-
scripts per ASO. Transcripts with the least number of mismatches were chosen first
before moving on to transcripts with more mismatches. If several equivalent tran-
scripts (i.e., with the same number of mismatches) were being considered for one
position, we chose the one with the higher reported Fpkm value in HeLa cells. The
selected transcripts were as follows, with the number of mismatches from the given
ASO sequence in parentheses: MYCASO-3: TAF1A (2), MTHFD1L (2), COL16A1
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(2); MYCASO-9: INCENP (2), QARS (3), RAB1B (3); MYCASO-13: HIVEP2 (3),
IFT140 (3), PABPN1 (4); NT-ASO: CEP41 (4), SGMS2 (4), BIRC3 (4).
qRT-PCR Cells were seeded in Corning TC-treated 6-well dishes at 2 mL/well,
allowed to recover overnight, treated as described above, and harvested after a treat-
ment time of 1 hr to 5 days. Harvested cells were placed on ice, centrifuged at 500xg
at 4∘C for 5 minutes, washed with cold PBS, and centrifuged again. RNA was isolated
using a QIAGEN RNeasy Mini Kit and eluted in RNAse-free water. cDNA synthesis
was carried out using the SuperScript VILO cDNA synthesis kit (ThermoFisher): 1
mg RNA, 4 mL of 5X VILO Reaction Mix, and 2 mL of 10X SuperScript Enzyme Mix
were diluted in DEPC-treated water to a final volume of 20 mL in 8-strip PCR tubes.
Samples were placed in a thermal cycler that ran the following program: 25∘C for
10 min., 42∘C for 60 min., 85∘C for 5 min. Each qRT-PCR reaction consisted of
0.1 mL cDNA, 10 mL SYBR Select Master Mix, 1 mL of each primer at 10 mM, and
nuclease-free water to a total volume of 20 mL in a MicroAmp Optical 384-well plate
(Applied Biosystems). The following PCR protocol was run on an Applied Biosys-
tems ViiA 7 qRT-PCR instrument: 50∘C for 2 minutes, 95∘C for 2 minutes, 40 cycles
of 95∘C for 15 seconds followed by 60∘C for 1 minute with a SYBR Green fluorescence
measurement made after every cycle, followed by a melting curve measurement. Ct
thresholds were determined automatically by the instrument software. Ct values were
converted to transcript abundance relative to vehicle-treated controls. The following
primers were used for qRT-PCR experiments:
MYC forward: 5’-GCTGCTTAGACGCTGGATTT-3’;
MYC reverse: 5’-CTCCTCCTCGTCGCAGTAGA-3’;
TAF1A forward: 5’-ACCTGGTCTGAAAAGAAGATGG-3’;
TAF1A reverse: 5’-CTTCCAGCTGTGGTTGAACA-3’;
MTHFD1L forward: 5’-TGTGCCAAGGGACTTCATCT-3’;
MTHFD1L reverse: 5’-AGTCCTGGCATGGTGCTC-3’;
COL16A1 forward: 5’-CTGGAGTACCTGGGCTGC-3’;
COL16A1 reverse: 5’-GGAGGTGCTGTTCAATTGGT-3’;
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INCENP forward: 5’-CAAGAAGACTGCCGAAGAGC-3’;
INCENP reverse: 5’-TCAGAACCAACTTTCTGGGG-3’;
QARS forward: 5’-GCGTCTTGGATATTTCTCCG-3’;
QARS reverse: 5’-GCTTCCAGCTCACACCTTTC-3’;
RAB1B forward: 5’-ACTTCCAGCTACTACCGGGG-3’;
RAB1B reverse: 5’-CATAGCGGTCAATCTCCTGC-3’;
HIVEP2 forward: 5’-ACCACAATAAGAGCGCCATC-3’;
HIVEP2 reverse: 5’-CCCAATACAATTGGCTCTGC-3’;
IFT140 forward: 5’-GACGCCATGCTCCACTTC-3’;
IFT140 reverse: 5’-AGACGGCCTCACTTTTGATG-3’;
PABPN1 forward: 5’-ACCAACTACAACAGCTCCCG-3’;
PABPN1 reverse: 5’-GGGAATACCATGATGTCGCT-3’;
BIRC3 forward: 5’-GGGAAGAGGAGAGAGAAAGAGC-3’;
BIRC3 reverse: 5’-GTCAAATGTTGAAAAAGTGCCA-3’;
CEP41 forward: 5’-TGGTCGGTTGGAGAAAATATG-3’;
CEP41 reverse: 5’-GCTGGTATCTTGGGTTCTGTG-3’;
SGMS2 forward: 5’-ACACGGTTACGCTGACACTG-3’;
SGMS2 reverse: 5’-TCAGCAGCCAGCAGATTAAA-3’;
GAPDH forward: 5’-GAAGGTGAAGGTCGGAGTCA-3’;
GAPDH reverse: 5’-TTGAGGTCAATGAAGGGGTC-3’.
5’ Rapid Amplification of cDNA Ends (RACE) HeLa cells were seeded in
Corning TC-treated 6-well dishes at 2 mL/well, allowed to recover overnight, treated
as described above with empty Lipofectamine 2000 control or with 10 nM MYCASO-3
formulated in Lipofectamine 2000, and harvested after a treatment time of two hours.
Harvested cells were placed on ice, centrifuged at 500xg at 4∘C for 5 min., washed
with cold PBS, and centrifuged again. RNA was isolated using a QIAGEN RNeasy
Mini Kit and eluted in RNAse-free water. The 5’ RACE assay was carried out as
described by Invitrogen using their 5’ RACE kit. A thermal cycler was used for all
incubations.
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First Strand cDNA Synthesis In 8-strip PCR tubes, 5 mg total RNA and
2.5 pmol gene specific primer 1 (GSP1-RT) were diluted to 15.5 mL in DEPC-treated
water, incubated for 10 minutes at 70∘C, then chilled for 1 minutes on ice. Next,
2.5 mL 10X PCR buffer, 2.5 mL 25 mM MgCl2, 1 mL 10 nM dNTP mix, and 2.5 mL
0.1 M DTT were added to the sample, followed by a 1 minute incubation at 42∘C.
1 mL SuperScript II RT was added to the reaction, followed by incubation at 42∘C
for 50 minutes, then 70∘C for 15 min. 1 mL RNase mix was then added, followed by
incubation at 37∘C for 30 minutes. The cDNA reaction was purified using a Qiagen
PCR purification kit and eluted in nuclease-free water.
TdT Tailing of cDNA The following components were added to an 8-strip
PCR tube: 6.5 mL DEPC-treated water, 5 mL 5X tailing buffer, 2.5 mL 2 mM dCTP,
and 10 mL cDNA sample. Reactions were incubated for 2.5 minutes at 94∘C, then
chilled for 1 minute on ice. 1 mL TdT was added, followed by incubation for 10
minutes at 37∘C, then 10 minutes at 65∘C.
PCR of dC-tailed cDNA The following components were added to an 8-strip
PCR tube: 32 mL nuclease-free water, 5 mL 10X PCR buffer, 3 mL 25 mM MgCl2, 1 mL
10 mM dNTP mix, 2 mL nested gene specific primer 2 (GSP2, 10 mM), 2 mL Abridged
Anchor Primer (AAP, 10 mM), 5 mL dC-tailed cDNA. 0.25 mL Taq DNA polymerase
(5 units/mL) was added immediately before mixing the reaction and placing in a
thermal cycler pre-equilibrated to 95∘C to run the following PCR protocol: 95∘C for
2 minutes; 30 cycles of 95∘C for 15 seconds, 58∘C for 15 seconds, and 68∘C for 1
minute; and final extension at 68∘C for 5 minutes.
Nested Amplification For improved visualization of PCR products, a second
PCR reaction was carried out using another nested gene specific primer (GSP3) and
the 5’ RACE abridged universal anchor primer (AUAP). The PCR products from
the previous step were diluted 1:100 in TE buffer. The following components were
added to an 8-strip PCR tube: 34 mL nuclease-free water, 5 mL 10X PCR buffer,
3 mL 25 mM MgCl2, 1 mL 10 mM dNTP mix, 1 mL GSP3 (10 mM), 1 mL AUAP,
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5 mL diluted primary PCR product. 0.25 mL Taq DNA polymerase (5 units/mL)
was added immediately before mixing the reaction and placing in a thermal cycler
pre-equilibrated to 95∘C to run the following PCR protocol: 95∘C for 2 minutes; 30
cycles of 95∘C for 15 seconds, 57∘C for 15 seconds, and 68∘C for 1 minutes; and final
extension at 68∘C for 5 minutes.
Gel Visualization of PCR Products 10 mL PCR product were loaded onto
an E-Gel 1.2% with Ethidium Bromide Agarose Gel (Invitrogen). Gels were run using
an E-Gel iBase Power System (Invitrogen) set to program 1 for 20 min. 5 mL of E-Gel
1 kb Plus DNA Ladder (Invitrogen) were loaded into one lane per gel.
Primer Sequences The following custom primers were ordered from Integrated
DNA Technologies (IDT) and used in 5’ RACE assays:
MYC GSP1-RT: 5’-TGTTTCAACTGTTCTC-3’;
MYC GSP2: 5’-CCTCTGCTTGGACGGACAGGA-3’;
MYC GSP3: 5’-CTGGTCACGCAGGGCAAAAA-3’;
TAF1A GSP1-RT: 5’-TAATACACTACATAAATAC-3’;
TAF1A GSP2: 5’-TAATACCTCCAACCCCAGTTTACG-3’;
TAF1A GSP3: 5’-TACATAACTCTTCACAAAAGGGTCCCAAAC-3’;
AAP: 5’-GGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG-3’;
AUAP: 5’-GGCCACGCGTCGACTAGTAC-3’.
5.2.2 Results
qRT-PCR results for one select predicted off-target binding partner transcript
for each of MYCASO-3, MYCASO-9, and MYCASO-13 are shown in Figure 5-1.
Transcript levels were measured following treatment with vehicle control, NT-ASO,
MYCASO-3, MYCASO-9, and MYCASO-13 in HeLa, CUTLL1, and HLF cells. In
general, transcript levels decreased with MYCASO treatment, most likely as a re-
sult of global transcriptional downregulation from loss of MYC. Transcripts were
particularly depleted upon treatment with their potential MYCASO binding part-
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Figure 5-1: qRT-PCR analysis of potential MYCASO o-target binding partner tran-
scripts. qRT-PCR for expression of potential o-target MYCASO binding partners
TAF1A (A), INCENP (B), and PABPN1 (C) following MYCASO treatment in HeLa
cells (10 nM in Lipofectamine for 24 hours), HLF cells (10 mM unformulated for 120
hours), and CUTLL1 cells (10 mM unformulated for 72 hours) normalized to vehicle-
treated control. Values represent quadruplicate means +/- SD. Above each bar graph
are the sequences of the MYCASO and its potential off-target binding partner; mis-
matches between the two are highlighted in red. Transcripts seem to be particularly
depleted following treatment with the MYCASO that may serve as a potential binding
partner, suggesting off-target antisense activity.
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ners compared to treatment with vehicle, NT-ASO, and the other two MYCASOs.
Results for other potential off-target transcripts are shown in Figure B-2.
We investigated the dynamics of off-target transcript downregulation with MYC-
ASO-3 treatment. qRT-PCR results for MYC, TAF1A, and MTHFD1L transcripts
at different doses of MYCASO-3 are shown in Figure 5-2 A. qRT-PCR results for
transcripts at different time points of MYCASO-3 treatment are shown in Figure 5-2
B. We see that the transcripts TAF1A and MTHFD1L —both containing sequences
complementary to fourteen out of sixteen bases of the MYCASO-3 sequence, or two
mismatches —are downregulated with MYCASO-3 treatment with similar dynamics
to MYC. Furthermore, downregulation of potential MYCASO-9 and MYCASO-13
off-target binding partner transcripts occurs on a delayed time scale, as depicted in
Figure 5-2 C.
To investigate the mechanism of selective transcript downregulation, we performed
a 5’ RACE assay with primers designed specifically to amplify TAF1A mRNA. In
vehicle-treated cells, we observed a band corresponding to the size of the full-length
TAF1A transcript; in MYCASO-3-treated cells, we observed a band of the predicted
size for cleavage of the transcript at the MYCASO-3 binding site (Figure 5-3).
Finally, we sought to investigate whether the NT-ASO non-targeting control
molecule exhibited similar off-target antisense activity. qRT-PCR results for potential
NT-ASO binding partner transcripts as well as MYC at different doses of NT-ASO
are shown in Figure 5-4. While MYC levels remain unchanged, the three off-target
transcripts are knocked down with NT-ASO treatment in a dose-dependent manner.
5.2.3 Discussion
Here we observed that transcripts containing sequences complementary to MYC-
ASOs with two to four mismatches were particularly depleted upon treatment with
their potential MYCASO binding partners compared to treatment with vehicle, NT-
ASO, and the other two MYCASOs. Furthermore, knockdown of two potential
MYCASO-3 off-target transcripts with MYCASO-3 treatment followed the same dy-
namics as MYC knockdown, while transcripts not possessing complementary sites
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Figure 5-2: qRT-PCR analysis of dose- and time-proportional effects of MYCASO-
3 treatment on potential MYCASO off-target binding partner transcripts. HeLa
cells were transfected with 10 nM MYCASO-3 in Lipofectamine 2000 for twenty-four
hours. RNA was isolated and relative expression of transcripts was determined via
qRT-PCR as described in the methods. (A) Dose-proportional effects of MYCASO-3
treatment on potential MYCASO-3 off-target binding partner transcripts. (B) Time-
proportional effects of MYCASO-3 treatment on potential MYCASO-3 off-target
binding partner transcripts. (C) Time-proportional effects of MYCASO-3 treatment
on potential MYCASO-9 and MYCASO-13 off-target binding partner transcripts.
Values represent quadruplicate means +/- SD.
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Figure 5-3: MYCASO-3-mediated cleavage of the TAF1A transcript. 5’ RACE was
carried out on HeLa cells after treatment for two hours with either empty Lipo-
fectamine 2000 vehicle or 10 nM MYCASO-3 formulated in Lipofectamine 2000.
Gene specific primers for the TAF1A transcript were used. Vehicle-treated cells pro-
duce a band corresponding to the size of the full-length TAF1A transcript, whereas
MYCASO-3-treated cells produce a fragment of the predicted size for cleavage of
TAF1A mRNA at the MYCASO-3 binding site.
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Figure 5-4: qRT-PCR analysis of dose-proportional effects of NT-ASO treatment on
potential off-target binding partner transcripts. HeLa cells were transfected with
the indicated doses of NT-ASO in Lipofectamine 2000 for twenty-four hours. RNA
was isolated and relative expression of transcripts was determined via qRT-PCR as
described in the methods. Values represent quadruplicate means +/- SD.
were down-regulated on a delayed time scale. These data suggest that this phe-
nomenon is due to more than the general transcriptional consequences of MYC knock-
down and may in fact be partially due to MYCASO sequence-specific activity, such as
off-target binding to transcripts with a small number of mismatches and recruitment
of RNase H to cleave those transcripts.
To investigate the mechanism of selective transcript downregulation, we performed
a 5’ RACE assay with primers designed specifically to amplify TAF1A mRNA. In
vehicle-treated cells, we observed a band corresponding to the size of the full-length
TAF1A transcript; in MYCASO-3-treated cells, we observed a band of the predicted
size for cleavage of the transcript at the MYCASO-3 binding site, consistent with
recruitment of RNase H. TAF1A is a critical component required for regulation of
RNA polymerase I-mediated transcription [258, 259] and is likely to be essential for
proliferation. Therefore knockdown of TAF1A with MYCASO-3 treatment might be
contributing to the phenotypic effects of MYCASO treatment, notably the decrease
in cell viability. The other identified potential MYCASO off-target binding partner
transcripts also carry out important cellular functions, and their knockdown with
MYCASO treatment may also be contributing to observed viability effects.
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Following these observations we sought to investigate whether NT-ASO exerts
any off-target antisense effects. NT-ASO is designed to not be complementary to any
known mRNA sequence. Indeed, a BLAST nucleotide search revealed that there are
no known transcripts containing sequences with three or fewer mismatches to the NT-
ASO sequence. However, we did observe that three transcripts containing sequences
complementary to NT-ASO with four mismatches were downregulated with NT-ASO
treatment in a dose-responsive manner. Two of these transcripts were knocked down
seventy percent at a 10 nM dose of NT-ASO, the dose typically used in these ASO
studies. Transfection of HeLa cells results in efficient delivery of ASO molecules,
and in these studies we have observed some signs of potential toxicity with NT-ASO
treatment; perhaps the off-target transcript knockdown observed here is responsible
for these phenomena.
Overall, these data suggest that MYCASOs may bind transcripts containing a
small number of mismatches, recruit RNase H, and induce cleavage of the off-target
mRNA. Furthermore, knockdown of off-target transcripts may contribute to
MYCASO effects on cell proliferation and viability.
As a final note, we observed that in general, levels of nearly all investigated tran-
scripts went down with treatment with all three tested targeting MYCASOs. We
have attributed this to global downregulation of transcription due to loss of the MYC
transcription factor protein. We normalized transcript abundance to GAPDH in an
effort to control for the phenomenon, but we still observed transcript downregulation.
Our hypothesis is that the tested transcripts may be more strongly affected by MYC
knockdown than GAPDH is, perhaps existing in MYC ‘target gene sets’ or directly
or indirectly regulated by the MYC transcription factor itself.
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5.3 Unbiased Transcriptomic Analysis to Evaluate
MYCASO Off-Target Activity
5.3.1 Experimental Design
Rationale
After observing that MYCASOs do indeed exhibit off-target activity, we sought to
perform a thorough and unbiased investigation of MYCASO activity at the level of the
transcriptome. As described in Chapter 3, we chose to utilize RNA-seq analysis for a
readout of the transcriptional profile of MYCASO-treated cells. We performed these
experiments in HeLa cells, as many of our experiments up to this point have been
performed in this cell line. Because HeLa cells are treated with Lipofecamine transfec-
tion of MYCASOs, we included empty Lipofectamine treatments, to control for any
transfection reagent-related cellular responses. We also included NT-ASO-treated
samples to control for generalized cellular responses to ASO exposure. Due to cost
limitations, we decided to test only one MYCASO molecule, MYCASO-3. Finally, we
chose two time points for our analysis: four hours and eighteen hours. At four hours,
we have observed that MYC mRNA is significantly knocked down, yet MYC protein
level has not yet changed and there have been no viability effects. We chose this time
point to investigate effects of MYCASO molecules at the mRNA level, before there
has been significant knockdown of MYC protein to alter the transcriptional profile of
the cells. We predict that at this time point, MYCASO off-target antisense activity
will be discernible. At eighteen hours, there has been sustained MYC mRNA and
protein knockdown, but there is not yet any significant viability effect. We chose this
time point to investigate the effects of sustained MYC protein knockdown, which we
predict will alter the transcriptome consistent with MYC’s role as a master regula-
tory transcription factor and amplifier of transcription.[10, 11, 15, 23, 24, 25, 216]
Furthermore, this time point will allow us to observe off-target effects of sustained
ASO exposure.
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Materials and Methods
Cell Culture HeLa cells (ATCC) were grown in Dulbecco’s Modified Eagle’s Med-
ium (DMEM, + 4.5 g/L D-glucose, + L-Glutamine, Sigma) supplemented with 10%
FBS. Cells were maintained in an incubator at 37∘C and 5% CO2. Cells were main-
tained in Corning TC-treated T-25, T-75, and T-175 flasks. Cells were harvested
by discarding used media, washing with PBS, adding 0.25% trypsin (Sigma) to just
cover the vessel surface, placing cells at 37∘C to detach, quenching trypsin with fresh
media, and collecting the cell suspension. For passaging, cells were spun at 200xg for
3 minutes, resuspended in fresh medium, and seeded in new flasks. Cells were split
1:4 or 1:5 every 2-3 days.
MYCASO Treatments MYCASO powders were suspended in 0.5% saline to a
concentration of 5 mM as confirmed spectroscopically. The day before treatment,
HeLa cells were seeded at a density of 100,000 cells/mL allowed to adhere overnight.
For transfection of HeLa cells, MYCASOs were mixed with Lipofectamine 2000 in
serum-free Opti-MEM (Sigma) and added to cell culture medium at a final concen-
tration of 10 nM MYCASO and 2.5 mL Lipofectamine / 1 mL medium.
RNA-seq Analysis RNA-seq analysis was performed as described in Chapter 3.
HeLa cells were seeded in Corning TC-treated 6-well dishes at 2 mL/well, allowed to
recover overnight, treated as described above, and harvested after treatment times
of 0, 4, and 18 hours. Harvested cells were placed on ice, centrifuged at 500xg at
4∘C for 5 min., washed with cold PBS, and centrifuged again. For each sample, 10
mL cells were mixed with 10 mL trypan blue dye, loaded onto a Countess cell count-
ing chamber slide, and counted using a Countess II Automated Cell Counter. Each
sample was adjusted to contain 400,000 cells. RNA was isolated using a QIAGEN
RNeasy Mini Kit and eluted in RNAse-free water, and ERCC synthetic spike-ins were
added per the manufacture’s instructions (Ambion). RNA samples were quantified
using a Qubit 2.0 Fluorometer (Life Technologies, Carlsbad, CA, USA) and RNA
integrity was checked with an Agilent TapeStation (Agilent Technologies, Palo Alto,
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CA, USA). RNA library preparations and sequencing reactions were conducted at
GENEWIZ, LLC. (South Plainfield, NJ, USA). RNA sequencing library preparation
was carried out using the NEBNext Ultra RNA Library Prep Kit for Illumina by fol-
lowing manufacturer’s recommendations (NEB, Ipswich, MA, USA). Briefly, mRNA
were first enriched with Oligod(T) beads. Enriched mRNAs were fragmented for 15
minutes at 94∘C. First strand and second strand cDNA were subsequently synthe-
sized. cDNA fragments were end repaired and adenylated at 3’ ends, and universal
adapter was ligated to cDNA fragments, followed by index addition and library en-
richment with limited cycle PCR. Sequencing libraries were validated on the Agilent
TapeStation (Agilent Technologies, Palo Alto, CA, USA), and quantified by using a
Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA) as well as by quantitative PCR
(Applied Biosystems, Carlsbad, CA, USA).
The sequencing libraries were multiplexed and clustered on two lanes of a flowcell.
After clustering, the flowcell was loaded on the Illumina HiSeq instrument according
to manufacturer’s instructions. The samples were sequenced using a 2x150 Paired
End (PE) configuration. Image analysis and base calling were conducted by the
HiSeq Control Software (HCS). Raw sequence data (.bcl files) generated from Illumina
HiSeq were converted into fastq files and de-multiplexed using Illumina’s bcl2fastq
2.17 software. One mis-match was allowed for index sequence identification.
To visualize reads at the MYC locus, paired-end FASTQs were aligned using
HISAT2 v2.0.5 using default parameters. The index used was constructed from all
contigs from hg19 (Feb. 2009, GRCh37 (GCA_000001405.1)) and ERCC sequences
obtained from ThermoFisher. Deeptools v2.5.3 was used to convert bams to bed-
graphs with RPKM normalization and 100 bp bins. The coordinates of the MYC
locus were obtained from the RefGene database, and the Sushi v1.14.0 Bioconductor
package was used to plot pileup in this region.
For differential expression analysis, transcripts were quantified from raw paired-
end FASTQs using Salmon 0.8.2 with automatic library type detection and default pa-
rameters. The index used was built from RefMrna sequences obtained from hg19 (Feb.
2009, GRCh37 (GCA_000001405.1)) and from ERCC sequences obtained from Ther-
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moFisher (https://assets.thermofisher.com/TFS-Assets/LSG/manuals/ERCC92.zip).
Transcript-level counts were imported and merged to gene-level counts via the Txim-
port v1.4.0 Bioconductor package using a transcript-to-gene key generated from the
UCSC RefGene database. ERCC transcripts were excluded from the analysis at this
stage. DESeq2 v1.14 was used with single-factor design formula (“˜ condition”) to
find differentially expressed genes.
To generate MYCASO-3 and ASO signatures, transcripts were quantified and
merged to the gene-level as described above. Prior to analysis with DESeq2 v1.14,
zero-hour samples were excluded and a three factor design formula was used to test
for expression changes attributable to the presence of a MYCASO-3 while controlling
for treatment time as well as the presence of any ASO (MYCASO-3 or NT-ASO).
We also used this approach to test for expression changes attributable to ASOs in
general while controlling for time and the presence of MYC-targeted ASO. For each
of these comparisons, all genes and their associated Wald statistic were exported for
use with the GSEA Preranked function.
5.3.2 Results
As described in Chapter 3, excellent concordance of mRNA expression was ob-
served between replicate samples (Figure B-1). Results of the RNA-seq analysis are
presented in Chapter 3 (Figure 3-8) but are reproduced here as well in Figure 5-5.
At each time point we observed a decrease in sequencing reads that map to MYC
exons specifically in MYCASO-3 treated cells (Figure 5-5 A and B). This loss of
MYC mRNA was slight but detectable after four hours of treatment, and reached
approximately 50% of total reads at the eighteen hour time point. In both NT-ASO
and MYCASO-3 treated cells, significant effects on other transcripts were observed
(Figure 5-5 B). However, much broader effects on the transcriptome were observed at
the eighteen hour time point, with dramatic effects on hundreds of transcripts in both
the NT-ASO and MYCASO-3 treated cells. After four hours of NT-ASO treatment
we detected a total of 771 genes downregulated and 308 genes upregulated, while
after eighteen hours 4319 genes were downregulated and 4047 genes were upregulated
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Figure 5-5: Transcriptomic analysis of MYCASO-3 treated cells. (A) RNA-
sequencing was performed on HeLa cells transfected with NT-ASO or MYCASO-3
(10 nM) for either 4 or 18 hours. Lipofectamine 2000 was used as a delivery vehi-
cle. mRNA reads that were mapped to MYC exons were plotted for each sample,
revealing a slight decrease in MYC -mapped reads at 4 hours, and a pronounced ef-
fect at 18 hours, specifically with MYCASO-3 treatment. (B) Volcano plots of gene
expression differences comparing NT-ASO and MYCASO-3 treated cells with vehicle
after 4 and 18 hours. (C) Gene set enrichment analysis (GSEA) normalized enrich-
ment scores for MYC-associated gene sets (red and blue) and the total C2 gene sets
as part of MSigDB. Differential expression analysis was performed with DESeq2 to
generate MYCASO-3 specific expression signatures and total ASO-treated signatures
(NT-ASO and MYCASO-3 samples) as described in Methods. (D) GSEA signatures
for two example gene sets of genes positively regulated by MYC (MYC ‘UP’). (E)
GSEA signatures for two example gene sets of the interferon response.
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(Log2 fold change <-0.2/>0.2, p value < 0.01). With MYCASO-3 treatment, 355
genes were downregulated at four hours, including MYC itself (p = 8.09e-16); 166
genes were upregulated. After eighteen hours of treatment with MYCASO-3, 3975
genes were downregulated with MYC ranked 23 in significance among downregu-
lated genes (p = 5.18e-261); 4075 genes were upregulated with MYCASO-3 including
CDKN1A, known to be negatively regulated by MYC (p = 6.32e-240).[217] MYC
mRNA levels were relatively unaffected by NT-ASO treatment when compared to
vehicle treated cells.
In order to reveal gene signatures that are affected by MYCASO-3 treatment
specifically and ASO treatment generally, we employed comprehensive gene set en-
richment analysis (GSEA) utilizing all curated gene sets available in the Molecular
Signatures Database (MSigDB ‘C2’, n = 3678 gene sets).[218] Global distributions
of gene set enrichment scores are shown in Figure 5-5 C. Among the library of gene
sets analyzed are 38 MYC-specific gene sets that have been experimentally defined
through functional assessments of genes up- or downregulated after selective pertur-
bation of MYC. We find that among the gene sets that are most highly negatively
enriched in MYCASO-3 treated cells are genes validated to be positively regulated by
MYC (MYC ‘UP’). 18 of 25 MYC ‘UP’ gene sets showed negative enrichment scores,
while only 5 of 25 did when all ASO (MYCASO-3 and NT-ASO) treated samples are
compared to vehicle control samples. All gene sets associated with negative regula-
tion by MYC (MYC ‘DOWN’) were conversely positively correlated with MYCASO-
3 treatment. This pattern was not conserved when all ASO-treated samples were
compared to vehicle controls, revealing that the selective repression of MYC tran-
scriptional networks is specifically an effect of MYCASO-3 and not associated with
general consequences of ASO exposure (Figure 5-5 C). Notably, ASO-treated samples
were significantly associated with a global interferon response, as 9 of the top 12 en-
riching gene sets were annotated as activated interferon signatures. Included in the
MYC ‘UP’ signatures specifically enriched in MYCASO-3 treated samples are from
studies from Coller et al and Schuhmacher et al. [219, 220] (Figure 5-5 D); exemplary
interferon signatures were annotated by Browne et al and Zhang et al.[221, 222]
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5.3.3 Discussion
As discussed in Chapter 3, RNA-seq analysis revealed a decrease in MYC reads
with MYCASO-3 treatment at both four (p = 8.09e-16) and eighteen hours (p =
5.18e-261), as expected. At the later time point MYC ranked 23 in significance among
downregulated genes. No significant change in MYC levels was observed with NT-
ASO activity, suggesting that MYC downregulation is a MYCASO-specific effect.
Comprehensive gene set enrichment analysis revealed down-regulation of gene sets
regulated by MYC consistent with the literature. Importantly, this pattern was not
conserved when all ASO-treated samples were compared to vehicle controls, revealing
that the selective repression of MYC transcriptional networks is specifically an effect
of MYCASO-3 and not associated with general consequences of ASO exposure.
In both NT-ASO and MYCASO-3 treated cells, significant effects on other tran-
scripts were observed, with dramatic effects on hundreds of transcripts seen in cells
treated with ASOs for eighteen hours. Notably, ASO-treated samples were signifi-
cantly associated with a global interferon response. This response to ASO exposure
may be responsible in part for toxicities observed with MYCASO treatment in vitro
and in vivo described throughout this manuscript.
These studies reveal that while global gene expression programs may be perturbed
non-specifically with ASO treatment, MYCASO treatment can have selective effects
on both MYC and the MYC-associated gene expression programs required for cancer
cell proliferation and survival.
Of particular interest in this study are the results of MYCASO-3 treatment for
four hours. As described above, this time point was chosen to investigate the on- and
off-target antisense activity of MYCASO-3 at the level of the transcriptome, before
sustained MYC knockdown leads to global and profound transcriptional changes.
After four hours of NT-ASO treatment we detected a total of 771 genes downregulated
and 308 genes upregulated. After four hours of MYCASO-3 treatment, 355 genes
were downregulated and 166 genes were upregulated. These are profound responses,
especially considering that MYCASO-3 is designed to recognize and downregulate
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only one transcript, and NT-ASO is designed to exhibit no antisense activity. As
mentioned above, many of the upregulated genes for both treatments correlate to an
interferon response. Importantly, TAF1A is included among the genes specifically
downregulted by MYCASO-3 treatment, consistent with observations in the previous
section that MYCASO-3 is able to bind to TAF1A mRNA, recruit RNase H, and
induce transcript degradation.
Overall, these studies confirm our findings that MYCASOs exhibit off-target ac-
tivity. This activity is both general to LNA-modified antisense agents and sequence-
specific. Nonetheless, MYC was among the most significantly down-regulated genes
with MYCASO treatment and not with NT-ASO treatment, confirming MYC-specific
on-target activity of MYCASO molecules.
5.4 Conclusions
In this chapter we sought to perform a thorough and unbiased investigation of
MYCASO activity to gain insights into the suggestions of off-target activity and tox-
icity observed throughout this manuscript. Importantly, we discovered that MYC
is among the most significantly downregulated genes with MYCASO treatment com-
pared to vehicle- and NT-ASO-treated controls, and that MYCASO treatment results
in downregulation in MYC target gene sets, confirming that MYCASOs can exert
MYC-specific effects.
We also discovered that MYCASO treatment results in profound changes in the
transcriptome of the cell that are not predicted to occur as a result of MYC per-
turbation, which we have labeled as off-target activity. Some cellular response to
MYCASO treatment is a generalized response to ASO treatment as it was observed
with treatment with both MYCASO-3 and NT-ASO, such as upregulation of genes as-
sociated with the interferon response. Other parts of the transcriptomic consequences
of MYCASO treatment are sequence-specific. Among this response, we observed that
MYCASOs are able to bind to mRNA transcripts containing sequences complemen-
tary to the MYCASO sequences with a small number of mismatches, recruit RNase
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H, and cleave the mRNA. Given that ASOs containing third generation chemical
modifications are often around 16 nucleotides in length, the existence of transcripts
within the cell containing two to four mismatches is statistically inevitable. Further-
more, this finding may be applicable to longer ASOs as well; the mechanisms of ASO
scanning and binding are not fully understood and the longer the ASO, the more
seed sites there are along the ASO strand to recognize and bind to mRNA within the
cell. This observation suggests an intriguing application of polypharmacology in ASO
design. The tolerance for mismatches in ASO binding and RNase H-mediated cleav-
age suggests that the effects of ASO therapeutics generally may be in part mediated
by polypharmacologic perturbation of multiple mRNAs. Furthermore, these findings
suggest that one may theoretically design an ASO that is partially complementary to
several different intended targets and still achieve potent knockdown of all targets.
Such a strategy would be especially useful for cancer therapeutics, allowing for the
targeting of several different oncogenic pathways with a single molecule, creating a
more efficacious treatment and potentially anticipating the emergence of resistance.
The results of our RNA-seq analysis of MYCASO treatment revealed hundreds
of genes perturbed by ASO treatment within four hours and thousands within eight
hours. We have not yet thoroughly analyzed these findings, and we certainly could
dive in to these gene sets to learn more about ASO- and MYCASO-specific signatures
and gain insight into other mechanisms that may be contributing to as yet undefined
MYCASO activity.
Importantly, we believe this study represents one of the only employments of a
complete transcriptomic analysis of ASO treatment in cancer cells for the investi-
gation of cancer-directed therapeutics. We have been able to identify a handful of
other studies that utilized microarray-based transcriptional profiling to investigate
transcriptome-wide responses to ASO treatment.[122, 123, 260, 261] A study con-
ducted by Burel et al. provides an interesting context for these observations. Firstly,
the authors observed that treatment with some LNA-modified ASOs in mice resulted
in general hepatotoxicity and knockdown of off-target transcripts associated with
ASO complementarity and RNase H activity. However, treatment with other LNA-
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modified ASOs did not lead to any hepatotoxicity or off-target transcript knockdown
despite comparable numbers of partially complementary transcript sequences and
comparable on-target in vivo activity. The authors were unable to identify any dis-
tinguishing differences between these two groups. These findings suggest that design
of ASOs that do not exhibit off-target antisense behavior may be possible, but at this
time we do not yet possess the understanding or the tools to do so. In the meantime,
in silico methods are being investigated [262, 263, 264], and the field continues to
grow in its understanding of ASO activity and toxicity.
Additionally, Burel et al. noted that transcripts that were knocked down with ASO
treatment possessed longer pre-mRNA transcripts than average. They concluded that
ASOs may bind and degrade pre-mRNA, and that the longer the RNA sequence, the
greater the chance of ASO binding and the more susceptible to ASO-mediated down-
regulation the transcript will be. We have not yet thoroughly investigated the large
number of transcripts downregulated by MYCASO treatment, but we hypothesize
that this phenomenon may be playing a role in MYCASO off-target activity.
Overall, our studies reveal that ASO molecules may exhibit profound off-target
activity even while all collected data suggest potent and specific on-target activity,
highlighting the need for the field to enforce higher standards of characterization and
carry out more thorough analyses in ASO development. Such stringency will help the
field to move towards greater understanding of ASO activity and toxicity as well as
the underlying cell biology and pharmacology, and will lead to development of more
effective therapeutics.
162
Chapter 6
Future Directions
In this dissertation, we described the synthesis and characterization of antisense
oligonucleotides targeted against the frequently dysregulated proto-oncogene MYC.
These MYCASO compounds potently decrease MYC protein expression through
RNase H-mediated cleavage of MYC mRNA and exert profound viability effects on a
variety of cancer cell lines from distinct lineages. Furthermore, MYCASO-mediated
MYC knockdown results in profound transcriptional changes in the cell, notably char-
acterized by decreased expression of MYC ‘target’ genes and increased expression of
the interferon response. We have demonstrated first indications of MYCASO efficacy
against a MYC-driven cancer model in vivo.
We have also demonstrated that MYCASOs exhibit off-target antisense activity,
profoundly modulate the transcriptome in a sequence-specific manner, exhibit un-
characterized general toxicity in vivo, and are difficult to deliver to tumor cells in
many in vivo settings. Despite these limitations, study of MYCASOs provides inter-
esting, novel, and valuable insights into antisense technology and informs MYC drug
development. In this final chapter we will explore exciting future directions for these
novel compounds.
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6.1 MYCASO In Vivo Studies
In Chapter 4 we explored MYCASO activity in a variety of in vivo tumor models.
In a mouse model of MYC-driven hepatocellular carcinoma, we demonstrated MYC-
ASO target engagement, RNase H-mediated cleavage of MYC mRNA, MYC protein
knockdown, and a decrease in tumor burden with MYCASO-3 treatment.
The next steps for in vivo investigation of MYCASO activity should involve scal-
ing up this model. Specifically, treatment with all three lead molecules MYCASO-3,
MYCASO-9, and MYCASO-13 should be investigated with NT-ASO treatment in-
cluded as a control. Furthermore, the number of animals included in each treatment
cohort should be increased, thus increasing the power of the study to achieve a sta-
tistically significant decrease in tumor burden. Finally, overall survival should be
measured as a primary endpoint to investigate whether MYCASO treatment may
prolong survival. Successful completion of these experiments will provide crucial pre-
clinical data for the advancement of MYCASOs, and antisense molecules in general,
towards the clinic.
In our study of MYCASO tolerability and toxicity in mice, we observed severe tox-
icity from MYCASO-13 treatment. The mechanisms behind this toxicity should be
investigated, including an analysis of the in vivo immune-stimulatory effects and hep-
atotoxicity of MYCASO treatment. With these data, we may determine whether the
toxicities associated with MYCASO treatment are tolerable and acceptable for devel-
opment of these molecules as therapeutics. We may investigate whether MYCASO-
mediated immune stimulation may be cooperating with anti-MYC effects to affect cell
viability. Furthermore, we may gain insight into the sequence- specific and chemical
modification-specific factors that contribute to ASO toxicity in vivo.
Additionally, we may consider utilizing alternative chemical modifications; the
LNA moiety has been shown to be particularly toxic in vivo.[121, 122, 123] Inter-
estingly, recent studies suggest that control of the stereochemical conformation of
phosphorothioate linkers may significantly enhance ASO stability and potency.[265]
Furthermore, we are interested in investigating the biodistribution, pharmacoki-
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netic, and pharmacodynamic profiles of MYCASO molecules. This information may
be useful for comparing alternative chemistries towards the goal of achieving improved
in vivo activity, as well as for potentially nominating other oncologic indications for
which MYCASOs may prove useful agents.
What we overwhelmingly observed was the inability of MYCASOs formulated in
saline solution and injected into mouse tail veins to be delivered into tumor cells.
Proposals to address this issue will be discussed below.
6.2 Cellular Uptake of Antisense Oligonucleotides
In Chapter 3 we observed that transfection of MYCASOs results in significant
MYC knockdown for nearly every MYCASO molecule, but that unformulated gym-
notic delivery of MYCASOs results in highly variable MYC knockdown activity, sug-
gesting that cellular uptake plays an important role in ASO activity. The mechanisms
governing cellular uptake of ASO molecules are incompletely understood, highly vari-
able across different cell types, and sequence-dependent.[126] Our observations under-
score the need to further elucidate these mechanisms, including identification of cell
surface receptors that recognize and internalize ASO molecules, the productive and
non-productive pathways an ASO may travel inside a cell, and the sequence speci-
ficity of these various parts. Increased understanding of these processes will allow for
smarter and more efficient ASO design.
We intend to carry out two experiments towards the goal of elucidating the mech-
anisms of ASO uptake. The first is a screen for MYCASO viability effects across a
panel of 500 cancer cell lines from over twenty different lineages utilizing the Broad
Institute’s Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) assay.[7]
In the PRISM assay, each of over 500 cancer cell lines is ‘barcoded’ via stable inte-
gration of a unique twenty-four base pair DNA sequence into the genome. The cell
lines are seeded together in a single flask, each at a very low density. Following treat-
ment, genomic DNA is isolated and barcodes are sequenced as a readout of relative
viability of the cancer cell lines. In this way, drug activity can be assessed in an enor-
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Figure 6-1: Pilot PRISM analysis of relative viability with MYCASO treatment across
a panel of cancer cell lines. The Broad Institute’s Profiling Relative Inhibition Simul-
taneously in Mixtures, or PRISM, assay was carried out as previously described.[7] A
panel of 100 cell lines was seeded at a very low density in wells of a 12-well plate. Fol-
lowing seeding, cells were treated with unformulated MYCASO, NT-ASO, or saline
vehicle control at the concentrations indicated. Every three days, cell culture medium
was replaced and cells were re-treated. After 7 or 14 days, cells were harvested, ge-
nomic DNA was isolated, and barcodes were sequenced as described. Barcode fre-
quency is presented as a heat map, with blue representing lower frequency, or more
cell death, and white representing higher frequency, or more cell proliferation. Re-
sults were normalized to the relative abundance of barcodes in the vehicle-treated
control samples, indicated as a heat map below the cell line names, with green repre-
senting greater frequency. This pilot experiment suggests that the PRISM assay can
indeed be utilized to capture a dynamic range of relative susceptibility to MYCASO
treatment that is both dose- and time-dependent.
mous number of cancer cell lines with a significant reduction in resources. We intend
to utilize this novel high-throughput platform to screen for susceptibility to MYC-
ASO treatment. Because MYC is an essential gene, and because MYCASOs have
exerted viability effects against many varied cancer cell lines in our hands, including
low MYC-expressing lines, we believe that resistance to MYCASO treatment can be
read as a surrogate for inability to take up ASOs. Following the completion of this
experiment, we will have data illustrating the relative ASO uptake proficiency of 500
unique cancer cell lines. Indeed, we conducted a pilot PRISM assay experiment on
100 cell lines. The results, shown in Figure 6-1, suggest that this assay can indeed be
utilized to assess relative susceptibility to MYCASO treatment. We observed a range
of activity of lead MYCASO molecules across these varied cell lines that appears to
be both dose- and time-dependent. We also observed potential toxicity associated
with treatment with the NT-ASO control molecule in some cell lines.
The second experiment that we intend to carry out is a genome-wide CRISPR
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screen [266, 267] for resistance to MYCASO treatment. We intend to utilize the
CUTLL1 T-cell lymphoma line, shown to exhibit MYC knockdown and profound
viability effects upon MYCASO treatment. A genome-wide CRISPR screen entails
knocking out every gene in the genome —one gene per cell —utilizing the CRISPR-
Cas9 system, treating with the drug of interest, and then sequencing to determine the
relative viability of each generated knockout cell line. Through this method, we may
identify genes that confer resistance to the viability effects of MYCASO treatment.
We hypothesize that many of these genes will be involved in ASO uptake, though
some may also play a role in MYC biology or other pathways targeted by MYCASOs.
We predict that by combining the genome-level data of the latter experiment with
the cell line screening data of the former experiment, we may be able to discover genes
and pathways that play key role in cellular ASO uptake.
6.3 Antisense Oligonucleotide Delivery
As mentioned above, in Chapter 4 we described our observations that MYCASOs
are immensely difficult to deliver into tumor cells. The only organ we were able to
achieve delivery to is the liver due to the hepatotropic nature of ASOs [141, 142], and
this only succeeded in one out of two models tested. We were additionally unable to
deliver MYCASOs to disseminated multiple myeloma that homes to the bone marrow,
or to a renal cell carcinoma.
We predict that efficient MYCASO absorption, distribution, and metabolism ki-
netics could be greatly enhanced with either specialized nanoparticles or other opti-
mized delivery modalities.[124, 125, 135] An expansive literature in drug delivery has
identified formulations from large collections of lipids and polymers that successfully
facilitate nucleic acid delivery to hepatocytes [136, 137, 138], monocytes [139], and
endothelial cells.[140]
In particular, we hypothesize that treatment of K-Ras driven non-small cell lung
cancer tumors in mice [268] with MYCASOs formulated in a lipid-based nanoparticle
developed by James Dalman et al. that specifically targets the lung endothelium and
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lung tumors [140, 269] could provide a promising model for demonstrating MYCASO
anti-tumor efficacy in vivo as well as the potential for specialized targeting nanopar-
ticles to enhance delivery and anti-tumor activity of ASOs.
Despite the great advances made in nanoparticle-mediated delivery to the cell
types mentioned, very little work has been done on drug delivery to other cancer-
relevant cell types, tissues, and organs. Notably, MYC deregulation is frequently a
characteristic of hematologic malignancies, often with disease localized to the bone
marrow. We anticipate that MYCASO use for these indications will specifically re-
quire formulation or dosing strategies to reach this tissue, which has historically been
exceptionally difficult to target with oligonucleotide therapeutics.
James Dalman et al. recently published a study on the use of a DNA barcoding
strategy for screening large numbers of nanoparticles for their biodistribution pro-
files in a single mouse.[270] We anticipate that such a relatively high-throughput, in
vivo screening tool could be utilized to identify formulations to enhance delivery of
MYCASOs in particular and ASOs in general to under-served cancer-relevant organs,
tissues, and cells, such as the bone marrow.
Furthermore, we anticipate that understanding of the mechanisms involved in
cellular uptake of ASOs (see above), in particular the cell surface receptors involved
in ASO binding and internalization, may be utilized to rationally design specific
targeting nanoparticles, for example nanoparticles decorated with a ligand with strong
affinity for an ASO-recognizing cell surface protein on cells within the target tissue.
6.4 Analysis of Off-Target Activity of Antisense
Oligonucleotides
In Chapter 5 we performed a thorough and unbiased transcriptomic analysis of
MYCASO activity in a cancer cell line. Our goal with this study was to identify effects
of MYCASO treatment at the transcription level that are both MYC-dependent and
that represent off-target activity. We observed perturbation of thousands of genes
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following eighteen hours of MYCASO treatment, a treatment time consistent with
prolonged MYC protein knockdown, and changes in expression of hundreds of genes
following four hours of MYCASO treatment, which we believe roughly represents
the cellular response to the presence of the MYCASO compound, as MYC protein
levels are minimally perturbed at this time point. Furthermore, we demonstrated
MYCASO-induced cleavage of an off-target transcript with two mismatches to the
MYCASO sequence. Overall, the results of these studies indicate that MYCASOs
can exert profound off-target effects.
We believe that these results strongly suggest that thorough analysis of ASO off-
target activity is a practice that ought to be widely adopted. We believe that the
standards in the field for publication of ASO development and characterization are
not stringent enough. Furthermore, it is likely that failure to investigate off-target
ASO activity has contributed in a big way to erroneous interpretation of results and
to the failure of most ASOs to advance clinically. Specifically, thorough analyses of
off-target antisense activity and of in vivo toxicity, including investigation of potential
immune-stimulatory activity, should be conducted. We believe that only through such
comprehensive study will the field grow in understanding and move closer towards
the goal of establishing ASOs as a viable therapeutic class. Furthermore, through the
participation of many, together we will be able to uncover patterns in ASO function to
reveal, for example, activity that is driven by chemical modifications, or the sequence
specificity of off-target activity. These discoveries will aid us towards developing
guidelines to efficiently design effective and non-toxic ASOs for cleaner modulation
of protein expression for studies in the lab and for translation to the clinic to treat
patients.
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Supplementary Materials and
Methods
From 3.5: Phenotypic Consequences of MYC-Targeting Antisense Oligo-
nucleotide Treatment
Plasmid Design for Generation of a Mutant MYC-Overexpressing Cell Line
List of mutations:
172A>G; 174C>G; 321A>C; 324A>C; 327C>T; 333G>A; 519C>A; 522C>G; 525C>T;
526T>C; 528G>A; 531C>T; 532C>T; 912A>G; 915T>C; 918G>A; 921C>T; 924C>T;
927C>T
Full Sequence (seed sites for MYCASO-3, MYCASO-9, and MYCASO-13 are CAPI-
TALIZED; mutations from wild-type MYC are in bold):
atgcccctcaacgttagcttcaccaacaggaactatgacctcgactacgactcggtgcagccgtatttctactgcgacgagga-
ggagaacttctaccagcagcagcagcagagcgagctgcagcccccggcgcccagcgaggatatctggaagaaattcgagct-
gctgcccgcgccgcccctgtcccctagccgccgctccgggctctgctcgccctcctacgttgcggtcacacccttctcccttcg-
gggagacaacgacggcggtggcgggagcttctccacggccgaccagctggagatggtgaccgagctgctggGCGGCG-
ATATGGTAAAccagagtttcatctgcgacccggacgacgagaccttcatcaaaaacatcatcatccaggactgtat-
gtggagcggcttctcggccgccgccaagctcgtctcagagaagctggcctcctaccaggctgcgcgcaaagacagcggcagc-
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ccgaaccccgcccgcggccacagcgtctgctccACATCGAGTCTATATTtgcaggatctgagcgccgccgcc-
tcagagtgcatcgacccctcggtggtcttcccctaccctctcaacgacagcagctcgcccaagtcctgcgcctcgcaagactcc-
agcgccttctctccgtcctcggattctctgctctcctcgacggagtcctccccgcagggcagccccgagcccctggtgctccatg-
aggagacaccgcccaccaccagcagcgactctgaggaggaacaagaagatgaggaagaaatcgatgttgtttctgtggaaa-
agaggcaggctcctggcaaaaggtcagagtctggatcaccttctgctggaggccacagcaaacctcctcacagcccactggtc-
ctcaagaggtgccacgtctccacGCACCAACATAATTATgcagcgcctccctccactcggaaggactatcctg-
ctgccaagagggtcaagttggacagtgtcagagtcctgagacagatcagcaacaaccgaaaatgcaccagccccaggtcctc-
ggacaccgaggagaatgtcaagaggcgaacacacaacgtcttggagcgccagaggaggaacgagctaaaacggagcttttt-
tgccctgcgtgaccagatcccggagttggaaaacaatgaaaaggcccccaaggtagttatccttaaaaaagccacagcatac-
atcctgtccgtccaagcagaggagcaaaagctcatttctgaagaggacttgttgcggaaacgacgagaacagttgaaacaca-
aacttgaacagctacggaactcttgtgcgtaa
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Figure B-1: Excellent concordance of mRNA expression is observed between replicate
RNA-seq samples. Transformed counts from RNA-seq samples are compared between
replicates.
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Figure B-2: qRT-PCR analysis of potential MYCASO o-target binding part-
ner transcripts. qRT-PCR for expression of potential o-target binding partners
for MYCASO-3 (TAF1A, MTHFD1L, and COL16A1, top row), MYCASO-9 (IN-
CENP, RAB1B, and QARS, second row), and MYCASO-13 (PABPN1, IFT140, and
HIVEP2, bottom row) following MYCASO treatment in HeLa cells (10 nM in Lipo-
fectamine for 24 hours), HLF cells (10 mM unformulated for 120 hours), and CUTLL1
cells (10 mM unformulated for 72 hours) normalized to vehicle-treated control. Values
represent quadruplicate means +/- SD. Transcripts seem to be particularly depleted
following treatment with the MYCASO that may serve as a potential binding partner,
suggesting off-target antisense activity.
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Table C.1: Sequences and characteristics of the MYCASO library.
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Table C.2: Quantification of MYC protein levels from dose- and time-course MYC-
ASO treatment immunoblots. Values are normalized to control.
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